other	 DRUG1 : Studies in animals demonstrate that the acute toxicity of  DRUGOTHER  is enhanced by the  DRUG2   DRUGOTHER  .	MAO Inhibitors	MAO inhibitor	CN(CC#C)CC1=CC=CC=C1	CN(CC#C)CC1=CC=CC=C1
other	 DRUG1 : Studies in animals demonstrate that the acute toxicity of  DRUGOTHER  is enhanced by the  DRUGOTHER   DRUG2  .	MAO Inhibitors	phenelzine	CN(CC#C)CC1=CC=CC=C1	NNCCC1=CC=CC=C1
other	 DRUGOTHER : Studies in animals demonstrate that the acute toxicity of  DRUG1  is enhanced by the  DRUG2   DRUGOTHER  .	bupropion	MAO inhibitor	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CN(CC#C)CC1=CC=CC=C1
effect	 DRUGOTHER : Studies in animals demonstrate that the acute toxicity of  DRUG1  is enhanced by the  DRUGOTHER   DRUG2  .	bupropion	phenelzine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NNCCC1=CC=CC=C1
other	 DRUGOTHER : Studies in animals demonstrate that the acute toxicity of  DRUGOTHER  is enhanced by the  DRUG1   DRUG2  .	MAO inhibitor	phenelzine	CN(CC#C)CC1=CC=CC=C1	NNCCC1=CC=CC=C1
other	 DRUG1  and  DRUG2 : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving  DRUGOTHER  concurrently with either  DRUGOTHER  or  DRUGOTHER .	Levodopa	Amantadine	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	NC12CC3CC(CC(C3)C1)C2
other	 DRUG1  and  DRUGOTHER : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving  DRUG2  concurrently with either  DRUGOTHER  or  DRUGOTHER .	Levodopa	bupropion	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	 DRUG1  and  DRUGOTHER : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving  DRUGOTHER  concurrently with either  DRUG2  or  DRUGOTHER .	Levodopa	levodopa	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	 DRUG1  and  DRUGOTHER : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving  DRUGOTHER  concurrently with either  DRUGOTHER  or  DRUG2 .	Levodopa	amantadine	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	NC12CC3CC(CC(C3)C1)C2
other	 DRUGOTHER  and  DRUG1 : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving  DRUG2  concurrently with either  DRUGOTHER  or  DRUGOTHER .	Amantadine	bupropion	NC12CC3CC(CC(C3)C1)C2	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	 DRUGOTHER  and  DRUG1 : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving  DRUGOTHER  concurrently with either  DRUG2  or  DRUGOTHER .	Amantadine	levodopa	NC12CC3CC(CC(C3)C1)C2	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	 DRUGOTHER  and  DRUG1 : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving  DRUGOTHER  concurrently with either  DRUGOTHER  or  DRUG2 .	Amantadine	amantadine	NC12CC3CC(CC(C3)C1)C2	NC12CC3CC(CC(C3)C1)C2
effect	 DRUGOTHER  and  DRUGOTHER : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving  DRUG1  concurrently with either  DRUG2  or  DRUGOTHER .	bupropion	levodopa	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
effect	 DRUGOTHER  and  DRUGOTHER : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving  DRUG1  concurrently with either  DRUGOTHER  or  DRUG2 .	bupropion	amantadine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NC12CC3CC(CC(C3)C1)C2
other	 DRUGOTHER  and  DRUGOTHER : Limited clinical data suggest a higher incidence of adverse experiences in patients receiving  DRUGOTHER  concurrently with either  DRUG1  or  DRUG2 .	levodopa	amantadine	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	NC12CC3CC(CC(C3)C1)C2
advise	"Administration of  DRUG1  Tablets to patients receiving either  DRUG2  or  DRUGOTHER  concurrently should be undertaken with caution, using small initial doses and small gradual dose increases."	WELLBUTRIN	levodopa	CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
advise	"Administration of  DRUG1  Tablets to patients receiving either  DRUGOTHER  or  DRUG2  concurrently should be undertaken with caution, using small initial doses and small gradual dose increases."	WELLBUTRIN	amantadine	CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1	NC12CC3CC(CC(C3)C1)C2
other	"Administration of  DRUGOTHER  Tablets to patients receiving either  DRUG1  or  DRUG2  concurrently should be undertaken with caution, using small initial doses and small gradual dose increases."	levodopa	amantadine	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	NC12CC3CC(CC(C3)C1)C2
advise	"Drugs that Lower Seizure Threshold: Concurrent administration of  DRUG1  and agents (e.g.,  DRUG2 , other  DRUGOTHER ,  DRUGOTHER , systemic  DRUGOTHER , etc.) that lower seizure threshold should be undertaken only with extreme caution."	WELLBUTRIN	antipsychotics	CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1	
advise	"Drugs that Lower Seizure Threshold: Concurrent administration of  DRUG1  and agents (e.g.,  DRUGOTHER , other  DRUG2 ,  DRUGOTHER , systemic  DRUGOTHER , etc.) that lower seizure threshold should be undertaken only with extreme caution."	WELLBUTRIN	antidepressants	CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
advise	"Drugs that Lower Seizure Threshold: Concurrent administration of  DRUG1  and agents (e.g.,  DRUGOTHER , other  DRUGOTHER ,  DRUG2 , systemic  DRUGOTHER , etc.) that lower seizure threshold should be undertaken only with extreme caution."	WELLBUTRIN	theophylline	CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
advise	"Drugs that Lower Seizure Threshold: Concurrent administration of  DRUG1  and agents (e.g.,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER , systemic  DRUG2 , etc.) that lower seizure threshold should be undertaken only with extreme caution."	WELLBUTRIN	steroids	CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"Drugs that Lower Seizure Threshold: Concurrent administration of  DRUGOTHER  and agents (e.g.,  DRUG1 , other  DRUG2 ,  DRUGOTHER , systemic  DRUGOTHER , etc.) that lower seizure threshold should be undertaken only with extreme caution."	antipsychotics	antidepressants		CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Drugs that Lower Seizure Threshold: Concurrent administration of  DRUGOTHER  and agents (e.g.,  DRUG1 , other  DRUGOTHER ,  DRUG2 , systemic  DRUGOTHER , etc.) that lower seizure threshold should be undertaken only with extreme caution."	antipsychotics	theophylline		CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Drugs that Lower Seizure Threshold: Concurrent administration of  DRUGOTHER  and agents (e.g.,  DRUG1 , other  DRUGOTHER ,  DRUGOTHER , systemic  DRUG2 , etc.) that lower seizure threshold should be undertaken only with extreme caution."	antipsychotics	steroids		[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"Drugs that Lower Seizure Threshold: Concurrent administration of  DRUGOTHER  and agents (e.g.,  DRUGOTHER , other  DRUG1 ,  DRUG2 , systemic  DRUGOTHER , etc.) that lower seizure threshold should be undertaken only with extreme caution."	antidepressants	theophylline	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Drugs that Lower Seizure Threshold: Concurrent administration of  DRUGOTHER  and agents (e.g.,  DRUGOTHER , other  DRUG1 ,  DRUGOTHER , systemic  DRUG2 , etc.) that lower seizure threshold should be undertaken only with extreme caution."	antidepressants	steroids	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"Drugs that Lower Seizure Threshold: Concurrent administration of  DRUGOTHER  and agents (e.g.,  DRUGOTHER , other  DRUGOTHER ,  DRUG1 , systemic  DRUG2 , etc.) that lower seizure threshold should be undertaken only with extreme caution."	theophylline	steroids	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	" DRUG1 : In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced  DRUG2  tolerance in patients who were drinking  DRUGOTHER  during treatment with  DRUGOTHER ."	Alcohol	alcohol	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUG1 : In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced  DRUGOTHER  tolerance in patients who were drinking  DRUG2  during treatment with  DRUGOTHER ."	Alcohol	alcohol	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUG1 : In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced  DRUGOTHER  tolerance in patients who were drinking  DRUGOTHER  during treatment with  DRUG2 ."	Alcohol	WELLBUTRIN	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
other	" DRUGOTHER : In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced  DRUG1  tolerance in patients who were drinking  DRUG2  during treatment with  DRUGOTHER ."	alcohol	alcohol	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER : In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced  DRUG1  tolerance in patients who were drinking  DRUGOTHER  during treatment with  DRUG2 ."	alcohol	WELLBUTRIN	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
effect	" DRUGOTHER : In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced  DRUGOTHER  tolerance in patients who were drinking  DRUG1  during treatment with  DRUG2 ."	alcohol	WELLBUTRIN	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
advise	The consumption of  DRUG1  during treatment with  DRUG2  should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)	alcohol	WELLBUTRIN	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
other	"Certain  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	antibiotic	cisplatin	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"Certain  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	antibiotic	cyclosporine	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Certain  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	antibiotic	diuretic	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"Certain  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	antibiotic	foscarnet	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	NC(=O)NC1NC(=O)NC1=O
other	"Certain  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	antibiotic	vaccines	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	
other	"Certain  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	cisplatin	cyclosporine	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Certain  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	cisplatin	diuretic	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"Certain  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	cisplatin	foscarnet	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	NC(=O)NC1NC(=O)NC1=O
other	"Certain  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	cisplatin	vaccines	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	
other	"Certain  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporine	diuretic	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"Certain  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	cyclosporine	foscarnet	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	NC(=O)NC1NC(=O)NC1=O
other	"Certain  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	cyclosporine	vaccines	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	
other	"Certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ."	diuretic	foscarnet	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	NC(=O)NC1NC(=O)NC1=O
other	"Certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ."	diuretic	vaccines	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	
other	"Certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ."	foscarnet	vaccines	NC(=O)NC1NC(=O)NC1=O	
other	"Oral  DRUG1  Multiple doses of  DRUG2  had no effect on the pharmacokinetics of  DRUGOTHER , the estrogenic component in most oral  DRUGOTHER ."	Contraceptives	cefditoren pivoxil	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
other	"Oral  DRUG1  Multiple doses of  DRUGOTHER  had no effect on the pharmacokinetics of  DRUG2 , the estrogenic component in most oral  DRUGOTHER ."	Contraceptives	ethinyl estradiol	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Oral  DRUG1  Multiple doses of  DRUGOTHER  had no effect on the pharmacokinetics of  DRUGOTHER , the estrogenic component in most oral  DRUG2 ."	Contraceptives	contraceptives	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Oral  DRUGOTHER  Multiple doses of  DRUG1  had no effect on the pharmacokinetics of  DRUG2 , the estrogenic component in most oral  DRUGOTHER ."	cefditoren pivoxil	ethinyl estradiol	[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Oral  DRUGOTHER  Multiple doses of  DRUG1  had no effect on the pharmacokinetics of  DRUGOTHER , the estrogenic component in most oral  DRUG2 ."	cefditoren pivoxil	contraceptives	[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	"Oral  DRUGOTHER  Multiple doses of  DRUGOTHER  had no effect on the pharmacokinetics of  DRUG1 , the estrogenic component in most oral  DRUG2 ."	ethinyl estradiol	contraceptives	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
advise	"Although the clinical significance is not known, it is not recommended that  DRUG1  be taken concomitantly with  DRUG2 ."	cefditoren pivoxil	antacids	[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O	
other	" DRUG1 : Co-administration of a single dose of intravenously administered  DRUG2  (20 mg) reduced the oral absorption of a single 400 mg dose of  DRUGOTHER  administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC."	H2-Receptor Antagonists	famotidine		OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	" DRUG1 : Co-administration of a single dose of intravenously administered  DRUGOTHER  (20 mg) reduced the oral absorption of a single 400 mg dose of  DRUG2  administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC."	H2-Receptor Antagonists	cefditoren pivoxil		[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
mechanism	" DRUGOTHER : Co-administration of a single dose of intravenously administered  DRUG1  (20 mg) reduced the oral absorption of a single 400 mg dose of  DRUG2  administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC."	famotidine	cefditoren pivoxil	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1	[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
other	"Although the clinical significance is not known, it is not recommended that  DRUG1  be taken concomitantly with  DRUG2 ."	cefditoren pivoxil	H2 receptor antagonists	[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O	
other	" DRUG1 : As with other  DRUG2 , co-administration of  DRUGOTHER  with  DRUGOTHER  resulted in an increase in the plasma exposure of  DRUGOTHER , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."	Probenecid	b-lactam antibiotics	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	" DRUG1 : As with other  DRUGOTHER , co-administration of  DRUG2  with  DRUGOTHER  resulted in an increase in the plasma exposure of  DRUGOTHER , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."	Probenecid	probenecid	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
other	" DRUG1 : As with other  DRUGOTHER , co-administration of  DRUGOTHER  with  DRUG2  resulted in an increase in the plasma exposure of  DRUGOTHER , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."	Probenecid	cefditoren pivoxil	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
other	" DRUG1 : As with other  DRUGOTHER , co-administration of  DRUGOTHER  with  DRUGOTHER  resulted in an increase in the plasma exposure of  DRUG2 , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."	Probenecid	cefditoren	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
other	" DRUGOTHER : As with other  DRUG1 , co-administration of  DRUG2  with  DRUGOTHER  resulted in an increase in the plasma exposure of  DRUGOTHER , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."	b-lactam antibiotics	probenecid	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O
mechanism	" DRUGOTHER : As with other  DRUG1 , co-administration of  DRUGOTHER  with  DRUG2  resulted in an increase in the plasma exposure of  DRUGOTHER , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."	b-lactam antibiotics	cefditoren pivoxil	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
other	" DRUGOTHER : As with other  DRUG1 , co-administration of  DRUGOTHER  with  DRUGOTHER  resulted in an increase in the plasma exposure of  DRUG2 , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."	b-lactam antibiotics	cefditoren	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
mechanism	" DRUGOTHER : As with other  DRUGOTHER , co-administration of  DRUG1  with  DRUG2  resulted in an increase in the plasma exposure of  DRUGOTHER , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."	probenecid	cefditoren pivoxil	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
other	" DRUGOTHER : As with other  DRUGOTHER , co-administration of  DRUG1  with  DRUGOTHER  resulted in an increase in the plasma exposure of  DRUG2 , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."	probenecid	cefditoren	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
other	" DRUGOTHER : As with other  DRUGOTHER , co-administration of  DRUGOTHER  with  DRUG1  resulted in an increase in the plasma exposure of  DRUG2 , with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life."	cefditoren pivoxil	cefditoren	[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O	[H][C@]12SCC(\C=C/C3=C(C)N=CS3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
other	" DRUG1  Absorption: The following agents may bind and decrease absorption of  DRUG2  from the gastrointestinal tract:  DRUGOTHER ,  DRUGOTHER  resin,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUGOTHER ."	Levothyroxine Sodium	levothyroxine sodium	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
other	" DRUG1  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUG2 ,  DRUGOTHER  resin,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUGOTHER ."	Levothyroxine Sodium	aluminum hydoxide	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21
other	" DRUG1  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUGOTHER ,  DRUG2  resin,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUGOTHER ."	Levothyroxine Sodium	cholestyramine	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	NCCC1=CC=C(O)C=C1
other	" DRUG1  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUGOTHER ,  DRUGOTHER  resin,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUGOTHER ."	Levothyroxine Sodium	colestipol hydrochloride	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	
other	" DRUG1  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUGOTHER ,  DRUGOTHER  resin,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUGOTHER ."	Levothyroxine Sodium	ferrous sulfate	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	" DRUG1  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUGOTHER ,  DRUGOTHER  resin,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , soybean flour (e.g., infant formula),  DRUGOTHER ."	Levothyroxine Sodium	sodium polystyrene sulfonate	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	
other	" DRUG1  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUGOTHER ,  DRUGOTHER  resin,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUG2 ."	Levothyroxine Sodium	sucralfate	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O
mechanism	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUG1  from the gastrointestinal tract:  DRUG2 ,  DRUGOTHER  resin,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUGOTHER ."	levothyroxine sodium	aluminum hydoxide	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21
mechanism	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUG1  from the gastrointestinal tract:  DRUGOTHER ,  DRUG2  resin,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUGOTHER ."	levothyroxine sodium	cholestyramine	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	NCCC1=CC=C(O)C=C1
mechanism	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUG1  from the gastrointestinal tract:  DRUGOTHER ,  DRUGOTHER  resin,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUGOTHER ."	levothyroxine sodium	colestipol hydrochloride	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	
mechanism	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUG1  from the gastrointestinal tract:  DRUGOTHER ,  DRUGOTHER  resin,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUGOTHER ."	levothyroxine sodium	ferrous sulfate	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
mechanism	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUG1  from the gastrointestinal tract:  DRUGOTHER ,  DRUGOTHER  resin,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , soybean flour (e.g., infant formula),  DRUGOTHER ."	levothyroxine sodium	sodium polystyrene sulfonate	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	
mechanism	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUG1  from the gastrointestinal tract:  DRUGOTHER ,  DRUGOTHER  resin,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUG2 ."	levothyroxine sodium	sucralfate	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O
other	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUG1 ,  DRUG2  resin,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUGOTHER ."	aluminum hydoxide	cholestyramine	CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21	NCCC1=CC=C(O)C=C1
other	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUG1 ,  DRUGOTHER  resin,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUGOTHER ."	aluminum hydoxide	colestipol hydrochloride	CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21	
other	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUG1 ,  DRUGOTHER  resin,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUGOTHER ."	aluminum hydoxide	ferrous sulfate	CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUG1 ,  DRUGOTHER  resin,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , soybean flour (e.g., infant formula),  DRUGOTHER ."	aluminum hydoxide	sodium polystyrene sulfonate	CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21	
other	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUG1 ,  DRUGOTHER  resin,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUG2 ."	aluminum hydoxide	sucralfate	CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21	O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O
other	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUGOTHER ,  DRUG1  resin,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUGOTHER ."	cholestyramine	colestipol hydrochloride	NCCC1=CC=C(O)C=C1	
other	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUGOTHER ,  DRUG1  resin,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUGOTHER ."	cholestyramine	ferrous sulfate	NCCC1=CC=C(O)C=C1	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUGOTHER ,  DRUG1  resin,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , soybean flour (e.g., infant formula),  DRUGOTHER ."	cholestyramine	sodium polystyrene sulfonate	NCCC1=CC=C(O)C=C1	
other	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUGOTHER ,  DRUG1  resin,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUG2 ."	cholestyramine	sucralfate	NCCC1=CC=C(O)C=C1	O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O
other	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUGOTHER ,  DRUGOTHER  resin,  DRUG1 ,  DRUG2 ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUGOTHER ."	colestipol hydrochloride	ferrous sulfate		OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1
other	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUGOTHER ,  DRUGOTHER  resin,  DRUG1 ,  DRUGOTHER ,  DRUG2 , soybean flour (e.g., infant formula),  DRUGOTHER ."	colestipol hydrochloride	sodium polystyrene sulfonate		
other	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUGOTHER ,  DRUGOTHER  resin,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUG2 ."	colestipol hydrochloride	sucralfate		O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O
other	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUGOTHER ,  DRUGOTHER  resin,  DRUGOTHER ,  DRUG1 ,  DRUG2 , soybean flour (e.g., infant formula),  DRUGOTHER ."	ferrous sulfate	sodium polystyrene sulfonate	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1	
other	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUGOTHER ,  DRUGOTHER  resin,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , soybean flour (e.g., infant formula),  DRUG2 ."	ferrous sulfate	sucralfate	OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1	O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O
other	" DRUGOTHER  Absorption: The following agents may bind and decrease absorption of  DRUGOTHER  from the gastrointestinal tract:  DRUGOTHER ,  DRUGOTHER  resin,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , soybean flour (e.g., infant formula),  DRUG2 ."	sodium polystyrene sulfonate	sucralfate		O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG2  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levothyroxine sodium	androgens	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levothyroxine sodium	anabolic hormones	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levothyroxine sodium	asparaginase	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levothyroxine sodium	clofibrate	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levothyroxine sodium	estrogens	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levothyroxine sodium	estrogen-containing compounds	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levothyroxine sodium	5-fluorouracil	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	FC1=CNC(=O)NC1=O
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levothyroxine sodium	furosemide	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levothyroxine sodium	glucocorticoids	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levothyroxine sodium	meclofenamic acid	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levothyroxine sodium	mefenamic acid	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levothyroxine sodium	methadone	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levothyroxine sodium	perphenazine	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levothyroxine sodium	phenylbutazone	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	levothyroxine sodium	phenytoin	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	levothyroxine sodium	salicylates	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
mechanism	"Binding to Serum Proteins: The following agents may either inhibit  DRUG1  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	levothyroxine sodium	tamoxifen	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG1  and related  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	anabolic hormones	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG1  and related  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	asparaginase	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG1  and related  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	clofibrate	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG1  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	estrogens	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG1  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	estrogen-containing compounds	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG1  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	5-fluorouracil	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	FC1=CNC(=O)NC1=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG1  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	furosemide	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG1  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	glucocorticoids	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG1  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	meclofenamic acid	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG1  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	mefenamic acid	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG1  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	methadone	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG1  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	perphenazine	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG1  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	phenylbutazone	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG1  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	androgens	phenytoin	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG1  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	androgens	salicylates	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUG1  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	androgens	tamoxifen	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	anabolic hormones	asparaginase		
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	anabolic hormones	clofibrate		CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	anabolic hormones	estrogens		C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	anabolic hormones	estrogen-containing compounds		C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	anabolic hormones	5-fluorouracil		FC1=CNC(=O)NC1=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	anabolic hormones	furosemide		NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	anabolic hormones	glucocorticoids		COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	anabolic hormones	meclofenamic acid		CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	anabolic hormones	mefenamic acid		CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	anabolic hormones	methadone		CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	anabolic hormones	perphenazine		CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	anabolic hormones	phenylbutazone		[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	anabolic hormones	phenytoin		CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	anabolic hormones	salicylates		CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	anabolic hormones	tamoxifen		CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	asparaginase	clofibrate		CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	asparaginase	estrogens		C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	asparaginase	estrogen-containing compounds		C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	asparaginase	5-fluorouracil		FC1=CNC(=O)NC1=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	asparaginase	furosemide		NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	asparaginase	glucocorticoids		COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	asparaginase	meclofenamic acid		CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	asparaginase	mefenamic acid		CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	asparaginase	methadone		CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	asparaginase	perphenazine		CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	asparaginase	phenylbutazone		[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	asparaginase	phenytoin		CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	asparaginase	salicylates		CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	asparaginase	tamoxifen		CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	clofibrate	estrogens	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	clofibrate	estrogen-containing compounds	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	clofibrate	5-fluorouracil	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	FC1=CNC(=O)NC1=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	clofibrate	furosemide	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	clofibrate	glucocorticoids	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	clofibrate	meclofenamic acid	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	clofibrate	mefenamic acid	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	clofibrate	methadone	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	clofibrate	perphenazine	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	clofibrate	phenylbutazone	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	clofibrate	phenytoin	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	clofibrate	salicylates	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	clofibrate	tamoxifen	CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1	CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogens	estrogen-containing compounds	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogens	5-fluorouracil	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	FC1=CNC(=O)NC1=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogens	furosemide	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogens	glucocorticoids	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogens	meclofenamic acid	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogens	mefenamic acid	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogens	methadone	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogens	perphenazine	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogens	phenylbutazone	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	estrogens	phenytoin	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	estrogens	salicylates	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	estrogens	tamoxifen	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogen-containing compounds	5-fluorouracil	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	FC1=CNC(=O)NC1=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogen-containing compounds	furosemide	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogen-containing compounds	glucocorticoids	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogen-containing compounds	meclofenamic acid	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogen-containing compounds	mefenamic acid	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogen-containing compounds	methadone	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogen-containing compounds	perphenazine	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	estrogen-containing compounds	phenylbutazone	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	estrogen-containing compounds	phenytoin	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	estrogen-containing compounds	salicylates	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	estrogen-containing compounds	tamoxifen	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	5-fluorouracil	furosemide	FC1=CNC(=O)NC1=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	5-fluorouracil	glucocorticoids	FC1=CNC(=O)NC1=O	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	5-fluorouracil	meclofenamic acid	FC1=CNC(=O)NC1=O	CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	5-fluorouracil	mefenamic acid	FC1=CNC(=O)NC1=O	CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	5-fluorouracil	methadone	FC1=CNC(=O)NC1=O	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	5-fluorouracil	perphenazine	FC1=CNC(=O)NC1=O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	5-fluorouracil	phenylbutazone	FC1=CNC(=O)NC1=O	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	5-fluorouracil	phenytoin	FC1=CNC(=O)NC1=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	5-fluorouracil	salicylates	FC1=CNC(=O)NC1=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	5-fluorouracil	tamoxifen	FC1=CNC(=O)NC1=O	CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	furosemide	glucocorticoids	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	furosemide	meclofenamic acid	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	furosemide	mefenamic acid	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	furosemide	methadone	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	furosemide	perphenazine	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	furosemide	phenylbutazone	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	furosemide	phenytoin	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	furosemide	salicylates	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	furosemide	tamoxifen	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	meclofenamic acid	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	mefenamic acid	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	methadone	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	perphenazine	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	phenylbutazone	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	phenytoin	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	glucocorticoids	salicylates	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	glucocorticoids	tamoxifen	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	meclofenamic acid	mefenamic acid	CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1	CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	meclofenamic acid	methadone	CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	meclofenamic acid	perphenazine	CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	meclofenamic acid	phenylbutazone	CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	meclofenamic acid	phenytoin	CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	meclofenamic acid	salicylates	CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	meclofenamic acid	tamoxifen	CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1	CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	mefenamic acid	methadone	CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	mefenamic acid	perphenazine	CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	mefenamic acid	phenylbutazone	CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	mefenamic acid	phenytoin	CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	mefenamic acid	salicylates	CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	mefenamic acid	tamoxifen	CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1	CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	methadone	perphenazine	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	methadone	phenylbutazone	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	methadone	phenytoin	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	methadone	salicylates	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	methadone	tamoxifen	CCC(=O)C(CCN(C)C)(C1=CC=CC=C1)C1=CC=CC=C1	CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perphenazine	phenylbutazone	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	perphenazine	phenytoin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	perphenazine	salicylates	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	perphenazine	tamoxifen	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	phenylbutazone	phenytoin	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	phenylbutazone	salicylates	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	phenylbutazone	tamoxifen	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O	CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ."	phenytoin	salicylates	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ."	phenytoin	tamoxifen	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Binding to Serum Proteins: The following agents may either inhibit  DRUGOTHER  binding to serum proteins or alter the concentrations of serum binding proteins:  DRUGOTHER  and related  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ."	salicylates	tamoxifen	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	p-aminosalicylic acid	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	NC1=CC(O)=C(C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	amiodarone	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	androgens	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	thiocyanate	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	S=C=NCCC1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	perchlorate	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	[O-][Cl](=O)(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	pertechnetate	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	O.O.O.O.[98Tc-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	antithyroid drugs	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	b-adrenergic blocking agents	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	carbamazepine	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	chloral hydrate	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	diazepam	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	dopamine	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	dopamine agonists	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	NCCC1=CC(O)=C(O)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	ethionamide	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	CCC1=NC=CC(=C1)C(N)=S
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	glucocorticoids	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	heparin	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	insulin	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	iodine-containing compounds	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	levodopa	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	lovastatin	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	lithium	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	6-mercaptopurine	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	metoclopramide	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	mitotane	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	nitroprusside	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	phenobarbital	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	phenytoin	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	resorcinol	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	rifampin	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	somatostatin analogs	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	aminoglutethimide	sulfonamides	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	aminoglutethimide	sulfonylureas	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	aminoglutethimide	thiazide diuretics	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	amiodarone	NC1=CC(O)=C(C=C1)C(O)=O	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	androgens	NC1=CC(O)=C(C=C1)C(O)=O	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	thiocyanate	NC1=CC(O)=C(C=C1)C(O)=O	S=C=NCCC1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	perchlorate	NC1=CC(O)=C(C=C1)C(O)=O	[O-][Cl](=O)(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	pertechnetate	NC1=CC(O)=C(C=C1)C(O)=O	O.O.O.O.[98Tc-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	antithyroid drugs	NC1=CC(O)=C(C=C1)C(O)=O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	b-adrenergic blocking agents	NC1=CC(O)=C(C=C1)C(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	carbamazepine	NC1=CC(O)=C(C=C1)C(O)=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	chloral hydrate	NC1=CC(O)=C(C=C1)C(O)=O	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	diazepam	NC1=CC(O)=C(C=C1)C(O)=O	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	dopamine	NC1=CC(O)=C(C=C1)C(O)=O	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	dopamine agonists	NC1=CC(O)=C(C=C1)C(O)=O	NCCC1=CC(O)=C(O)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	ethionamide	NC1=CC(O)=C(C=C1)C(O)=O	CCC1=NC=CC(=C1)C(N)=S
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	glucocorticoids	NC1=CC(O)=C(C=C1)C(O)=O	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	heparin	NC1=CC(O)=C(C=C1)C(O)=O	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	insulin	NC1=CC(O)=C(C=C1)C(O)=O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	iodine-containing compounds	NC1=CC(O)=C(C=C1)C(O)=O	[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	levodopa	NC1=CC(O)=C(C=C1)C(O)=O	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	lovastatin	NC1=CC(O)=C(C=C1)C(O)=O	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	lithium	NC1=CC(O)=C(C=C1)C(O)=O	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	6-mercaptopurine	NC1=CC(O)=C(C=C1)C(O)=O	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	metoclopramide	NC1=CC(O)=C(C=C1)C(O)=O	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	mitotane	NC1=CC(O)=C(C=C1)C(O)=O	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	nitroprusside	NC1=CC(O)=C(C=C1)C(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	phenobarbital	NC1=CC(O)=C(C=C1)C(O)=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	phenytoin	NC1=CC(O)=C(C=C1)C(O)=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	resorcinol	NC1=CC(O)=C(C=C1)C(O)=O	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	rifampin	NC1=CC(O)=C(C=C1)C(O)=O	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	somatostatin analogs	NC1=CC(O)=C(C=C1)C(O)=O	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	p-aminosalicylic acid	sulfonamides	NC1=CC(O)=C(C=C1)C(O)=O	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	p-aminosalicylic acid	sulfonylureas	NC1=CC(O)=C(C=C1)C(O)=O	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	p-aminosalicylic acid	thiazide diuretics	NC1=CC(O)=C(C=C1)C(O)=O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	androgens	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	thiocyanate	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	S=C=NCCC1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	perchlorate	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	[O-][Cl](=O)(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	pertechnetate	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	O.O.O.O.[98Tc-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	antithyroid drugs	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	b-adrenergic blocking agents	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	carbamazepine	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	chloral hydrate	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	diazepam	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	dopamine	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	dopamine agonists	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	NCCC1=CC(O)=C(O)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	ethionamide	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CCC1=NC=CC(=C1)C(N)=S
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	glucocorticoids	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	heparin	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	insulin	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	iodine-containing compounds	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	levodopa	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	lovastatin	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	lithium	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	6-mercaptopurine	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	metoclopramide	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	mitotane	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	nitroprusside	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	phenobarbital	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	phenytoin	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	resorcinol	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	rifampin	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	somatostatin analogs	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	amiodarone	sulfonamides	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	amiodarone	sulfonylureas	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	amiodarone	thiazide diuretics	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	thiocyanate	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	S=C=NCCC1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	perchlorate	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	[O-][Cl](=O)(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	pertechnetate	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	O.O.O.O.[98Tc-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	antithyroid drugs	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	b-adrenergic blocking agents	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	carbamazepine	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	chloral hydrate	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	diazepam	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	dopamine	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	dopamine agonists	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	NCCC1=CC(O)=C(O)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	ethionamide	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CCC1=NC=CC(=C1)C(N)=S
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	glucocorticoids	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	heparin	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	insulin	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	iodine-containing compounds	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	levodopa	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	lovastatin	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	lithium	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	6-mercaptopurine	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	metoclopramide	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	mitotane	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	nitroprusside	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	phenobarbital	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	phenytoin	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	resorcinol	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	rifampin	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	androgens	somatostatin analogs	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	androgens	sulfonamides	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	androgens	sulfonylureas	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	androgens	thiazide diuretics	C[C@]12CC[C@H]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	perchlorate	S=C=NCCC1=CC=CC=C1	[O-][Cl](=O)(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	pertechnetate	S=C=NCCC1=CC=CC=C1	O.O.O.O.[98Tc-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	antithyroid drugs	S=C=NCCC1=CC=CC=C1	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	b-adrenergic blocking agents	S=C=NCCC1=CC=CC=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	carbamazepine	S=C=NCCC1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	chloral hydrate	S=C=NCCC1=CC=CC=C1	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	diazepam	S=C=NCCC1=CC=CC=C1	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	dopamine	S=C=NCCC1=CC=CC=C1	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	dopamine agonists	S=C=NCCC1=CC=CC=C1	NCCC1=CC(O)=C(O)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	ethionamide	S=C=NCCC1=CC=CC=C1	CCC1=NC=CC(=C1)C(N)=S
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	glucocorticoids	S=C=NCCC1=CC=CC=C1	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	heparin	S=C=NCCC1=CC=CC=C1	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	insulin	S=C=NCCC1=CC=CC=C1	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	iodine-containing compounds	S=C=NCCC1=CC=CC=C1	[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	levodopa	S=C=NCCC1=CC=CC=C1	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	lovastatin	S=C=NCCC1=CC=CC=C1	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	lithium	S=C=NCCC1=CC=CC=C1	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	6-mercaptopurine	S=C=NCCC1=CC=CC=C1	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	metoclopramide	S=C=NCCC1=CC=CC=C1	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	mitotane	S=C=NCCC1=CC=CC=C1	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	nitroprusside	S=C=NCCC1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	phenobarbital	S=C=NCCC1=CC=CC=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	phenytoin	S=C=NCCC1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	resorcinol	S=C=NCCC1=CC=CC=C1	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	rifampin	S=C=NCCC1=CC=CC=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	somatostatin analogs	S=C=NCCC1=CC=CC=C1	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	thiocyanate	sulfonamides	S=C=NCCC1=CC=CC=C1	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	thiocyanate	sulfonylureas	S=C=NCCC1=CC=CC=C1	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	thiocyanate	thiazide diuretics	S=C=NCCC1=CC=CC=C1	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	pertechnetate	[O-][Cl](=O)(=O)=O	O.O.O.O.[98Tc-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	antithyroid drugs	[O-][Cl](=O)(=O)=O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	b-adrenergic blocking agents	[O-][Cl](=O)(=O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	carbamazepine	[O-][Cl](=O)(=O)=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	chloral hydrate	[O-][Cl](=O)(=O)=O	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	diazepam	[O-][Cl](=O)(=O)=O	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	dopamine	[O-][Cl](=O)(=O)=O	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	dopamine agonists	[O-][Cl](=O)(=O)=O	NCCC1=CC(O)=C(O)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	ethionamide	[O-][Cl](=O)(=O)=O	CCC1=NC=CC(=C1)C(N)=S
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	glucocorticoids	[O-][Cl](=O)(=O)=O	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	heparin	[O-][Cl](=O)(=O)=O	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	insulin	[O-][Cl](=O)(=O)=O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	iodine-containing compounds	[O-][Cl](=O)(=O)=O	[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	levodopa	[O-][Cl](=O)(=O)=O	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	lovastatin	[O-][Cl](=O)(=O)=O	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	lithium	[O-][Cl](=O)(=O)=O	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	6-mercaptopurine	[O-][Cl](=O)(=O)=O	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	metoclopramide	[O-][Cl](=O)(=O)=O	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	mitotane	[O-][Cl](=O)(=O)=O	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	nitroprusside	[O-][Cl](=O)(=O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	phenobarbital	[O-][Cl](=O)(=O)=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	phenytoin	[O-][Cl](=O)(=O)=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	resorcinol	[O-][Cl](=O)(=O)=O	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	rifampin	[O-][Cl](=O)(=O)=O	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	somatostatin analogs	[O-][Cl](=O)(=O)=O	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	perchlorate	sulfonamides	[O-][Cl](=O)(=O)=O	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	perchlorate	sulfonylureas	[O-][Cl](=O)(=O)=O	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	perchlorate	thiazide diuretics	[O-][Cl](=O)(=O)=O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	antithyroid drugs	O.O.O.O.[98Tc-]	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	b-adrenergic blocking agents	O.O.O.O.[98Tc-]	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	carbamazepine	O.O.O.O.[98Tc-]	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	chloral hydrate	O.O.O.O.[98Tc-]	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	diazepam	O.O.O.O.[98Tc-]	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	dopamine	O.O.O.O.[98Tc-]	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	dopamine agonists	O.O.O.O.[98Tc-]	NCCC1=CC(O)=C(O)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	ethionamide	O.O.O.O.[98Tc-]	CCC1=NC=CC(=C1)C(N)=S
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	glucocorticoids	O.O.O.O.[98Tc-]	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	heparin	O.O.O.O.[98Tc-]	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	insulin	O.O.O.O.[98Tc-]	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	iodine-containing compounds	O.O.O.O.[98Tc-]	[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	levodopa	O.O.O.O.[98Tc-]	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	lovastatin	O.O.O.O.[98Tc-]	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	lithium	O.O.O.O.[98Tc-]	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	6-mercaptopurine	O.O.O.O.[98Tc-]	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	metoclopramide	O.O.O.O.[98Tc-]	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	mitotane	O.O.O.O.[98Tc-]	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	nitroprusside	O.O.O.O.[98Tc-]	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	phenobarbital	O.O.O.O.[98Tc-]	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	phenytoin	O.O.O.O.[98Tc-]	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	resorcinol	O.O.O.O.[98Tc-]	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	rifampin	O.O.O.O.[98Tc-]	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	somatostatin analogs	O.O.O.O.[98Tc-]	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	pertechnetate	sulfonamides	O.O.O.O.[98Tc-]	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	pertechnetate	sulfonylureas	O.O.O.O.[98Tc-]	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	pertechnetate	thiazide diuretics	O.O.O.O.[98Tc-]	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	b-adrenergic blocking agents		CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	carbamazepine		NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	chloral hydrate		CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	diazepam		CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	dopamine		[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	dopamine agonists		NCCC1=CC(O)=C(O)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	ethionamide		CCC1=NC=CC(=C1)C(N)=S
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	glucocorticoids		COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	heparin		[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	insulin		
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	iodine-containing compounds		[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	levodopa		N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	lovastatin		[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	lithium		[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	6-mercaptopurine		S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	metoclopramide		OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	mitotane		ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	nitroprusside		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	phenobarbital		CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	phenytoin		CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	resorcinol		OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	rifampin		CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	somatostatin analogs		C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	antithyroid drugs	sulfonamides		OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	antithyroid drugs	sulfonylureas		NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	antithyroid drugs	thiazide diuretics		
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	carbamazepine	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	chloral hydrate	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	diazepam	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	dopamine	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	dopamine agonists	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	NCCC1=CC(O)=C(O)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	ethionamide	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCC1=NC=CC(=C1)C(N)=S
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	glucocorticoids	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	heparin	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	insulin	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	iodine-containing compounds	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	levodopa	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	lovastatin	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	lithium	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	6-mercaptopurine	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	metoclopramide	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	mitotane	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	nitroprusside	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	phenobarbital	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	phenytoin	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	resorcinol	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	rifampin	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	somatostatin analogs	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	b-adrenergic blocking agents	sulfonamides	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	b-adrenergic blocking agents	sulfonylureas	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	b-adrenergic blocking agents	thiazide diuretics	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	chloral hydrate	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	diazepam	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	dopamine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	dopamine agonists	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NCCC1=CC(O)=C(O)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	ethionamide	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CCC1=NC=CC(=C1)C(N)=S
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	glucocorticoids	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	heparin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	insulin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	iodine-containing compounds	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	levodopa	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	lovastatin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	lithium	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	6-mercaptopurine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	metoclopramide	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	mitotane	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	nitroprusside	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	phenobarbital	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	phenytoin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	resorcinol	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	rifampin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	somatostatin analogs	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	carbamazepine	sulfonamides	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	carbamazepine	sulfonylureas	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	carbamazepine	thiazide diuretics	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	diazepam	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	dopamine	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	dopamine agonists	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	NCCC1=CC(O)=C(O)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	ethionamide	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	CCC1=NC=CC(=C1)C(N)=S
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	glucocorticoids	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	heparin	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	insulin	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	iodine-containing compounds	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	levodopa	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	lovastatin	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	lithium	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	6-mercaptopurine	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	metoclopramide	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	mitotane	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	nitroprusside	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	phenobarbital	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	phenytoin	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	resorcinol	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	rifampin	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	somatostatin analogs	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	chloral hydrate	sulfonamides	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	chloral hydrate	sulfonylureas	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	chloral hydrate	thiazide diuretics	CC(CC(C)(C)O)OC(O)C(Cl)(Cl)Cl	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	dopamine	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	dopamine agonists	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	NCCC1=CC(O)=C(O)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	ethionamide	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CCC1=NC=CC(=C1)C(N)=S
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	glucocorticoids	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	heparin	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	insulin	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	iodine-containing compounds	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	levodopa	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	lovastatin	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	lithium	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	6-mercaptopurine	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	metoclopramide	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	mitotane	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	nitroprusside	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	phenobarbital	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	phenytoin	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	resorcinol	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	rifampin	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	somatostatin analogs	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	diazepam	sulfonamides	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	diazepam	sulfonylureas	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	diazepam	thiazide diuretics	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	dopamine agonists	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	NCCC1=CC(O)=C(O)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	ethionamide	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	CCC1=NC=CC(=C1)C(N)=S
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	glucocorticoids	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	heparin	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	insulin	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	iodine-containing compounds	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	levodopa	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	lovastatin	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	lithium	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	6-mercaptopurine	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	metoclopramide	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	mitotane	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	nitroprusside	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	phenobarbital	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	phenytoin	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	resorcinol	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	rifampin	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	somatostatin analogs	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	dopamine	sulfonamides	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	dopamine	sulfonylureas	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	dopamine	thiazide diuretics	[Br-].[H][C@]12C[C@@H](C[C@@]([H])(C3OC13)[N+]2(C)C)OC(=O)[C@H](CO)C1=CC=CC=C1	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	ethionamide	NCCC1=CC(O)=C(O)C=C1	CCC1=NC=CC(=C1)C(N)=S
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	glucocorticoids	NCCC1=CC(O)=C(O)C=C1	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	heparin	NCCC1=CC(O)=C(O)C=C1	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	insulin	NCCC1=CC(O)=C(O)C=C1	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	iodine-containing compounds	NCCC1=CC(O)=C(O)C=C1	[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	levodopa	NCCC1=CC(O)=C(O)C=C1	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	lovastatin	NCCC1=CC(O)=C(O)C=C1	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	lithium	NCCC1=CC(O)=C(O)C=C1	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	6-mercaptopurine	NCCC1=CC(O)=C(O)C=C1	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	metoclopramide	NCCC1=CC(O)=C(O)C=C1	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	mitotane	NCCC1=CC(O)=C(O)C=C1	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	nitroprusside	NCCC1=CC(O)=C(O)C=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	phenobarbital	NCCC1=CC(O)=C(O)C=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	phenytoin	NCCC1=CC(O)=C(O)C=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	resorcinol	NCCC1=CC(O)=C(O)C=C1	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	rifampin	NCCC1=CC(O)=C(O)C=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	somatostatin analogs	NCCC1=CC(O)=C(O)C=C1	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	dopamine agonists	sulfonamides	NCCC1=CC(O)=C(O)C=C1	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	dopamine agonists	sulfonylureas	NCCC1=CC(O)=C(O)C=C1	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	dopamine agonists	thiazide diuretics	NCCC1=CC(O)=C(O)C=C1	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	glucocorticoids	CCC1=NC=CC(=C1)C(N)=S	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	heparin	CCC1=NC=CC(=C1)C(N)=S	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	insulin	CCC1=NC=CC(=C1)C(N)=S	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	iodine-containing compounds	CCC1=NC=CC(=C1)C(N)=S	[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	levodopa	CCC1=NC=CC(=C1)C(N)=S	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	lovastatin	CCC1=NC=CC(=C1)C(N)=S	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	lithium	CCC1=NC=CC(=C1)C(N)=S	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	6-mercaptopurine	CCC1=NC=CC(=C1)C(N)=S	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	metoclopramide	CCC1=NC=CC(=C1)C(N)=S	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	mitotane	CCC1=NC=CC(=C1)C(N)=S	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	nitroprusside	CCC1=NC=CC(=C1)C(N)=S	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	phenobarbital	CCC1=NC=CC(=C1)C(N)=S	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	phenytoin	CCC1=NC=CC(=C1)C(N)=S	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	resorcinol	CCC1=NC=CC(=C1)C(N)=S	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	rifampin	CCC1=NC=CC(=C1)C(N)=S	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	somatostatin analogs	CCC1=NC=CC(=C1)C(N)=S	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	ethionamide	sulfonamides	CCC1=NC=CC(=C1)C(N)=S	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	ethionamide	sulfonylureas	CCC1=NC=CC(=C1)C(N)=S	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	ethionamide	thiazide diuretics	CCC1=NC=CC(=C1)C(N)=S	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	heparin	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	insulin	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	iodine-containing compounds	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	levodopa	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	lovastatin	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	lithium	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	6-mercaptopurine	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	metoclopramide	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	mitotane	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	nitroprusside	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	phenobarbital	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	phenytoin	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	resorcinol	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	rifampin	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	somatostatin analogs	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	glucocorticoids	sulfonamides	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	glucocorticoids	sulfonylureas	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	glucocorticoids	thiazide diuretics	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUG2 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	heparin	insulin	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	heparin	iodine-containing compounds	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	heparin	levodopa	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	heparin	lovastatin	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	heparin	lithium	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	heparin	6-mercaptopurine	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	heparin	metoclopramide	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	heparin	mitotane	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	heparin	nitroprusside	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	heparin	phenobarbital	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	heparin	phenytoin	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	heparin	resorcinol	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	heparin	rifampin	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	heparin	somatostatin analogs	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	heparin	sulfonamides	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	heparin	sulfonylureas	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	heparin	thiazide diuretics	[H][C@]1(O)O[C@]([H])(COS([O-])(=O)=O)[C@@]([H])(O[C@]2([H])OC(=C[C@]([H])(O)[C@@]2([H])OS([O-])(=O)=O)C([O-])=O)[C@]([H])(O)[C@@]1([H])NS([O-])(=O)=O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG1 , iodinated cholestographic agents,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	insulin	iodine-containing compounds		[Na+].[I-]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG1 , iodinated cholestographic agents,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	insulin	levodopa		N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG1 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	insulin	lovastatin		[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG1 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	insulin	lithium		[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG1 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	insulin	6-mercaptopurine		S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG1 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	insulin	metoclopramide		OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG1 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	insulin	mitotane		ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG1 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	insulin	nitroprusside		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG1 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	insulin	phenobarbital		CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG1 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	insulin	phenytoin		CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG1 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	insulin	resorcinol		OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG1 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	insulin	rifampin		CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG1 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	insulin	somatostatin analogs		C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG1 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	insulin	sulfonamides		OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG1 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	insulin	sulfonylureas		NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUG1 , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	insulin	thiazide diuretics		
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	iodine-containing compounds	levodopa	[Na+].[I-]	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	iodine-containing compounds	lovastatin	[Na+].[I-]	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	iodine-containing compounds	lithium	[Na+].[I-]	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	iodine-containing compounds	6-mercaptopurine	[Na+].[I-]	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	iodine-containing compounds	metoclopramide	[Na+].[I-]	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	iodine-containing compounds	mitotane	[Na+].[I-]	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	iodine-containing compounds	nitroprusside	[Na+].[I-]	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	iodine-containing compounds	phenobarbital	[Na+].[I-]	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	iodine-containing compounds	phenytoin	[Na+].[I-]	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	iodine-containing compounds	resorcinol	[Na+].[I-]	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	iodine-containing compounds	rifampin	[Na+].[I-]	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	iodine-containing compounds	somatostatin analogs	[Na+].[I-]	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	iodine-containing compounds	sulfonamides	[Na+].[I-]	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	iodine-containing compounds	sulfonylureas	[Na+].[I-]	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	iodine-containing compounds	thiazide diuretics	[Na+].[I-]	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levodopa	lovastatin	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levodopa	lithium	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levodopa	6-mercaptopurine	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levodopa	metoclopramide	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levodopa	mitotane	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levodopa	nitroprusside	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levodopa	phenobarbital	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levodopa	phenytoin	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levodopa	resorcinol	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levodopa	rifampin	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	levodopa	somatostatin analogs	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	levodopa	sulfonamides	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	levodopa	sulfonylureas	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	levodopa	thiazide diuretics	N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lovastatin	lithium	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	[Li+]
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lovastatin	6-mercaptopurine	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lovastatin	metoclopramide	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lovastatin	mitotane	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lovastatin	nitroprusside	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lovastatin	phenobarbital	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lovastatin	phenytoin	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lovastatin	resorcinol	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lovastatin	rifampin	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lovastatin	somatostatin analogs	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	lovastatin	sulfonamides	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	lovastatin	sulfonylureas	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	lovastatin	thiazide diuretics	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lithium	6-mercaptopurine	[Li+]	S=C1N=CNC2=C1NC=N2
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lithium	metoclopramide	[Li+]	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lithium	mitotane	[Li+]	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lithium	nitroprusside	[Li+]	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lithium	phenobarbital	[Li+]	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lithium	phenytoin	[Li+]	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lithium	resorcinol	[Li+]	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lithium	rifampin	[Li+]	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	lithium	somatostatin analogs	[Li+]	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	lithium	sulfonamides	[Li+]	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	lithium	sulfonylureas	[Li+]	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	lithium	thiazide diuretics	[Li+]	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	6-mercaptopurine	metoclopramide	S=C1N=CNC2=C1NC=N2	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	6-mercaptopurine	mitotane	S=C1N=CNC2=C1NC=N2	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	6-mercaptopurine	nitroprusside	S=C1N=CNC2=C1NC=N2	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	6-mercaptopurine	phenobarbital	S=C1N=CNC2=C1NC=N2	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	6-mercaptopurine	phenytoin	S=C1N=CNC2=C1NC=N2	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	6-mercaptopurine	resorcinol	S=C1N=CNC2=C1NC=N2	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	6-mercaptopurine	rifampin	S=C1N=CNC2=C1NC=N2	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	6-mercaptopurine	somatostatin analogs	S=C1N=CNC2=C1NC=N2	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	6-mercaptopurine	sulfonamides	S=C1N=CNC2=C1NC=N2	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	6-mercaptopurine	sulfonylureas	S=C1N=CNC2=C1NC=N2	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	6-mercaptopurine	thiazide diuretics	S=C1N=CNC2=C1NC=N2	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	metoclopramide	mitotane	OC(=O)CCCCCCCC(O)=O	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	metoclopramide	nitroprusside	OC(=O)CCCCCCCC(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	metoclopramide	phenobarbital	OC(=O)CCCCCCCC(O)=O	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	metoclopramide	phenytoin	OC(=O)CCCCCCCC(O)=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	metoclopramide	resorcinol	OC(=O)CCCCCCCC(O)=O	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	metoclopramide	rifampin	OC(=O)CCCCCCCC(O)=O	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	metoclopramide	somatostatin analogs	OC(=O)CCCCCCCC(O)=O	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	metoclopramide	sulfonamides	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	metoclopramide	sulfonylureas	OC(=O)CCCCCCCC(O)=O	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	metoclopramide	thiazide diuretics	OC(=O)CCCCCCCC(O)=O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	mitotane	nitroprusside	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	mitotane	phenobarbital	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	mitotane	phenytoin	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	mitotane	resorcinol	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	mitotane	rifampin	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	mitotane	somatostatin analogs	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	mitotane	sulfonamides	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	mitotane	sulfonylureas	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	mitotane	thiazide diuretics	ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=CC=CC=C1Cl	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	nitroprusside	phenobarbital	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	nitroprusside	phenytoin	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	nitroprusside	resorcinol	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	nitroprusside	rifampin	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	nitroprusside	somatostatin analogs	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	nitroprusside	sulfonamides	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	nitroprusside	sulfonylureas	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	nitroprusside	thiazide diuretics	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	phenobarbital	phenytoin	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	phenobarbital	resorcinol	CCC1(CC)C(=O)NC(=O)NC1=O	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	phenobarbital	rifampin	CCC1(CC)C(=O)NC(=O)NC1=O	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	phenobarbital	somatostatin analogs	CCC1(CC)C(=O)NC(=O)NC1=O	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	phenobarbital	sulfonamides	CCC1(CC)C(=O)NC(=O)NC1=O	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	phenobarbital	sulfonylureas	CCC1(CC)C(=O)NC(=O)NC1=O	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	phenobarbital	thiazide diuretics	CCC1(CC)C(=O)NC(=O)NC1=O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	phenytoin	resorcinol	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	OC1=CC(O)=CC=C1
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	phenytoin	rifampin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	phenytoin	somatostatin analogs	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	phenytoin	sulfonamides	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	phenytoin	sulfonylureas	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	phenytoin	thiazide diuretics	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	resorcinol	rifampin	OC1=CC(O)=CC=C1	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	resorcinol	somatostatin analogs	OC1=CC(O)=CC=C1	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	resorcinol	sulfonamides	OC1=CC(O)=CC=C1	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	resorcinol	sulfonylureas	OC1=CC(O)=CC=C1	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	resorcinol	thiazide diuretics	OC1=CC(O)=CC=C1	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ."	rifampin	somatostatin analogs	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	rifampin	sulfonamides	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	rifampin	sulfonylureas	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	rifampin	thiazide diuretics	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ."	somatostatin analogs	sulfonamides	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O	OC(=O)CCCCCCCC(O)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ."	somatostatin analogs	sulfonylureas	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ."	somatostatin analogs	thiazide diuretics	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ."	sulfonamides	sulfonylureas	OC(=O)CCCCCCCC(O)=O	NC(N)=O
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ."	sulfonamides	thiazide diuretics	OC(=O)CCCCCCCC(O)=O	
other	"Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and related anabolic hormones, complex anions ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , hepatic enzyme inducers,  DRUGOTHER , iodinated cholestographic agents,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ."	sulfonylureas	thiazide diuretics	NC(N)=O	
other	 DRUG1 :  DRUG2  therapy alone can cause hypothyroidism or hyperthyroidism.	Amiodarone	Amiodarone	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	" DRUG1  (Oral): The hypoprothrombinemic effect of  DRUG2  may be potentiated, apparently by increased catabloism of vitamin K-dependent clotting factors."	Anticoagulants	anticoagulants		
other	" DRUG1  ( DRUG2 ,  DRUGOTHER ): Requirements for  DRUGOTHER  or oral  DRUGOTHER  may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy."	Antidiabetic Agents	Insulin	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	
other	" DRUG1  ( DRUGOTHER ,  DRUG2 ): Requirements for  DRUGOTHER  or oral  DRUGOTHER  may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy."	Antidiabetic Agents	Sulfonylureas	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	NC(N)=O
other	" DRUG1  ( DRUGOTHER ,  DRUGOTHER ): Requirements for  DRUG2  or oral  DRUGOTHER  may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy."	Antidiabetic Agents	insulin	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	
other	" DRUG1  ( DRUGOTHER ,  DRUGOTHER ): Requirements for  DRUGOTHER  or oral  DRUG2  may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy."	Antidiabetic Agents	antidiabetic agents	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	" DRUGOTHER  ( DRUG1 ,  DRUG2 ): Requirements for  DRUGOTHER  or oral  DRUGOTHER  may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy."	Insulin	Sulfonylureas		NC(N)=O
other	" DRUGOTHER  ( DRUG1 ,  DRUGOTHER ): Requirements for  DRUG2  or oral  DRUGOTHER  may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy."	Insulin	insulin		
other	" DRUGOTHER  ( DRUG1 ,  DRUGOTHER ): Requirements for  DRUGOTHER  or oral  DRUG2  may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy."	Insulin	antidiabetic agents		CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	" DRUGOTHER  ( DRUGOTHER ,  DRUG1 ): Requirements for  DRUG2  or oral  DRUGOTHER  may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy."	Sulfonylureas	insulin	NC(N)=O	
other	" DRUGOTHER  ( DRUGOTHER ,  DRUG1 ): Requirements for  DRUGOTHER  or oral  DRUG2  may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy."	Sulfonylureas	antidiabetic agents	NC(N)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	" DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ): Requirements for  DRUG1  or oral  DRUG2  may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy."	insulin	antidiabetic agents		CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	 DRUG1 : Actions of some of  DRUG2  may be impaired when hypothyroid patients become euthyroid.	b-Adrenergic Blocking Agents	beta-blocking agents	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	" DRUG1  ( DRUG2 ,  DRUGOTHER ):  DRUGOTHER  have been reported to induce both hyperthyroidism and hypothyroidism."	Cytokines	interferon		
other	" DRUG1  ( DRUGOTHER ,  DRUG2 ):  DRUGOTHER  have been reported to induce both hyperthyroidism and hypothyroidism."	Cytokines	interleukin		
other	" DRUG1  ( DRUGOTHER ,  DRUGOTHER ):  DRUG2  have been reported to induce both hyperthyroidism and hypothyroidism."	Cytokines	Cytokines		
other	" DRUGOTHER  ( DRUG1 ,  DRUG2 ):  DRUGOTHER  have been reported to induce both hyperthyroidism and hypothyroidism."	interferon	interleukin		
other	" DRUGOTHER  ( DRUG1 ,  DRUGOTHER ):  DRUG2  have been reported to induce both hyperthyroidism and hypothyroidism."	interferon	Cytokines		
other	" DRUGOTHER  ( DRUGOTHER ,  DRUG1 ):  DRUG2  have been reported to induce both hyperthyroidism and hypothyroidism."	interleukin	Cytokines		
other	 DRUG1 : Therapeutic effects of  DRUG2  may be reduced.	Digitalis Glycosides	digitalis glycosides	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	 DRUG1 : Marked hypertension and tachycardia have been reported in association with concomitant administration of  DRUG2  and  DRUGOTHER .	Ketamine	levothyroxine sodium	CN[C@@]1(CCCCC1=O)C1=CC=CC=C1Cl	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
other	 DRUG1 : Marked hypertension and tachycardia have been reported in association with concomitant administration of  DRUGOTHER  and  DRUG2 .	Ketamine	ketamine	CN[C@@]1(CCCCC1=O)C1=CC=CC=C1Cl	CN[C@@]1(CCCCC1=O)C1=CC=CC=C1Cl
effect	 DRUGOTHER : Marked hypertension and tachycardia have been reported in association with concomitant administration of  DRUG1  and  DRUG2 .	levothyroxine sodium	ketamine	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O	CN[C@@]1(CCCCC1=O)C1=CC=CC=C1Cl
other	" DRUG1  (123I and 131I),  DRUG2 : Uptake of radiolabeled ions may be decreased."	Sodium Iodide	Sodium Pertechnetate Tc99m	[123I-]	
other	 DRUG1 / DRUG2 : Excessive concurrent use of  DRUGOTHER  may accelerate epiphyseal closure.	Somatrem	Somatropin		
other	 DRUG1 / DRUGOTHER : Excessive concurrent use of  DRUG2  may accelerate epiphyseal closure.	Somatrem	thyroid hormone		
other	 DRUGOTHER / DRUG1 : Excessive concurrent use of  DRUG2  may accelerate epiphyseal closure.	Somatropin	thyroid hormone		
other	Untreated hypothyroidism may interfere with the growth response to  DRUG1  or  DRUG2 .	somatrem	somatropin		
other	 DRUG1 :  DRUG2  clearance may decrease in hypothyroid patients and return toward normal when a euthyroid state is achieved.	Theophylline	Theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
advise	"Because the  DRUG1  have been shown to depress plasma prothrombin activity, patients who are on  DRUG2  therapy may require downward adjustment of their  DRUGOTHER  dosage."	tetracyclines	anticoagulant	[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
other	"Because the  DRUG1  have been shown to depress plasma prothrombin activity, patients who are on  DRUGOTHER  therapy may require downward adjustment of their  DRUG2  dosage."	tetracyclines	anticoagulant	[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
other	"Because the  DRUGOTHER  have been shown to depress plasma prothrombin activity, patients who are on  DRUG1  therapy may require downward adjustment of their  DRUG2  dosage."	anticoagulant	anticoagulant	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
other	"Since bacteriostatic drugs, such as the  DRUG1  of  DRUG2 , may interfere with the bactericidal action of  DRUGOTHER , it is not advisable to administer these drugs concomitantly."	tetracycline class	antibiotics	[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
effect	"Since bacteriostatic drugs, such as the  DRUG1  of  DRUGOTHER , may interfere with the bactericidal action of  DRUG2 , it is not advisable to administer these drugs concomitantly."	tetracycline class	penicillins	[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Since bacteriostatic drugs, such as the  DRUGOTHER  of  DRUG1 , may interfere with the bactericidal action of  DRUG2 , it is not advisable to administer these drugs concomitantly."	antibiotics	penicillins	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
effect	Concurrent use of  DRUG1  with oral  DRUG2  may render oral  DRUGOTHER  less effective.	tetracyclines	contraceptives	[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	Concurrent use of  DRUG1  with oral  DRUGOTHER  may render oral  DRUG2  less effective.	tetracyclines	contraceptives	[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	Concurrent use of  DRUGOTHER  with oral  DRUG1  may render oral  DRUG2  less effective.	contraceptives	contraceptives	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
other	 DRUG1  - Concomitant use of  DRUG2  and  DRUGOTHER  may enhance nutrient absorption in those with severe short bowel syndrome.	Human growth hormone	L-glutamine	OCC(O)CO	N[C@@H](CCC(N)=O)C(O)=O
other	 DRUG1  - Concomitant use of  DRUGOTHER  and  DRUG2  may enhance nutrient absorption in those with severe short bowel syndrome.	Human growth hormone	human growth hormone	OCC(O)CO	OCC(O)CO
mechanism	 DRUGOTHER  - Concomitant use of  DRUG1  and  DRUG2  may enhance nutrient absorption in those with severe short bowel syndrome.	L-glutamine	human growth hormone	N[C@@H](CCC(N)=O)C(O)=O	OCC(O)CO
other	 DRUG1  - Concomitant use of  DRUG2  and  DRUGOTHER  may ameliorate increased intestinal permeability caused by  DRUGOTHER .	Indomethacin	L-glutamine	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	N[C@@H](CCC(N)=O)C(O)=O
other	 DRUG1  - Concomitant use of  DRUGOTHER  and  DRUG2  may ameliorate increased intestinal permeability caused by  DRUGOTHER .	Indomethacin	indomethacin	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	 DRUG1  - Concomitant use of  DRUGOTHER  and  DRUGOTHER  may ameliorate increased intestinal permeability caused by  DRUG2 .	Indomethacin	indomethacin	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
effect	 DRUGOTHER  - Concomitant use of  DRUG1  and  DRUG2  may ameliorate increased intestinal permeability caused by  DRUGOTHER .	L-glutamine	indomethacin	N[C@@H](CCC(N)=O)C(O)=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	 DRUGOTHER  - Concomitant use of  DRUG1  and  DRUGOTHER  may ameliorate increased intestinal permeability caused by  DRUG2 .	L-glutamine	indomethacin	N[C@@H](CCC(N)=O)C(O)=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	 DRUGOTHER  - Concomitant use of  DRUGOTHER  and  DRUG1  may ameliorate increased intestinal permeability caused by  DRUG2 .	indomethacin	indomethacin	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
other	 DRUG1  - There is one report that  DRUG2  may decrease the possible effectiveness of supplemental  DRUGOTHER  for chemotherapy-induced mucositis.	Methotrexate	methotrexate	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
other	 DRUG1  - There is one report that  DRUGOTHER  may decrease the possible effectiveness of supplemental  DRUG2  for chemotherapy-induced mucositis.	Methotrexate	L-glutamine	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	N[C@@H](CCC(N)=O)C(O)=O
effect	 DRUGOTHER  - There is one report that  DRUG1  may decrease the possible effectiveness of supplemental  DRUG2  for chemotherapy-induced mucositis.	methotrexate	L-glutamine	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	N[C@@H](CCC(N)=O)C(O)=O
effect	"In another report, nine patients with breast cancer were reported to have decreased symptoms of  DRUG1 -related toxicity when given supplemental  DRUG2  at a dose of 0.5 gram/kilogram/day."	methotrexate	L-glutamine	CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	N[C@@H](CCC(N)=O)C(O)=O
other	" DRUG1  - In one report,  DRUG2  at a dose of 10 grams three times daily, given 24 hours after receiving  DRUGOTHER , appeared to prevent the development of myalgia and arthralgia, adverse reactions of  DRUGOTHER ."	Paclitaxel	L-glutamine	COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1	N[C@@H](CCC(N)=O)C(O)=O
other	" DRUG1  - In one report,  DRUGOTHER  at a dose of 10 grams three times daily, given 24 hours after receiving  DRUG2 , appeared to prevent the development of myalgia and arthralgia, adverse reactions of  DRUGOTHER ."	Paclitaxel	paclitaxel	COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1	COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1
other	" DRUG1  - In one report,  DRUGOTHER  at a dose of 10 grams three times daily, given 24 hours after receiving  DRUGOTHER , appeared to prevent the development of myalgia and arthralgia, adverse reactions of  DRUG2 ."	Paclitaxel	paclitaxel	COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1	COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1
effect	" DRUGOTHER  - In one report,  DRUG1  at a dose of 10 grams three times daily, given 24 hours after receiving  DRUG2 , appeared to prevent the development of myalgia and arthralgia, adverse reactions of  DRUGOTHER ."	L-glutamine	paclitaxel	N[C@@H](CCC(N)=O)C(O)=O	COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1
other	" DRUGOTHER  - In one report,  DRUG1  at a dose of 10 grams three times daily, given 24 hours after receiving  DRUGOTHER , appeared to prevent the development of myalgia and arthralgia, adverse reactions of  DRUG2 ."	L-glutamine	paclitaxel	N[C@@H](CCC(N)=O)C(O)=O	COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1
other	" DRUGOTHER  - In one report,  DRUGOTHER  at a dose of 10 grams three times daily, given 24 hours after receiving  DRUG1 , appeared to prevent the development of myalgia and arthralgia, adverse reactions of  DRUG2 ."	paclitaxel	paclitaxel	COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1	COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1
advise	"If you are also using a  DRUG1  inhaler, take  DRUG2  first and then wait about 15 minutes before using the  DRUGOTHER  inhaler."	steroid	bitolterol	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	CC1=CC=C(C=C1)C(=O)OC1=C(OC(=O)C2=CC=C(C)C=C2)C=C(C=C1)C(O)CNC(C)(C)C
other	"If you are also using a  DRUG1  inhaler, take  DRUGOTHER  first and then wait about 15 minutes before using the  DRUG2  inhaler."	steroid	steroid	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
advise	"If you are also using a  DRUGOTHER  inhaler, take  DRUG1  first and then wait about 15 minutes before using the  DRUG2  inhaler."	bitolterol	steroid	CC1=CC=C(C=C1)C(=O)OC1=C(OC(=O)C2=CC=C(C)C=C2)C=C(C=C1)C(O)CNC(C)(C)C	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
effect	"This allows  DRUG1  to open air passages, increasing the effectiveness of the  DRUG2 ."	bitolterol	steroid	CC1=CC=C(C=C1)C(=O)OC1=C(OC(=O)C2=CC=C(C)C=C2)C=C(C=C1)C(O)CNC(C)(C)C	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N
other	"The administration of local  DRUG1  containing  DRUG2  or  DRUGOTHER  to patients receiving  DRUGOTHER  or  DRUGOTHER  may produce severe, prolonged hypertension."	anesthetic solutions	epinephrine	CCOC(=O)C1=CC=C(N)C=C1	
other	"The administration of local  DRUG1  containing  DRUGOTHER  or  DRUG2  to patients receiving  DRUGOTHER  or  DRUGOTHER  may produce severe, prolonged hypertension."	anesthetic solutions	norepinephrine	CCOC(=O)C1=CC=C(N)C=C1	CNC[C@H](O)C1=CC(O)=C(O)C=C1
other	"The administration of local  DRUG1  containing  DRUGOTHER  or  DRUGOTHER  to patients receiving  DRUG2  or  DRUGOTHER  may produce severe, prolonged hypertension."	anesthetic solutions	monoamine oxidase inhibitors	CCOC(=O)C1=CC=C(N)C=C1	OC(=O)CCCCCCCC(O)=O
other	"The administration of local  DRUG1  containing  DRUGOTHER  or  DRUGOTHER  to patients receiving  DRUGOTHER  or  DRUG2  may produce severe, prolonged hypertension."	anesthetic solutions	tricyclic antidepressants	CCOC(=O)C1=CC=C(N)C=C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"The administration of local  DRUGOTHER  containing  DRUG1  or  DRUG2  to patients receiving  DRUGOTHER  or  DRUGOTHER  may produce severe, prolonged hypertension."	epinephrine	norepinephrine		CNC[C@H](O)C1=CC(O)=C(O)C=C1
effect	"The administration of local  DRUGOTHER  containing  DRUG1  or  DRUGOTHER  to patients receiving  DRUG2  or  DRUGOTHER  may produce severe, prolonged hypertension."	epinephrine	monoamine oxidase inhibitors		OC(=O)CCCCCCCC(O)=O
effect	"The administration of local  DRUGOTHER  containing  DRUG1  or  DRUGOTHER  to patients receiving  DRUGOTHER  or  DRUG2  may produce severe, prolonged hypertension."	epinephrine	tricyclic antidepressants		CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
effect	"The administration of local  DRUGOTHER  containing  DRUGOTHER  or  DRUG1  to patients receiving  DRUG2  or  DRUGOTHER  may produce severe, prolonged hypertension."	norepinephrine	monoamine oxidase inhibitors	CNC[C@H](O)C1=CC(O)=C(O)C=C1	OC(=O)CCCCCCCC(O)=O
effect	"The administration of local  DRUGOTHER  containing  DRUGOTHER  or  DRUG1  to patients receiving  DRUGOTHER  or  DRUG2  may produce severe, prolonged hypertension."	norepinephrine	tricyclic antidepressants	CNC[C@H](O)C1=CC(O)=C(O)C=C1	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"The administration of local  DRUGOTHER  containing  DRUGOTHER  or  DRUGOTHER  to patients receiving  DRUG1  or  DRUG2  may produce severe, prolonged hypertension."	monoamine oxidase inhibitors	tricyclic antidepressants	OC(=O)CCCCCCCC(O)=O	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Concurrent administration of  DRUG1  and of  DRUG2  may cause severe, persistent hypertension or cerebrovascular accidents."	vasopressor drugs	ergot-type oxytocic drugs	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	
other	 DRUG1  and  DRUG2  may reduce or reverse the pressor effect of  DRUGOTHER .	Phenothiazines	butyrophenones	N1C2=CC=CC=C2SC2=CC=CC=C12	
effect	 DRUG1  and  DRUGOTHER  may reduce or reverse the pressor effect of  DRUG2 .	Phenothiazines	epinephrine	N1C2=CC=CC=C2SC2=CC=CC=C12	
effect	 DRUGOTHER  and  DRUG1  may reduce or reverse the pressor effect of  DRUG2 .	butyrophenones	epinephrine		
other	"However, neither  DRUG1  nor  DRUG2  appears to affect  DRUGOTHER  metabolism."	phenobarbital	diazepam	CCC1(CC)C(=O)NC(=O)NC1=O	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
other	"However, neither  DRUG1  nor  DRUGOTHER  appears to affect  DRUG2  metabolism."	phenobarbital	Dantrium	CCC1(CC)C(=O)NC(=O)NC1=O	[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)C=NN1CC(=O)NC1=O
other	"However, neither  DRUGOTHER  nor  DRUG1  appears to affect  DRUG2  metabolism."	diazepam	Dantrium	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)C=NN1CC(=O)NC1=O
other	"Binding to plasma protein is not significantly altered by  DRUG1 ,  DRUG2 , or  DRUGOTHER ."	diazepam	diphenylhydantoin	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
other	"Binding to plasma protein is not significantly altered by  DRUG1 ,  DRUGOTHER , or  DRUG2 ."	diazepam	phenylbutazone	CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	"Binding to plasma protein is not significantly altered by  DRUGOTHER ,  DRUG1 , or  DRUG2 ."	diphenylhydantoin	phenylbutazone	CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1	[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
other	Binding to plasma proteins is reduced by  DRUG1  and clotibrate and increased by  DRUG2 .	warfarin	tolbutamide	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	
other	The combination of therapeutic doses of intravenous  DRUG1  and  DRUG2  in  DRUGOTHER  a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.	dantrolene sodium	verapamil	[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)C=NN1CC(=O)NC1=O	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	The combination of therapeutic doses of intravenous  DRUG1  and  DRUGOTHER  in  DRUG2  a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.	dantrolene sodium	halothane	[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)C=NN1CC(=O)NC1=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	The combination of therapeutic doses of intravenous  DRUGOTHER  and  DRUG1  in  DRUG2  a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.	verapamil	halothane	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
advise	"It is recommended that the combination of intravenous  DRUG1  and  DRUG2 , such as  DRUGOTHER , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established."	dantrolene sodium	calcium channel blockers	[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)C=NN1CC(=O)NC1=O	[Ca]
advise	"It is recommended that the combination of intravenous  DRUG1  and  DRUGOTHER , such as  DRUG2 , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established."	dantrolene sodium	verapamil	[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)C=NN1CC(=O)NC1=O	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	"It is recommended that the combination of intravenous  DRUGOTHER  and  DRUG1 , such as  DRUG2 , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established."	calcium channel blockers	verapamil	[Ca]	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
effect	Administration of  DRUG1  may potentiate  DRUG2 -induced neuromuscular block.	dantrolene	vecuronium	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1
other	 DRUG1   may interact with drugs known to interact with the conventional formulation of  DRUG2 .	DOXIL	doxorubicin HCl	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
other	" DRUG1  requirements (i.e.,  DRUG2 ) may be altered."	Antidiabetic drug	insulin		
int	"conversely,  DRUG1  may interfere with  DRUG2  (i.e.,  DRUGOTHER ,  DRUGOTHER )."	diethylpropion	antihypertensive drugs	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
int	"conversely,  DRUG1  may interfere with  DRUGOTHER  (i.e.,  DRUG2 ,  DRUGOTHER )."	diethylpropion	guanethidine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NC(N)=NCCN1CCCCCCC1
int	"conversely,  DRUG1  may interfere with  DRUGOTHER  (i.e.,  DRUGOTHER ,  DRUG2 )."	diethylpropion	a-methyldopa	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O
other	"conversely,  DRUGOTHER  may interfere with  DRUG1  (i.e.,  DRUG2 ,  DRUGOTHER )."	antihypertensive drugs	guanethidine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	NC(N)=NCCN1CCCCCCC1
other	"conversely,  DRUGOTHER  may interfere with  DRUG1  (i.e.,  DRUGOTHER ,  DRUG2 )."	antihypertensive drugs	a-methyldopa	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O
other	"conversely,  DRUGOTHER  may interfere with  DRUGOTHER  (i.e.,  DRUG1 ,  DRUG2 )."	guanethidine	a-methyldopa	NC(N)=NCCN1CCCCCCC1	C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O
effect	Concurrent use of  DRUG1  may antagonize the anorectic effect of  DRUG2 .	phenothiazines	diethylpropion	N1C2=CC=CC=C2SC2=CC=CC=C12	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUG1 :  DRUG2 , given concomitantly with  DRUGOTHER  or 60 minutes following  DRUGOTHER  administration, decreased  DRUGOTHER  bioavailability by approximately 25%."	Bismuth	Bismuth subsalicylate	[Bi+3]	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	" DRUG1 :  DRUGOTHER , given concomitantly with  DRUG2  or 60 minutes following  DRUGOTHER  administration, decreased  DRUGOTHER  bioavailability by approximately 25%."	Bismuth	enoxacin	[Bi+3]	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	" DRUG1 :  DRUGOTHER , given concomitantly with  DRUGOTHER  or 60 minutes following  DRUG2  administration, decreased  DRUGOTHER  bioavailability by approximately 25%."	Bismuth	enoxacin	[Bi+3]	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	" DRUG1 :  DRUGOTHER , given concomitantly with  DRUGOTHER  or 60 minutes following  DRUGOTHER  administration, decreased  DRUG2  bioavailability by approximately 25%."	Bismuth	enoxacin	[Bi+3]	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
mechanism	" DRUGOTHER :  DRUG1 , given concomitantly with  DRUG2  or 60 minutes following  DRUGOTHER  administration, decreased  DRUGOTHER  bioavailability by approximately 25%."	Bismuth subsalicylate	enoxacin	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	" DRUGOTHER :  DRUG1 , given concomitantly with  DRUGOTHER  or 60 minutes following  DRUG2  administration, decreased  DRUGOTHER  bioavailability by approximately 25%."	Bismuth subsalicylate	enoxacin	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	" DRUGOTHER :  DRUG1 , given concomitantly with  DRUGOTHER  or 60 minutes following  DRUGOTHER  administration, decreased  DRUG2  bioavailability by approximately 25%."	Bismuth subsalicylate	enoxacin	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	" DRUGOTHER :  DRUGOTHER , given concomitantly with  DRUG1  or 60 minutes following  DRUG2  administration, decreased  DRUGOTHER  bioavailability by approximately 25%."	enoxacin	enoxacin	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	" DRUGOTHER :  DRUGOTHER , given concomitantly with  DRUG1  or 60 minutes following  DRUGOTHER  administration, decreased  DRUG2  bioavailability by approximately 25%."	enoxacin	enoxacin	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	" DRUGOTHER :  DRUGOTHER , given concomitantly with  DRUGOTHER  or 60 minutes following  DRUG1  administration, decreased  DRUG2  bioavailability by approximately 25%."	enoxacin	enoxacin	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
advise	"Thus, concomitant administration of  DRUG1  and  DRUG2  should be avoided."	enoxacin	bismuth subsalicylate	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1
other	 DRUG1 :  DRUG2  is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of  DRUGOTHER .	Caffeine	Enoxacin	COC1=CC=CC=C1OCC(O)CO	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	 DRUG1 :  DRUGOTHER  is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of  DRUG2 .	Caffeine	methylxanthines	COC1=CC=CC=C1OCC(O)CO	O=C1NC2=C(NC=N2)C(=O)N1
mechanism	 DRUGOTHER :  DRUG1  is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of  DRUG2 .	Enoxacin	methylxanthines	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	O=C1NC2=C(NC=N2)C(=O)N1
mechanism	"In a multiple-dose study,  DRUG1  caused a dose-related increase in the mean elimination half-life of  DRUG2 , thereby decreasing the clearance of  DRUGOTHER  by up to 80% and leading to a five-fold increase in the AUC and the half-life of  DRUGOTHER ."	enoxacin	caffeine	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	COC1=CC=CC=C1OCC(O)CO
other	"In a multiple-dose study,  DRUG1  caused a dose-related increase in the mean elimination half-life of  DRUGOTHER , thereby decreasing the clearance of  DRUG2  by up to 80% and leading to a five-fold increase in the AUC and the half-life of  DRUGOTHER ."	enoxacin	caffeine	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	COC1=CC=CC=C1OCC(O)CO
other	"In a multiple-dose study,  DRUG1  caused a dose-related increase in the mean elimination half-life of  DRUGOTHER , thereby decreasing the clearance of  DRUGOTHER  by up to 80% and leading to a five-fold increase in the AUC and the half-life of  DRUG2 ."	enoxacin	caffeine	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	COC1=CC=CC=C1OCC(O)CO
other	"In a multiple-dose study,  DRUGOTHER  caused a dose-related increase in the mean elimination half-life of  DRUG1 , thereby decreasing the clearance of  DRUG2  by up to 80% and leading to a five-fold increase in the AUC and the half-life of  DRUGOTHER ."	caffeine	caffeine	COC1=CC=CC=C1OCC(O)CO	COC1=CC=CC=C1OCC(O)CO
other	"In a multiple-dose study,  DRUGOTHER  caused a dose-related increase in the mean elimination half-life of  DRUG1 , thereby decreasing the clearance of  DRUGOTHER  by up to 80% and leading to a five-fold increase in the AUC and the half-life of  DRUG2 ."	caffeine	caffeine	COC1=CC=CC=C1OCC(O)CO	COC1=CC=CC=C1OCC(O)CO
other	"In a multiple-dose study,  DRUGOTHER  caused a dose-related increase in the mean elimination half-life of  DRUGOTHER , thereby decreasing the clearance of  DRUG1  by up to 80% and leading to a five-fold increase in the AUC and the half-life of  DRUG2 ."	caffeine	caffeine	COC1=CC=CC=C1OCC(O)CO	COC1=CC=CC=C1OCC(O)CO
other	Trough plasma  DRUG1  levels were also 20% higher when  DRUG2  and  DRUGOTHER  were administered concomitantly.	enoxacin	caffeine	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	COC1=CC=CC=C1OCC(O)CO
other	Trough plasma  DRUG1  levels were also 20% higher when  DRUGOTHER  and  DRUG2  were administered concomitantly.	enoxacin	enoxacin	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
mechanism	Trough plasma  DRUGOTHER  levels were also 20% higher when  DRUG1  and  DRUG2  were administered concomitantly.	caffeine	enoxacin	COC1=CC=CC=C1OCC(O)CO	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	 DRUG1 -related adverse effects have occurred in patients consuming  DRUG2  while on therapy with  DRUGOTHER .	Caffeine	caffeine	COC1=CC=CC=C1OCC(O)CO	COC1=CC=CC=C1OCC(O)CO
other	 DRUG1 -related adverse effects have occurred in patients consuming  DRUGOTHER  while on therapy with  DRUG2 .	Caffeine	enoxacin	COC1=CC=CC=C1OCC(O)CO	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
effect	 DRUGOTHER -related adverse effects have occurred in patients consuming  DRUG1  while on therapy with  DRUG2 .	caffeine	enoxacin	COC1=CC=CC=C1OCC(O)CO	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	 DRUG1 : Elevated serum levels of  DRUG2  have been reported with concomitant use of  DRUGOTHER  with other members of the  DRUGOTHER .	Cyclosporine	cyclosporine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	 DRUG1 : Elevated serum levels of  DRUGOTHER  have been reported with concomitant use of  DRUG2  with other members of the  DRUGOTHER .	Cyclosporine	cyclosporine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	 DRUG1 : Elevated serum levels of  DRUGOTHER  have been reported with concomitant use of  DRUGOTHER  with other members of the  DRUG2 .	Cyclosporine	quinolone class	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	
other	 DRUGOTHER : Elevated serum levels of  DRUG1  have been reported with concomitant use of  DRUG2  with other members of the  DRUGOTHER .	cyclosporine	cyclosporine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	 DRUGOTHER : Elevated serum levels of  DRUG1  have been reported with concomitant use of  DRUGOTHER  with other members of the  DRUG2 .	cyclosporine	quinolone class	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	
mechanism	 DRUGOTHER : Elevated serum levels of  DRUGOTHER  have been reported with concomitant use of  DRUG1  with other members of the  DRUG2 .	cyclosporine	quinolone class	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	
other	 DRUG1 :  DRUG2  may raise serum  DRUGOTHER  levels in some individuals.	Digoxin	Enoxacin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	 DRUG1 :  DRUGOTHER  may raise serum  DRUG2  levels in some individuals.	Digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
mechanism	 DRUGOTHER :  DRUG1  may raise serum  DRUG2  levels in some individuals.	Enoxacin	digoxin	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"If signs and symptoms suggestive of  DRUG1  toxicity occur when  DRUG2  and  DRUGOTHER  are given concomitantly, physicians are advised to obtain serum  DRUGOTHER  levels and adjust  DRUGOTHER  doses appropriately."	digoxin	enoxacin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	"If signs and symptoms suggestive of  DRUG1  toxicity occur when  DRUGOTHER  and  DRUG2  are given concomitantly, physicians are advised to obtain serum  DRUGOTHER  levels and adjust  DRUGOTHER  doses appropriately."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"If signs and symptoms suggestive of  DRUG1  toxicity occur when  DRUGOTHER  and  DRUGOTHER  are given concomitantly, physicians are advised to obtain serum  DRUG2  levels and adjust  DRUGOTHER  doses appropriately."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"If signs and symptoms suggestive of  DRUG1  toxicity occur when  DRUGOTHER  and  DRUGOTHER  are given concomitantly, physicians are advised to obtain serum  DRUGOTHER  levels and adjust  DRUG2  doses appropriately."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
effect	"If signs and symptoms suggestive of  DRUGOTHER  toxicity occur when  DRUG1  and  DRUG2  are given concomitantly, physicians are advised to obtain serum  DRUGOTHER  levels and adjust  DRUGOTHER  doses appropriately."	enoxacin	digoxin	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"If signs and symptoms suggestive of  DRUGOTHER  toxicity occur when  DRUG1  and  DRUGOTHER  are given concomitantly, physicians are advised to obtain serum  DRUG2  levels and adjust  DRUGOTHER  doses appropriately."	enoxacin	digoxin	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"If signs and symptoms suggestive of  DRUGOTHER  toxicity occur when  DRUG1  and  DRUGOTHER  are given concomitantly, physicians are advised to obtain serum  DRUGOTHER  levels and adjust  DRUG2  doses appropriately."	enoxacin	digoxin	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"If signs and symptoms suggestive of  DRUGOTHER  toxicity occur when  DRUGOTHER  and  DRUG1  are given concomitantly, physicians are advised to obtain serum  DRUG2  levels and adjust  DRUGOTHER  doses appropriately."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"If signs and symptoms suggestive of  DRUGOTHER  toxicity occur when  DRUGOTHER  and  DRUG1  are given concomitantly, physicians are advised to obtain serum  DRUGOTHER  levels and adjust  DRUG2  doses appropriately."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"If signs and symptoms suggestive of  DRUGOTHER  toxicity occur when  DRUGOTHER  and  DRUGOTHER  are given concomitantly, physicians are advised to obtain serum  DRUG1  levels and adjust  DRUG2  doses appropriately."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	 DRUG1 : Seizures have been reported in patients taking  DRUG2  concomitantly with the  DRUGOTHER   DRUGOTHER .	Non-steroidal anti-inflammatory agents	enoxacin	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	 DRUG1 : Seizures have been reported in patients taking  DRUGOTHER  concomitantly with the  DRUG2   DRUGOTHER .	Non-steroidal anti-inflammatory agents	nonsteroidal anti-inflammatory drug	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	 DRUG1 : Seizures have been reported in patients taking  DRUGOTHER  concomitantly with the  DRUGOTHER   DRUG2 .	Non-steroidal anti-inflammatory agents	fenbufen	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1
other	 DRUGOTHER : Seizures have been reported in patients taking  DRUG1  concomitantly with the  DRUG2   DRUGOTHER .	enoxacin	nonsteroidal anti-inflammatory drug	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	 DRUGOTHER : Seizures have been reported in patients taking  DRUG1  concomitantly with the  DRUGOTHER   DRUG2 .	enoxacin	fenbufen	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1
other	 DRUGOTHER : Seizures have been reported in patients taking  DRUGOTHER  concomitantly with the  DRUG1   DRUG2 .	nonsteroidal anti-inflammatory drug	fenbufen	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1
other	 DRUG1  and  DRUG2 :  DRUGOTHER  form chelates with metal cations.	Sucralfate	antacids	O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O	
other	 DRUG1  and  DRUGOTHER :  DRUG2  form chelates with metal cations.	Sucralfate	Quinolones	O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O	
other	 DRUGOTHER  and  DRUG1 :  DRUG2  form chelates with metal cations.	antacids	Quinolones		
other	"Therefore, administration of  DRUG1  with  DRUG2  containing  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER ;"	quinolones	antacids		
other	"Therefore, administration of  DRUG1  with  DRUGOTHER  containing  DRUG2 ,  DRUGOTHER , or  DRUGOTHER ;"	quinolones	calcium		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Therefore, administration of  DRUG1  with  DRUGOTHER  containing  DRUGOTHER ,  DRUG2 , or  DRUGOTHER ;"	quinolones	magnesium		[Mg++]
other	"Therefore, administration of  DRUG1  with  DRUGOTHER  containing  DRUGOTHER ,  DRUGOTHER , or  DRUG2 ;"	quinolones	aluminum		CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21
other	"Therefore, administration of  DRUGOTHER  with  DRUG1  containing  DRUG2 ,  DRUGOTHER , or  DRUGOTHER ;"	antacids	calcium		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Therefore, administration of  DRUGOTHER  with  DRUG1  containing  DRUGOTHER ,  DRUG2 , or  DRUGOTHER ;"	antacids	magnesium		[Mg++]
other	"Therefore, administration of  DRUGOTHER  with  DRUG1  containing  DRUGOTHER ,  DRUGOTHER , or  DRUG2 ;"	antacids	aluminum		CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21
other	"Therefore, administration of  DRUGOTHER  with  DRUGOTHER  containing  DRUG1 ,  DRUG2 , or  DRUGOTHER ;"	calcium	magnesium	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[Mg++]
other	"Therefore, administration of  DRUGOTHER  with  DRUGOTHER  containing  DRUG1 ,  DRUGOTHER , or  DRUG2 ;"	calcium	aluminum	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21
other	"Therefore, administration of  DRUGOTHER  with  DRUGOTHER  containing  DRUGOTHER ,  DRUG1 , or  DRUG2 ;"	magnesium	aluminum	[Mg++]	CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21
other	or with  DRUG1  containing  DRUG2  may substantially interfere with drug absorption and result in insufficient plasma and tissue  DRUGOTHER  concentrations.	multivitamins	zinc	NC(=O)C1=CC=CN=C1	O=[Zn]
other	or with  DRUG1  containing  DRUGOTHER  may substantially interfere with drug absorption and result in insufficient plasma and tissue  DRUG2  concentrations.	multivitamins	quinolone	NC(=O)C1=CC=CN=C1	CN1C(=O)C=CC2=CC=CC=C12
mechanism	or with  DRUGOTHER  containing  DRUG1  may substantially interfere with drug absorption and result in insufficient plasma and tissue  DRUG2  concentrations.	zinc	quinolone	O=[Zn]	CN1C(=O)C=CC2=CC=CC=C12
other	 DRUG1  containing  DRUG2  and  DRUGOTHER  reduce the oral absorption of  DRUGOTHER  by 75%.	Antacids	aluminum hydroxide		[OH-].[OH-].[OH-].[Al+3]
other	 DRUG1  containing  DRUGOTHER  and  DRUG2  reduce the oral absorption of  DRUGOTHER  by 75%.	Antacids	magnesium hydroxide		[OH-].[OH-].[Mg++]
other	 DRUG1  containing  DRUGOTHER  and  DRUGOTHER  reduce the oral absorption of  DRUG2  by 75%.	Antacids	enoxacin		CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	 DRUGOTHER  containing  DRUG1  and  DRUG2  reduce the oral absorption of  DRUGOTHER  by 75%.	aluminum hydroxide	magnesium hydroxide	[OH-].[OH-].[OH-].[Al+3]	[OH-].[OH-].[Mg++]
mechanism	 DRUGOTHER  containing  DRUG1  and  DRUGOTHER  reduce the oral absorption of  DRUG2  by 75%.	aluminum hydroxide	enoxacin	[OH-].[OH-].[OH-].[Al+3]	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
mechanism	 DRUGOTHER  containing  DRUGOTHER  and  DRUG1  reduce the oral absorption of  DRUG2  by 75%.	magnesium hydroxide	enoxacin	[OH-].[OH-].[Mg++]	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
mechanism	The oral bioavailability of  DRUG1  is reduced by 60% with coadministration of  DRUG2 .	enoxacin	ranitidine	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
other	 DRUG1 :  DRUG2  is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of  DRUGOTHER .	Theophylline	Enoxacin	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	 DRUG1 :  DRUGOTHER  is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of  DRUG2 .	Theophylline	methylxanthines	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	O=C1NC2=C(NC=N2)C(=O)N1
mechanism	 DRUGOTHER :  DRUG1  is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of  DRUG2 .	Enoxacin	methylxanthines	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	O=C1NC2=C(NC=N2)C(=O)N1
mechanism	 DRUG1  interferes with the metabolism of  DRUG2  resulting in a 42% to 74% dose-related decrease in  DRUGOTHER  clearance and a subsequent 260% to 350% increase in serum theophylline levels.	Enoxacin	theophylline	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	 DRUG1  interferes with the metabolism of  DRUGOTHER  resulting in a 42% to 74% dose-related decrease in  DRUG2  clearance and a subsequent 260% to 350% increase in serum theophylline levels.	Enoxacin	theophylline	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	 DRUGOTHER  interferes with the metabolism of  DRUG1  resulting in a 42% to 74% dose-related decrease in  DRUG2  clearance and a subsequent 260% to 350% increase in serum theophylline levels.	theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	 DRUG1 -related adverse effects have occurred in patients when  DRUG2  and  DRUGOTHER  were coadministered.	Theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	 DRUG1 -related adverse effects have occurred in patients when  DRUGOTHER  and  DRUG2  were coadministered.	Theophylline	enoxacin	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
effect	 DRUGOTHER -related adverse effects have occurred in patients when  DRUG1  and  DRUG2  were coadministered.	theophylline	enoxacin	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	" DRUG1 :  DRUG2 , including  DRUGOTHER , decrease the clearance of  DRUGOTHER , the less active isomer of racemic  DRUGOTHER ."	Warfarin	Quinolones	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	
other	" DRUG1 :  DRUGOTHER , including  DRUG2 , decrease the clearance of  DRUGOTHER , the less active isomer of racemic  DRUGOTHER ."	Warfarin	enoxacin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	" DRUG1 :  DRUGOTHER , including  DRUGOTHER , decrease the clearance of  DRUG2 , the less active isomer of racemic  DRUGOTHER ."	Warfarin	R-warfarin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
other	" DRUG1 :  DRUGOTHER , including  DRUGOTHER , decrease the clearance of  DRUGOTHER , the less active isomer of racemic  DRUG2 ."	Warfarin	warfarin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	" DRUGOTHER :  DRUG1 , including  DRUG2 , decrease the clearance of  DRUGOTHER , the less active isomer of racemic  DRUGOTHER ."	Quinolones	enoxacin		CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
mechanism	" DRUGOTHER :  DRUG1 , including  DRUGOTHER , decrease the clearance of  DRUG2 , the less active isomer of racemic  DRUGOTHER ."	Quinolones	R-warfarin		CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
other	" DRUGOTHER :  DRUG1 , including  DRUGOTHER , decrease the clearance of  DRUGOTHER , the less active isomer of racemic  DRUG2 ."	Quinolones	warfarin		[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
mechanism	" DRUGOTHER :  DRUGOTHER , including  DRUG1 , decrease the clearance of  DRUG2 , the less active isomer of racemic  DRUGOTHER ."	enoxacin	R-warfarin	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
other	" DRUGOTHER :  DRUGOTHER , including  DRUG1 , decrease the clearance of  DRUGOTHER , the less active isomer of racemic  DRUG2 ."	enoxacin	warfarin	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	" DRUGOTHER :  DRUGOTHER , including  DRUGOTHER , decrease the clearance of  DRUG1 , the less active isomer of racemic  DRUG2 ."	R-warfarin	warfarin	CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	" DRUG1  does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when  DRUG2  and  DRUGOTHER  were coadministered."	Enoxacin	enoxacin	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	" DRUG1  does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when  DRUGOTHER  and  DRUG2  were coadministered."	Enoxacin	warfarin	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	" DRUGOTHER  does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when  DRUG1  and  DRUG2  were coadministered."	enoxacin	warfarin	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
advise	"Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when  DRUG1  or its derivatives and  DRUG2  are given concomitantly."	warfarin	enoxacin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N1CCNCC1
other	"Concomitant treatment with  DRUG1  (eg, rt-PA or  DRUG2 ) may: - increase the risk of bleeding complications - considerably enhance the effect of  DRUGOTHER  on aPTT prolongation"	thrombolytics	streptokinase		
other	"Concomitant treatment with  DRUG1  (eg, rt-PA or  DRUGOTHER ) may: - increase the risk of bleeding complications - considerably enhance the effect of  DRUG2  on aPTT prolongation"	thrombolytics	REFLUDAN		
other	"Concomitant treatment with  DRUGOTHER  (eg, rt-PA or  DRUG1 ) may: - increase the risk of bleeding complications - considerably enhance the effect of  DRUG2  on aPTT prolongation"	streptokinase	REFLUDAN		
other	Concomitant treatment with  DRUG1  ( DRUG2 ) and drugs that affect platelet function may also increase the risk of bleeding.	coumarin derivatives	vitamin K antagonists	O=C1OC2=CC=CC=C2C=C1	OC(=O)CCCCCCCC(O)=O
int	Interactions may occur between  DRUG1  supplements and  DRUG2  and other  DRUGOTHER  and herbs such as garlic (Allium sativum) and  DRUGOTHER  ( DRUGOTHER ).	EPA	aspirin	C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1	CC(=O)OC1=CC=CC=C1C(O)=O
int	Interactions may occur between  DRUG1  supplements and  DRUGOTHER  and other  DRUG2  and herbs such as garlic (Allium sativum) and  DRUGOTHER  ( DRUGOTHER ).	EPA	non-steroidal anti-inflammatory drugs	C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
int	Interactions may occur between  DRUG1  supplements and  DRUGOTHER  and other  DRUGOTHER  and herbs such as garlic (Allium sativum) and  DRUG2  ( DRUGOTHER ).	EPA	ginkgo	C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1	C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O
int	Interactions may occur between  DRUG1  supplements and  DRUGOTHER  and other  DRUGOTHER  and herbs such as garlic (Allium sativum) and  DRUGOTHER  ( DRUG2 ).	EPA	Ginkgo biloba	C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1	
other	Interactions may occur between  DRUGOTHER  supplements and  DRUG1  and other  DRUG2  and herbs such as garlic (Allium sativum) and  DRUGOTHER  ( DRUGOTHER ).	aspirin	non-steroidal anti-inflammatory drugs	CC(=O)OC1=CC=CC=C1C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	Interactions may occur between  DRUGOTHER  supplements and  DRUG1  and other  DRUGOTHER  and herbs such as garlic (Allium sativum) and  DRUG2  ( DRUGOTHER ).	aspirin	ginkgo	CC(=O)OC1=CC=CC=C1C(O)=O	C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O
other	Interactions may occur between  DRUGOTHER  supplements and  DRUG1  and other  DRUGOTHER  and herbs such as garlic (Allium sativum) and  DRUGOTHER  ( DRUG2 ).	aspirin	Ginkgo biloba	CC(=O)OC1=CC=CC=C1C(O)=O	
other	Interactions may occur between  DRUGOTHER  supplements and  DRUGOTHER  and other  DRUG1  and herbs such as garlic (Allium sativum) and  DRUG2  ( DRUGOTHER ).	non-steroidal anti-inflammatory drugs	ginkgo	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O
other	Interactions may occur between  DRUGOTHER  supplements and  DRUGOTHER  and other  DRUG1  and herbs such as garlic (Allium sativum) and  DRUGOTHER  ( DRUG2 ).	non-steroidal anti-inflammatory drugs	Ginkgo biloba	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	Interactions may occur between  DRUGOTHER  supplements and  DRUGOTHER  and other  DRUGOTHER  and herbs such as garlic (Allium sativum) and  DRUG1  ( DRUG2 ).	ginkgo	Ginkgo biloba	C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	
advise	"Concomitant use of  DRUG1  with other cardioactive compounds that could cause heart failure (e.g.,  DRUG2 ), requires close monitoring of cardiac function throughout treatment."	ELLENCE	calcium channel blockers	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O	[Ca]
mechanism	 DRUG1  increased the AUC of  DRUG2  by 50%.	Cimetidine	epirubicin	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
advise	 DRUG1  treatment should be stopped during treatment with  DRUG2 .	Cimetidine	ELLENCE	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
advise	"Patients who are applying  DRUG1  gel should not concurrently use products that contain  DRUG2  (N,  DRUGOTHER ), a common component of insect repellent products."	Panretin	DEET	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O	
advise	"Patients who are applying  DRUG1  gel should not concurrently use products that contain  DRUGOTHER  (N,  DRUG2 ), a common component of insect repellent products."	Panretin	N-diethyl-m-toluamide	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O	OC(=O)CCCCCCCC(O)=O
other	"Patients who are applying  DRUGOTHER  gel should not concurrently use products that contain  DRUG1  (N,  DRUG2 ), a common component of insect repellent products."	DEET	N-diethyl-m-toluamide		OC(=O)CCCCCCCC(O)=O
other	Animal toxicology studies showed increased  DRUG1  toxicity when  DRUG2  was included as proof of the formulation.	DEET	DEET		
other	"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic  DRUG1 , including  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , the effect of  DRUGOTHER  gel on the steady-state concentrations of these drugs is not known."	antiretroviral agents	protease inhibitors	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	
other	"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic  DRUG1 , including  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , the effect of  DRUGOTHER  gel on the steady-state concentrations of these drugs is not known."	antiretroviral agents	macrolide antibiotics	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic  DRUG1 , including  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , the effect of  DRUGOTHER  gel on the steady-state concentrations of these drugs is not known."	antiretroviral agents	azole antifungals	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	OC(=O)CCCCCCCCC=C
other	"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic  DRUG1 , including  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , the effect of  DRUG2  gel on the steady-state concentrations of these drugs is not known."	antiretroviral agents	Panretin	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
other	"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic  DRUGOTHER , including  DRUG1 ,  DRUG2 , and  DRUGOTHER , the effect of  DRUGOTHER  gel on the steady-state concentrations of these drugs is not known."	protease inhibitors	macrolide antibiotics		[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic  DRUGOTHER , including  DRUG1 ,  DRUGOTHER , and  DRUG2 , the effect of  DRUGOTHER  gel on the steady-state concentrations of these drugs is not known."	protease inhibitors	azole antifungals		OC(=O)CCCCCCCCC=C
other	"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic  DRUGOTHER , including  DRUG1 ,  DRUGOTHER , and  DRUGOTHER , the effect of  DRUG2  gel on the steady-state concentrations of these drugs is not known."	protease inhibitors	Panretin		C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
other	"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic  DRUGOTHER , including  DRUGOTHER ,  DRUG1 , and  DRUG2 , the effect of  DRUGOTHER  gel on the steady-state concentrations of these drugs is not known."	macrolide antibiotics	azole antifungals	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	OC(=O)CCCCCCCCC=C
other	"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic  DRUGOTHER , including  DRUGOTHER ,  DRUG1 , and  DRUGOTHER , the effect of  DRUG2  gel on the steady-state concentrations of these drugs is not known."	macrolide antibiotics	Panretin	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
other	"Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic  DRUGOTHER , including  DRUGOTHER ,  DRUGOTHER , and  DRUG1 , the effect of  DRUG2  gel on the steady-state concentrations of these drugs is not known."	azole antifungals	Panretin	OC(=O)CCCCCCCCC=C	C\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=O
other	 DRUG1  has been shown to have no effect on the pharmacokinetics of  DRUG2  and the pharmacodynamics of  DRUGOTHER  and  DRUGOTHER .	Eprosartan	digoxin	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	 DRUG1  has been shown to have no effect on the pharmacokinetics of  DRUGOTHER  and the pharmacodynamics of  DRUG2  and  DRUGOTHER .	Eprosartan	warfarin	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	 DRUG1  has been shown to have no effect on the pharmacokinetics of  DRUGOTHER  and the pharmacodynamics of  DRUGOTHER  and  DRUG2 .	Eprosartan	glyburide	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	 DRUGOTHER  has been shown to have no effect on the pharmacokinetics of  DRUG1  and the pharmacodynamics of  DRUG2  and  DRUGOTHER .	digoxin	warfarin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	 DRUGOTHER  has been shown to have no effect on the pharmacokinetics of  DRUG1  and the pharmacodynamics of  DRUGOTHER  and  DRUG2 .	digoxin	glyburide	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	 DRUGOTHER  has been shown to have no effect on the pharmacokinetics of  DRUGOTHER  and the pharmacodynamics of  DRUG1  and  DRUG2 .	warfarin	glyburide	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
other	"Because  DRUG1  is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and  DRUG2  and  DRUGOTHER , potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on  DRUGOTHER  pharmacokinetics."	eprosartan	ketoconazole	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Because  DRUG1  is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and  DRUGOTHER  and  DRUG2 , potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on  DRUGOTHER  pharmacokinetics."	eprosartan	fluconazole	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Because  DRUG1  is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and  DRUGOTHER  and  DRUGOTHER , potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on  DRUG2  pharmacokinetics."	eprosartan	eprosartan	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Because  DRUGOTHER  is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and  DRUG1  and  DRUG2 , potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on  DRUGOTHER  pharmacokinetics."	ketoconazole	fluconazole	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Because  DRUGOTHER  is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and  DRUG1  and  DRUGOTHER , potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on  DRUG2  pharmacokinetics."	ketoconazole	eprosartan	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Because  DRUGOTHER  is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and  DRUGOTHER  and  DRUG1 , potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on  DRUG2  pharmacokinetics."	fluconazole	eprosartan	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	 DRUG1  also has no effect on  DRUG2  pharmacokinetics.	Ranitidine	eprosartan	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	 DRUG1  (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a  DRUG2  ( DRUGOTHER ).	Eprosartan	thiazide diuretic	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	
other	 DRUG1  (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a  DRUGOTHER  ( DRUG2 ).	Eprosartan	hydrochlorothiazide	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	 DRUGOTHER  (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a  DRUG1  ( DRUG2 ).	thiazide diuretic	hydrochlorothiazide		NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	 DRUG1  doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release  DRUG2  (sustained-release  DRUGOTHER ) with no clinically significant adverse interactions.	Eprosartan	calcium channel blockers	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	[Ca]
other	 DRUG1  doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release  DRUGOTHER  (sustained-release  DRUG2 ) with no clinically significant adverse interactions.	Eprosartan	nifedipine	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	 DRUGOTHER  doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release  DRUG1  (sustained-release  DRUG2 ) with no clinically significant adverse interactions.	calcium channel blockers	nifedipine	[Ca]	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Also, the potential for hepatic injury should be considered when  DRUG1   is used in combination with other products associated with hepatic injury, or when new agents are added to the regimen of patients already on  DRUG2  ."	Rebif	Rebif	[Na+].[Cl-]	[Na+].[Cl-]
mechanism	"The absorption of  DRUG1  may be affected by the simultaneous administration of indigestion remedies,  DRUG2  or  DRUGOTHER  supplements."	lymecycline	iron	[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@H]2N(C)C	
mechanism	"The absorption of  DRUG1  may be affected by the simultaneous administration of indigestion remedies,  DRUGOTHER  or  DRUG2  supplements."	lymecycline	zinc	[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@H]2N(C)C	O=[Zn]
other	"The absorption of  DRUGOTHER  may be affected by the simultaneous administration of indigestion remedies,  DRUG1  or  DRUG2  supplements."	iron	zinc		O=[Zn]
effect	Oral  DRUG1  may be less effective while you are taking  DRUG2 .	contraceptives	lymecycline	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@H]2N(C)C
effect	"Additional reductions in blood pressure may occur when  DRUG1  is administered with  DRUG2 ,  DRUGOTHER , or other  DRUGOTHER ."	FLOLAN	diuretics	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
effect	"Additional reductions in blood pressure may occur when  DRUG1  is administered with  DRUGOTHER ,  DRUG2 , or other  DRUGOTHER ."	FLOLAN	antihypertensive agents	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	"Additional reductions in blood pressure may occur when  DRUG1  is administered with  DRUGOTHER ,  DRUGOTHER , or other  DRUG2 ."	FLOLAN	vasodilators	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	
other	"Additional reductions in blood pressure may occur when  DRUGOTHER  is administered with  DRUG1 ,  DRUG2 , or other  DRUGOTHER ."	diuretics	antihypertensive agents	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Additional reductions in blood pressure may occur when  DRUGOTHER  is administered with  DRUG1 ,  DRUGOTHER , or other  DRUG2 ."	diuretics	vasodilators	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	
other	"Additional reductions in blood pressure may occur when  DRUGOTHER  is administered with  DRUGOTHER ,  DRUG1 , or other  DRUG2 ."	antihypertensive agents	vasodilators	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	
other	"When other  DRUG1  or  DRUG2  are used concomitantly, there is the potential for  DRUGOTHER  to increase the risk of bleeding."	antiplatelet agents	anticoagulants	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	
effect	"When other  DRUG1  or  DRUGOTHER  are used concomitantly, there is the potential for  DRUG2  to increase the risk of bleeding."	antiplatelet agents	FLOLAN	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O
effect	"When other  DRUGOTHER  or  DRUG1  are used concomitantly, there is the potential for  DRUG2  to increase the risk of bleeding."	anticoagulants	FLOLAN		[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O
other	"However, patients receiving infusions of  DRUG1  in clinical trials were maintained on  DRUG2  without evidence of increased bleeding."	FLOLAN	anticoagulants	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	
other	"In clinical trials,  DRUG1  was used with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	FLOLAN	digoxin	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical trials,  DRUG1  was used with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	FLOLAN	diuretics	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"In clinical trials,  DRUG1  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	FLOLAN	anticoagulants	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	
other	"In clinical trials,  DRUG1  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	FLOLAN	vasodilators	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	
other	"In clinical trials,  DRUG1  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUG2 .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	FLOLAN	oxygen	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br
other	"In clinical trials,  DRUG1  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUG2  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	FLOLAN	furosemide	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"In clinical trials,  DRUG1  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUG2  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	FLOLAN	digoxin	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical trials,  DRUG1  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUG2  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	FLOLAN	FLOLAN	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O
other	"In clinical trials,  DRUG1  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUG2  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	FLOLAN	furosemide	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"In clinical trials,  DRUG1  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUG2  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	FLOLAN	digoxin	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical trials,  DRUGOTHER  was used with  DRUG1 ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	digoxin	diuretics	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"In clinical trials,  DRUGOTHER  was used with  DRUG1 ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	digoxin	anticoagulants	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	
other	"In clinical trials,  DRUGOTHER  was used with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	digoxin	vasodilators	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	
other	"In clinical trials,  DRUGOTHER  was used with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUG2 .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	digoxin	oxygen	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br
other	"In clinical trials,  DRUGOTHER  was used with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUG2  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	digoxin	furosemide	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUG2  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical trials,  DRUGOTHER  was used with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUG2  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	digoxin	FLOLAN	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUG2  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	digoxin	furosemide	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUG2  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUG1 ,  DRUG2 , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	diuretics	anticoagulants	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUG2 , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	diuretics	vasodilators	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUG2 .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	diuretics	oxygen	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUG2  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	diuretics	furosemide	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUG2  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	diuretics	digoxin	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUG2  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	diuretics	FLOLAN	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUG2  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	diuretics	furosemide	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUG2  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	diuretics	digoxin	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUG2 , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	anticoagulants	vasodilators		
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER , and supplemental  DRUG2 .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	anticoagulants	oxygen		FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUG2  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	anticoagulants	furosemide		NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUG2  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	anticoagulants	digoxin		[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUG2  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	anticoagulants	FLOLAN		[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUG2  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	anticoagulants	furosemide		NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUG2  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	anticoagulants	digoxin		[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1 , and supplemental  DRUG2 .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	vasodilators	oxygen		FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1 , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUG2  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	vasodilators	furosemide		NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1 , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUG2  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	vasodilators	digoxin		[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1 , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUG2  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	vasodilators	FLOLAN		[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1 , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUG2  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	vasodilators	furosemide		NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1 , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUG2  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	vasodilators	digoxin		[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUG1 .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUG2  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	oxygen	furosemide	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUG1 .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUG2  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	oxygen	digoxin	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUG1 .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUG2  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	oxygen	FLOLAN	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUG1 .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUG2  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	oxygen	furosemide	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUG1 .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUG2  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	oxygen	digoxin	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUG1  or  DRUG2  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	furosemide	digoxin	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
mechanism	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUG1  or  DRUGOTHER  in whom therapy with  DRUG2  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	furosemide	FLOLAN	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUG1  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUG2  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	furosemide	furosemide	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUG1  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUG2  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	furosemide	digoxin	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
mechanism	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUG1  in whom therapy with  DRUG2  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	digoxin	FLOLAN	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUG1  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUG2  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	digoxin	furosemide	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUG1  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUG2  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUG1  was initiated, apparent oral clearance values for  DRUG2  (n = 23) and  DRUGOTHER  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	FLOLAN	furosemide	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUG1  was initiated, apparent oral clearance values for  DRUGOTHER  (n = 23) and  DRUG2  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	FLOLAN	digoxin	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"In clinical trials,  DRUGOTHER  was used with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and supplemental  DRUGOTHER .In a pharmacokinetic substudy in patients with congestive heart failure receiving  DRUGOTHER  or  DRUGOTHER  in whom therapy with  DRUGOTHER  was initiated, apparent oral clearance values for  DRUG1  (n = 23) and  DRUG2  (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87."	furosemide	digoxin	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"However, patients on  DRUG1  may show elevations of  DRUG2  concentrations after initiation of therapy with  DRUGOTHER , which may be clinically significant in patients prone to  DRUGOTHER  toxicity."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
mechanism	"However, patients on  DRUG1  may show elevations of  DRUGOTHER  concentrations after initiation of therapy with  DRUG2 , which may be clinically significant in patients prone to  DRUGOTHER  toxicity."	digoxin	FLOLAN	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O
other	"However, patients on  DRUG1  may show elevations of  DRUGOTHER  concentrations after initiation of therapy with  DRUGOTHER , which may be clinically significant in patients prone to  DRUG2  toxicity."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"However, patients on  DRUGOTHER  may show elevations of  DRUG1  concentrations after initiation of therapy with  DRUG2 , which may be clinically significant in patients prone to  DRUGOTHER  toxicity."	digoxin	FLOLAN	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O
other	"However, patients on  DRUGOTHER  may show elevations of  DRUG1  concentrations after initiation of therapy with  DRUGOTHER , which may be clinically significant in patients prone to  DRUG2  toxicity."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"However, patients on  DRUGOTHER  may show elevations of  DRUGOTHER  concentrations after initiation of therapy with  DRUG1 , which may be clinically significant in patients prone to  DRUG2  toxicity."	FLOLAN	digoxin	[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
mechanism	Elevated plasma levels of  DRUG1  have been reported with concomitant  DRUG2  use.	theophylline	quinolone	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C(=O)C=CC2=CC=CC=C12
other	There have been reports of  DRUG1 -related side effects in patients on concomitant therapy with  DRUG2  and  DRUGOTHER .	theophylline	quinolones	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	
other	There have been reports of  DRUG1 -related side effects in patients on concomitant therapy with  DRUGOTHER  and  DRUG2 .	theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
effect	There have been reports of  DRUGOTHER -related side effects in patients on concomitant therapy with  DRUG1  and  DRUG2 .	quinolones	theophylline		CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"Therefore, monitoring of  DRUG1  plasma levels should be considered and dosage of  DRUG2  adjusted, as required."	theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
mechanism	 DRUG1  have been shown to interfere with the metabolism of  DRUG2 .	Quinolones	caffeine		COC1=CC=CC=C1OCC(O)CO
other	" DRUG1 , including  DRUG2 , may enhance the effects of the oral  DRUGOTHER   DRUGOTHER  or its derivatives."	Quinolones	nalidixic acid		CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2
other	" DRUG1 , including  DRUGOTHER , may enhance the effects of the oral  DRUG2   DRUGOTHER  or its derivatives."	Quinolones	anticoagulant		[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
effect	" DRUG1 , including  DRUGOTHER , may enhance the effects of the oral  DRUGOTHER   DRUG2  or its derivatives."	Quinolones	warfarin		[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	" DRUGOTHER , including  DRUG1 , may enhance the effects of the oral  DRUG2   DRUGOTHER  or its derivatives."	nalidixic acid	anticoagulant	CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
effect	" DRUGOTHER , including  DRUG1 , may enhance the effects of the oral  DRUGOTHER   DRUG2  or its derivatives."	nalidixic acid	warfarin	CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	" DRUGOTHER , including  DRUGOTHER , may enhance the effects of the oral  DRUG1   DRUG2  or its derivatives."	anticoagulant	warfarin	[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
effect	 DRUG1  interferes with the therapeutic action of  DRUG2 .	Nitrofurantoin	nalidixic acid	[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O	CCN1C=C(C(O)=O)C(=O)C2=C1N=C(C)C=C2
other	" DRUG1  containing  DRUG2 ,  DRUGOTHER , or  DRUGOTHER ;"	Antacids	magnesium		[Mg++]
other	" DRUG1  containing  DRUGOTHER ,  DRUG2 , or  DRUGOTHER ;"	Antacids	aluminum		CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21
other	" DRUG1  containing  DRUGOTHER ,  DRUGOTHER , or  DRUG2 ;"	Antacids	calcium		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  containing  DRUG1 ,  DRUG2 , or  DRUGOTHER ;"	magnesium	aluminum	[Mg++]	CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21
other	" DRUGOTHER  containing  DRUG1 ,  DRUGOTHER , or  DRUG2 ;"	magnesium	calcium	[Mg++]	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  containing  DRUGOTHER ,  DRUG1 , or  DRUG2 ;"	aluminum	calcium	CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	 DRUG1  or divalent or trivalent cations such as  DRUG2 ;	sucralfate	iron	O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O	
other	 DRUG1  containing  DRUG2 ;	multivitamins	zinc	NC(=O)C1=CC=CN=C1	O=[Zn]
other	"and  DRUG1  , ( DRUG2 ), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of  DRUGOTHER , resulting in systemic levels considerably lower than desired."	Videx	Didanosine	CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O
mechanism	"and  DRUG1  , ( DRUGOTHER ), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of  DRUG2 , resulting in systemic levels considerably lower than desired."	Videx	quinolones	CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	
mechanism	"and  DRUGOTHER  , ( DRUG1 ), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of  DRUG2 , resulting in systemic levels considerably lower than desired."	Didanosine	quinolones	OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O	
other	Elevated serum levels of  DRUG1  have been reported with the concomitant use of some  DRUG2  and  DRUGOTHER .	cyclosporine	quinolones	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	
other	Elevated serum levels of  DRUG1  have been reported with the concomitant use of some  DRUGOTHER  and  DRUG2 .	cyclosporine	cyclosporine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
mechanism	Elevated serum levels of  DRUGOTHER  have been reported with the concomitant use of some  DRUG1  and  DRUG2 .	quinolones	cyclosporine		CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Therefore,  DRUG1  serum levels should be monitored and appropriate  DRUG2  dosage adjustments made when these drugs are used concomitantly."	cyclosporine	cyclosporine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	" DRUG1 , such as  DRUG2 ,  DRUGOTHER  and  DRUGOTHER , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly."	Slow-channel calcium blockers	verapamil	[Ca]	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	" DRUG1 , such as  DRUGOTHER ,  DRUG2  and  DRUGOTHER , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly."	Slow-channel calcium blockers	diltiazem	[Ca]	
other	" DRUG1 , such as  DRUGOTHER ,  DRUGOTHER  and  DRUG2 , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly."	Slow-channel calcium blockers	nifedipine	[Ca]	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	" DRUGOTHER , such as  DRUG1 ,  DRUG2  and  DRUGOTHER , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly."	verapamil	diltiazem	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	
other	" DRUGOTHER , such as  DRUG1 ,  DRUGOTHER  and  DRUG2 , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly."	verapamil	nifedipine	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	" DRUGOTHER , such as  DRUGOTHER ,  DRUG1  and  DRUG2 , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly."	diltiazem	nifedipine		CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
effect	"The use of  DRUG1  may result in additive CNS depressant effects when coadministered with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or other drugs that produce CNS depression."	codeine	alcohol		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	"The use of  DRUG1  may result in additive CNS depressant effects when coadministered with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or other drugs that produce CNS depression."	codeine	antihistamines		NCCC1=CNC=N1
effect	"The use of  DRUG1  may result in additive CNS depressant effects when coadministered with  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or other drugs that produce CNS depression."	codeine	psychotropics		
other	"The use of  DRUGOTHER  may result in additive CNS depressant effects when coadministered with  DRUG1 ,  DRUG2 ,  DRUGOTHER  or other drugs that produce CNS depression."	alcohol	antihistamines	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	NCCC1=CNC=N1
other	"The use of  DRUGOTHER  may result in additive CNS depressant effects when coadministered with  DRUG1 ,  DRUGOTHER ,  DRUG2  or other drugs that produce CNS depression."	alcohol	psychotropics	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	"The use of  DRUGOTHER  may result in additive CNS depressant effects when coadministered with  DRUGOTHER ,  DRUG1 ,  DRUG2  or other drugs that produce CNS depression."	antihistamines	psychotropics	NCCC1=CNC=N1	
effect	Serious toxicity may result if  DRUG1  is coadministered with  DRUG2  ( DRUGOTHER ).	dextromethorphan	monoamine oxidase inhibitors	[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C	OC(=O)CCCCCCCC(O)=O
effect	Serious toxicity may result if  DRUG1  is coadministered with  DRUGOTHER  ( DRUG2 ).	dextromethorphan	MAOIs	[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C	
other	Serious toxicity may result if  DRUGOTHER  is coadministered with  DRUG1  ( DRUG2 ).	monoamine oxidase inhibitors	MAOIs	OC(=O)CCCCCCCC(O)=O	
effect	"The use of  DRUG1  may result in additive CNS depressant effects when coadministered with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or other drugs that produce CNS depression."	dextromethorphan hydrobromide	alcohol	[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
effect	"The use of  DRUG1  may result in additive CNS depressant effects when coadministered with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or other drugs that produce CNS depression."	dextromethorphan hydrobromide	antihistamines	[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C	NCCC1=CNC=N1
effect	"The use of  DRUG1  may result in additive CNS depressant effects when coadministered with  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or other drugs that produce CNS depression."	dextromethorphan hydrobromide	psychotropics	[H][C@]12CC3=C(C=C(OC)C=C3)[C@@]3(CCCC[C@]13[H])CCN2C	
other	"The use of  DRUGOTHER  may result in additive CNS depressant effects when coadministered with  DRUG1 ,  DRUG2 ,  DRUGOTHER  or other drugs that produce CNS depression."	alcohol	antihistamines	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	NCCC1=CNC=N1
other	"The use of  DRUGOTHER  may result in additive CNS depressant effects when coadministered with  DRUG1 ,  DRUGOTHER ,  DRUG2  or other drugs that produce CNS depression."	alcohol	psychotropics	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	"The use of  DRUGOTHER  may result in additive CNS depressant effects when coadministered with  DRUGOTHER ,  DRUG1 ,  DRUG2  or other drugs that produce CNS depression."	antihistamines	psychotropics	NCCC1=CNC=N1	
other	" DRUG1 , a  DRUG2 , may antagonize the bactercidal effect of  DRUGOTHER  and concurrent use of these drugs should be avoided."	Tetracycline	bacteriostatic antibiotic	[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
effect	" DRUG1 , a  DRUGOTHER , may antagonize the bactercidal effect of  DRUG2  and concurrent use of these drugs should be avoided."	Tetracycline	penicillin	[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C	[H][C@](N)(CCCC(O)=N[C@]1([H])C(=O)N2[C@]1([H])SC(C)(C)[C@]2([H])C(O)=O)C(O)=O
other	" DRUGOTHER , a  DRUG1 , may antagonize the bactercidal effect of  DRUG2  and concurrent use of these drugs should be avoided."	bacteriostatic antibiotic	penicillin	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	[H][C@](N)(CCCC(O)=N[C@]1([H])C(=O)N2[C@]1([H])SC(C)(C)[C@]2([H])C(O)=O)C(O)=O
mechanism	 DRUG1  accelerates the metabolism of  DRUG2 ;	Cytadren	dexamethasone	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
other	"therefore, if  DRUG1  replacement is needed,  DRUG2  should be prescribed."	glucocorticoid	hydrocortisone	COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1	[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
effect	 DRUG1  diminishes the effect of  DRUG2  and  DRUGOTHER .	Aminoglutethimide	coumarin	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	O=C1OC2=CC=CC=C2C=C1
effect	 DRUG1  diminishes the effect of  DRUGOTHER  and  DRUG2 .	Aminoglutethimide	warfarin	CCC1(CCC(=O)NC1=O)C1=CC=C(N)C=C1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	 DRUGOTHER  diminishes the effect of  DRUG1  and  DRUG2 .	coumarin	warfarin	O=C1OC2=CC=CC=C2C=C1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of  DRUG1  than when  DRUG2  or  DRUGOTHER  with a balanced technique are used."	Enflurane	halothane	FC(F)OC(F)(F)C(F)Cl	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of  DRUG1  than when  DRUGOTHER  or  DRUG2  with a balanced technique are used."	Enflurane	nitrous oxide	FC(F)OC(F)(F)C(F)Cl	[O-][N+]#N
other	"If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of  DRUGOTHER  than when  DRUG1  or  DRUG2  with a balanced technique are used."	halothane	nitrous oxide	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[O-][N+]#N
effect	"Concurrent administration of  DRUG1  and  DRUG2  may cause severe orthostatic hypotension. DRUGOTHER , an inhibitor of microsomal drug metabolism, increased  DRUGOTHER s half-life and toxicity in a rat model."	HEXALEN	antidepressants of the MAO inhibitor class	CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
other	"Concurrent administration of  DRUG1  and  DRUGOTHER  may cause severe orthostatic hypotension. DRUG2 , an inhibitor of microsomal drug metabolism, increased  DRUGOTHER s half-life and toxicity in a rat model."	HEXALEN	Cimetidine	CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"Concurrent administration of  DRUG1  and  DRUGOTHER  may cause severe orthostatic hypotension. DRUGOTHER , an inhibitor of microsomal drug metabolism, increased  DRUG2 s half-life and toxicity in a rat model."	HEXALEN	altretamine	CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C	CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C
other	"Concurrent administration of  DRUGOTHER  and  DRUG1  may cause severe orthostatic hypotension. DRUG2 , an inhibitor of microsomal drug metabolism, increased  DRUGOTHER s half-life and toxicity in a rat model."	antidepressants of the MAO inhibitor class	Cimetidine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N
other	"Concurrent administration of  DRUGOTHER  and  DRUG1  may cause severe orthostatic hypotension. DRUGOTHER , an inhibitor of microsomal drug metabolism, increased  DRUG2 s half-life and toxicity in a rat model."	antidepressants of the MAO inhibitor class	altretamine	CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12	CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C
mechanism	"Concurrent administration of  DRUGOTHER  and  DRUGOTHER  may cause severe orthostatic hypotension. DRUG1 , an inhibitor of microsomal drug metabolism, increased  DRUG2 s half-life and toxicity in a rat model."	Cimetidine	altretamine	CN\C(NCCSCC1=C(C)NC=N1)=N\C#N	CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C
effect	Data from a randomized trial of  DRUG1  and  DRUG2  plus or minus  DRUGOTHER  in ovarian cancer indicated that  DRUGOTHER  significantly reduced neurotoxicity;	HEXALEN	cisplatin	CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	Data from a randomized trial of  DRUG1  and  DRUGOTHER  plus or minus  DRUG2  in ovarian cancer indicated that  DRUGOTHER  significantly reduced neurotoxicity;	HEXALEN	pyridoxine	CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C	CC1=NC=C(COP(O)(O)=O)C(CO)=C1O
other	Data from a randomized trial of  DRUG1  and  DRUGOTHER  plus or minus  DRUGOTHER  in ovarian cancer indicated that  DRUG2  significantly reduced neurotoxicity;	HEXALEN	pyridoxine	CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C	CC1=NC=C(COP(O)(O)=O)C(CO)=C1O
other	Data from a randomized trial of  DRUGOTHER  and  DRUG1  plus or minus  DRUG2  in ovarian cancer indicated that  DRUGOTHER  significantly reduced neurotoxicity;	cisplatin	pyridoxine	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	CC1=NC=C(COP(O)(O)=O)C(CO)=C1O
other	Data from a randomized trial of  DRUGOTHER  and  DRUG1  plus or minus  DRUGOTHER  in ovarian cancer indicated that  DRUG2  significantly reduced neurotoxicity;	cisplatin	pyridoxine	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]	CC1=NC=C(COP(O)(O)=O)C(CO)=C1O
other	Data from a randomized trial of  DRUGOTHER  and  DRUGOTHER  plus or minus  DRUG1  in ovarian cancer indicated that  DRUG2  significantly reduced neurotoxicity;	pyridoxine	pyridoxine	CC1=NC=C(COP(O)(O)=O)C(CO)=C1O	CC1=NC=C(COP(O)(O)=O)C(CO)=C1O
advise	"however, it adversely affected response duration suggesting that  DRUG1  should not be administered with  DRUG2  and/or  DRUGOTHER .1"	pyridoxine	HEXALEN	CC1=NC=C(COP(O)(O)=O)C(CO)=C1O	CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C
advise	"however, it adversely affected response duration suggesting that  DRUG1  should not be administered with  DRUGOTHER  and/or  DRUG2 .1"	pyridoxine	cisplatin	CC1=NC=C(COP(O)(O)=O)C(CO)=C1O	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	"however, it adversely affected response duration suggesting that  DRUGOTHER  should not be administered with  DRUG1  and/or  DRUG2 .1"	HEXALEN	cisplatin	CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C	[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
other	 DRUG1  Supplements/ DRUG2 	Calcium	Antacids	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	"Products containing  DRUG1  and other multivalent cations (such as  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) are likely to interfere with absorption of  DRUGOTHER ."	calcium	aluminum	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21
other	"Products containing  DRUG1  and other multivalent cations (such as  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) are likely to interfere with absorption of  DRUGOTHER ."	calcium	magnesium	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[Mg++]
other	"Products containing  DRUG1  and other multivalent cations (such as  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) are likely to interfere with absorption of  DRUGOTHER ."	calcium	iron	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
mechanism	"Products containing  DRUG1  and other multivalent cations (such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) are likely to interfere with absorption of  DRUG2 ."	calcium	Ibandronate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	NCCCC(O)(P(O)(O)=O)P(O)(O)=O
other	"Products containing  DRUGOTHER  and other multivalent cations (such as  DRUG1 ,  DRUG2 ,  DRUGOTHER ) are likely to interfere with absorption of  DRUGOTHER ."	aluminum	magnesium	CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21	[Mg++]
other	"Products containing  DRUGOTHER  and other multivalent cations (such as  DRUG1 ,  DRUGOTHER ,  DRUG2 ) are likely to interfere with absorption of  DRUGOTHER ."	aluminum	iron	CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21	
mechanism	"Products containing  DRUGOTHER  and other multivalent cations (such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) are likely to interfere with absorption of  DRUG2 ."	aluminum	Ibandronate	CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21	NCCCC(O)(P(O)(O)=O)P(O)(O)=O
other	"Products containing  DRUGOTHER  and other multivalent cations (such as  DRUGOTHER ,  DRUG1 ,  DRUG2 ) are likely to interfere with absorption of  DRUGOTHER ."	magnesium	iron	[Mg++]	
mechanism	"Products containing  DRUGOTHER  and other multivalent cations (such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) are likely to interfere with absorption of  DRUG2 ."	magnesium	Ibandronate	[Mg++]	NCCCC(O)(P(O)(O)=O)P(O)(O)=O
mechanism	"Products containing  DRUGOTHER  and other multivalent cations (such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) are likely to interfere with absorption of  DRUG2 ."	iron	Ibandronate		NCCCC(O)(P(O)(O)=O)P(O)(O)=O
advise	" DRUG1  should be taken at least 60 minutes before any oral medications containing multivalent cations (including  DRUG2 , supplements or  DRUGOTHER )."	Ibandronate	antacids	NCCCC(O)(P(O)(O)=O)P(O)(O)=O	
advise	" DRUG1  should be taken at least 60 minutes before any oral medications containing multivalent cations (including  DRUGOTHER , supplements or  DRUG2 )."	Ibandronate	vitamins	NCCCC(O)(P(O)(O)=O)P(O)(O)=O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  should be taken at least 60 minutes before any oral medications containing multivalent cations (including  DRUG1 , supplements or  DRUG2 )."	antacids	vitamins		OC(=O)CCCCCCCC(O)=O
other	 DRUG1  and  DRUG2  ( DRUGOTHER )	H2 Blockers	Proton Pump Inhibitors		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	 DRUG1  and  DRUGOTHER  ( DRUG2 )	H2 Blockers	PPIs		
other	 DRUGOTHER  and  DRUG1  ( DRUG2 )	Proton Pump Inhibitors	PPIs	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	
other	"Of over 3500 patients enrolled in the  DRUG1  osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily  DRUG2  and  DRUGOTHER )."	Ibandronate	H2 blockers	NCCCC(O)(P(O)(O)=O)P(O)(O)=O	
other	"Of over 3500 patients enrolled in the  DRUG1  osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily  DRUGOTHER  and  DRUG2 )."	Ibandronate	PPIs	NCCCC(O)(P(O)(O)=O)P(O)(O)=O	
other	"Of over 3500 patients enrolled in the  DRUGOTHER  osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily  DRUG1  and  DRUG2 )."	H2 blockers	PPIs		
other	"Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with  DRUG1  150 mg once monthly was similar to that in patients treated with  DRUG2  2.5 mg once daily."	Ibandronate	Ibandronate	NCCCC(O)(P(O)(O)=O)P(O)(O)=O	NCCCC(O)(P(O)(O)=O)P(O)(O)=O
other	 DRUG1 / DRUG2 s ( DRUGOTHER )	Aspirin	Nonsteroidal Antiinflammatory Drug	CC(=O)OC1=CC=CC=C1C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	 DRUG1 / DRUGOTHER s ( DRUG2 )	Aspirin	NSAIDs	CC(=O)OC1=CC=CC=C1C(O)=O	
other	 DRUGOTHER / DRUG1 s ( DRUG2 )	Nonsteroidal Antiinflammatory Drug	NSAIDs	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	"In the large, placebo-controlled osteoporosis Treatment Study,  DRUG1  and  DRUG2  were taken by 62% of the 2946 patients."	aspirin	nonsteroidal anti-inflammatory drugs	CC(=O)OC1=CC=CC=C1C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Among  DRUG1  or  DRUG2  users, the incidence of upper gastrointestinal adverse events in patients treated with  DRUGOTHER  2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%)."	aspirin	NSAID	CC(=O)OC1=CC=CC=C1C(O)=O	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
other	"Among  DRUG1  or  DRUGOTHER  users, the incidence of upper gastrointestinal adverse events in patients treated with  DRUG2  2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%)."	aspirin	ibandronate	CC(=O)OC1=CC=CC=C1C(O)=O	NCCCC(O)(P(O)(O)=O)P(O)(O)=O
other	"Among  DRUGOTHER  or  DRUG1  users, the incidence of upper gastrointestinal adverse events in patients treated with  DRUG2  2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%)."	NSAID	ibandronate	OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl	NCCCC(O)(P(O)(O)=O)P(O)(O)=O
other	"Similarly, in the 1-year monthly comparison study,  DRUG1  and  DRUG2  were taken by 39% of the 1602 patients."	aspirin	nonsteroidal anti-inflammatory drugs	CC(=O)OC1=CC=CC=C1C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	The incidence of upper gastrointestinal events in patients concomitantly taking  DRUG1  or  DRUG2  was similar in patients taking  DRUGOTHER  2.5 mg daily (21.7%) and 150 mg once monthly (22.0%).	aspirin	NSAIDs	CC(=O)OC1=CC=CC=C1C(O)=O	
other	The incidence of upper gastrointestinal events in patients concomitantly taking  DRUG1  or  DRUGOTHER  was similar in patients taking  DRUG2  2.5 mg daily (21.7%) and 150 mg once monthly (22.0%).	aspirin	ibandronate	CC(=O)OC1=CC=CC=C1C(O)=O	NCCCC(O)(P(O)(O)=O)P(O)(O)=O
other	The incidence of upper gastrointestinal events in patients concomitantly taking  DRUGOTHER  or  DRUG1  was similar in patients taking  DRUG2  2.5 mg daily (21.7%) and 150 mg once monthly (22.0%).	NSAIDs	ibandronate		NCCCC(O)(P(O)(O)=O)P(O)(O)=O
other	"However, since  DRUG1 ,  DRUG2 , and  DRUGOTHER  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  DRUGOTHER  or  DRUGOTHER  with  DRUGOTHER ."	aspirin	NSAIDs	CC(=O)OC1=CC=CC=C1C(O)=O	
other	"However, since  DRUG1 ,  DRUGOTHER , and  DRUG2  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  DRUGOTHER  or  DRUGOTHER  with  DRUGOTHER ."	aspirin	bisphosphonates	CC(=O)OC1=CC=CC=C1C(O)=O	
other	"However, since  DRUG1 ,  DRUGOTHER , and  DRUGOTHER  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  DRUG2  or  DRUGOTHER  with  DRUGOTHER ."	aspirin	aspirin	CC(=O)OC1=CC=CC=C1C(O)=O	CC(=O)OC1=CC=CC=C1C(O)=O
other	"However, since  DRUG1 ,  DRUGOTHER , and  DRUGOTHER  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  DRUGOTHER  or  DRUG2  with  DRUGOTHER ."	aspirin	NSAIDs	CC(=O)OC1=CC=CC=C1C(O)=O	
other	"However, since  DRUG1 ,  DRUGOTHER , and  DRUGOTHER  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  DRUGOTHER  or  DRUGOTHER  with  DRUG2 ."	aspirin	Ibandronate	CC(=O)OC1=CC=CC=C1C(O)=O	NCCCC(O)(P(O)(O)=O)P(O)(O)=O
other	"However, since  DRUGOTHER ,  DRUG1 , and  DRUG2  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  DRUGOTHER  or  DRUGOTHER  with  DRUGOTHER ."	NSAIDs	bisphosphonates		
other	"However, since  DRUGOTHER ,  DRUG1 , and  DRUGOTHER  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  DRUG2  or  DRUGOTHER  with  DRUGOTHER ."	NSAIDs	aspirin		CC(=O)OC1=CC=CC=C1C(O)=O
other	"However, since  DRUGOTHER ,  DRUG1 , and  DRUGOTHER  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  DRUGOTHER  or  DRUG2  with  DRUGOTHER ."	NSAIDs	NSAIDs		
other	"However, since  DRUGOTHER ,  DRUG1 , and  DRUGOTHER  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  DRUGOTHER  or  DRUGOTHER  with  DRUG2 ."	NSAIDs	Ibandronate		NCCCC(O)(P(O)(O)=O)P(O)(O)=O
other	"However, since  DRUGOTHER ,  DRUGOTHER , and  DRUG1  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  DRUG2  or  DRUGOTHER  with  DRUGOTHER ."	bisphosphonates	aspirin		CC(=O)OC1=CC=CC=C1C(O)=O
other	"However, since  DRUGOTHER ,  DRUGOTHER , and  DRUG1  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  DRUGOTHER  or  DRUG2  with  DRUGOTHER ."	bisphosphonates	NSAIDs		
other	"However, since  DRUGOTHER ,  DRUGOTHER , and  DRUG1  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  DRUGOTHER  or  DRUGOTHER  with  DRUG2 ."	bisphosphonates	Ibandronate		NCCCC(O)(P(O)(O)=O)P(O)(O)=O
other	"However, since  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  DRUG1  or  DRUG2  with  DRUGOTHER ."	aspirin	NSAIDs	CC(=O)OC1=CC=CC=C1C(O)=O	
advise	"However, since  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  DRUG1  or  DRUGOTHER  with  DRUG2 ."	aspirin	Ibandronate	CC(=O)OC1=CC=CC=C1C(O)=O	NCCCC(O)(P(O)(O)=O)P(O)(O)=O
advise	"However, since  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of  DRUGOTHER  or  DRUG1  with  DRUG2 ."	NSAIDs	Ibandronate		NCCCC(O)(P(O)(O)=O)P(O)(O)=O
other	"The  DRUG1 , including  DRUG2 , produce additive CNS depressant effects when co-administered with other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs which themselves produce CNS depression."	benzodiazepines	alprazolam	N1N=CC=CC2=CC=CC=C12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
effect	"The  DRUG1 , including  DRUGOTHER , produce additive CNS depressant effects when co-administered with other  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs which themselves produce CNS depression."	benzodiazepines	psychotropic medications	N1N=CC=CC2=CC=CC=C12	
effect	"The  DRUG1 , including  DRUGOTHER , produce additive CNS depressant effects when co-administered with other  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other drugs which themselves produce CNS depression."	benzodiazepines	anticonvulsants	N1N=CC=CC2=CC=CC=C12	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
effect	"The  DRUG1 , including  DRUGOTHER , produce additive CNS depressant effects when co-administered with other  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other drugs which themselves produce CNS depression."	benzodiazepines	antihistaminics	N1N=CC=CC2=CC=CC=C12	OC(=O)CCCCCCCC(O)=O
effect	"The  DRUG1 , including  DRUGOTHER , produce additive CNS depressant effects when co-administered with other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other drugs which themselves produce CNS depression."	benzodiazepines	ethanol	N1N=CC=CC2=CC=CC=C12	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
effect	"The  DRUGOTHER , including  DRUG1 , produce additive CNS depressant effects when co-administered with other  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs which themselves produce CNS depression."	alprazolam	psychotropic medications	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	
effect	"The  DRUGOTHER , including  DRUG1 , produce additive CNS depressant effects when co-administered with other  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other drugs which themselves produce CNS depression."	alprazolam	anticonvulsants	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
effect	"The  DRUGOTHER , including  DRUG1 , produce additive CNS depressant effects when co-administered with other  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other drugs which themselves produce CNS depression."	alprazolam	antihistaminics	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	OC(=O)CCCCCCCC(O)=O
effect	"The  DRUGOTHER , including  DRUG1 , produce additive CNS depressant effects when co-administered with other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other drugs which themselves produce CNS depression."	alprazolam	ethanol	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"The  DRUGOTHER , including  DRUGOTHER , produce additive CNS depressant effects when co-administered with other  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other drugs which themselves produce CNS depression."	psychotropic medications	anticonvulsants		NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
other	"The  DRUGOTHER , including  DRUGOTHER , produce additive CNS depressant effects when co-administered with other  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other drugs which themselves produce CNS depression."	psychotropic medications	antihistaminics		OC(=O)CCCCCCCC(O)=O
other	"The  DRUGOTHER , including  DRUGOTHER , produce additive CNS depressant effects when co-administered with other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other drugs which themselves produce CNS depression."	psychotropic medications	ethanol		OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"The  DRUGOTHER , including  DRUGOTHER , produce additive CNS depressant effects when co-administered with other  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and other drugs which themselves produce CNS depression."	anticonvulsants	antihistaminics	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1	OC(=O)CCCCCCCC(O)=O
other	"The  DRUGOTHER , including  DRUGOTHER , produce additive CNS depressant effects when co-administered with other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and other drugs which themselves produce CNS depression."	anticonvulsants	ethanol	NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"The  DRUGOTHER , including  DRUGOTHER , produce additive CNS depressant effects when co-administered with other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and other drugs which themselves produce CNS depression."	antihistaminics	ethanol	OC(=O)CCCCCCCC(O)=O	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
other	"The steady state plasma concentrations of  DRUG1  and  DRUG2  have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of  DRUGOTHER  tablets in doses up to 4 mg/day."	imipramine	desipramine	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
mechanism	"The steady state plasma concentrations of  DRUG1  and  DRUGOTHER  have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of  DRUG2  tablets in doses up to 4 mg/day."	imipramine	alprazolam	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
mechanism	"The steady state plasma concentrations of  DRUGOTHER  and  DRUG1  have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of  DRUG2  tablets in doses up to 4 mg/day."	desipramine	alprazolam	CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	Drugs That Inhibit  DRUG1  Metabolism Via Cytochrome P450 3A: The initial step in  DRUG2  metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A).	Alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving  DRUG1  (caution is recommended during coadministration with  DRUG2 ): Coadministration of  DRUGOTHER  with  DRUGOTHER  increased the maximum plasma concentration of  DRUGOTHER  by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance."	Alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving  DRUG1  (caution is recommended during coadministration with  DRUGOTHER ): Coadministration of  DRUG2  with  DRUGOTHER  increased the maximum plasma concentration of  DRUGOTHER  by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance."	Alprazolam	fluoxetine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving  DRUG1  (caution is recommended during coadministration with  DRUGOTHER ): Coadministration of  DRUGOTHER  with  DRUG2  increased the maximum plasma concentration of  DRUGOTHER  by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance."	Alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving  DRUG1  (caution is recommended during coadministration with  DRUGOTHER ): Coadministration of  DRUGOTHER  with  DRUGOTHER  increased the maximum plasma concentration of  DRUG2  by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance."	Alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving  DRUGOTHER  (caution is recommended during coadministration with  DRUG1 ): Coadministration of  DRUG2  with  DRUGOTHER  increased the maximum plasma concentration of  DRUGOTHER  by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance."	alprazolam	fluoxetine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	"Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving  DRUGOTHER  (caution is recommended during coadministration with  DRUG1 ): Coadministration of  DRUGOTHER  with  DRUG2  increased the maximum plasma concentration of  DRUGOTHER  by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance."	alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving  DRUGOTHER  (caution is recommended during coadministration with  DRUG1 ): Coadministration of  DRUGOTHER  with  DRUGOTHER  increased the maximum plasma concentration of  DRUG2  by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance."	alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
mechanism	"Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Coadministration of  DRUG1  with  DRUG2  increased the maximum plasma concentration of  DRUGOTHER  by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance."	fluoxetine	alprazolam	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Coadministration of  DRUG1  with  DRUGOTHER  increased the maximum plasma concentration of  DRUG2  by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance."	fluoxetine	alprazolam	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Coadministration of  DRUGOTHER  with  DRUG1  increased the maximum plasma concentration of  DRUG2  by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance."	alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
mechanism	"Coadministration of  DRUG1  decreased the maximum plasma concentration of  DRUG2  by 6%, decreased clearance by 38%, and increased half-life by 58%."	propoxyphene	alprazolam	[H][C@](C)(CN(C)C)[C@@](CC1=CC=CC=C1)(OC(=O)CC)C1=CC=CC=C1	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
mechanism	"Coadministration of oral  DRUG1  increased the maximum plasma concentration of  DRUG2  by 18%, decreased clearance by 22%, and increased half-life by 29%."	contraceptives	alprazolam	[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUG1  metabolized similarly to  DRUG2  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	alprazolam	N1N=CC=CC2=CC=CC=C12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUG1  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUG2  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	alprazolam	N1N=CC=CC2=CC=CC=C12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUG1  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUG2  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	benzodiazepines	N1N=CC=CC2=CC=CC=C12	N1N=CC=CC2=CC=CC=C12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUG1  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUG2 ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	alprazolam	N1N=CC=CC2=CC=CC=C12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUG1  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUG2  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	benzodiazepines	N1N=CC=CC2=CC=CC=C12	N1N=CC=CC2=CC=CC=C12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUG1  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUG2  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	alprazolam	N1N=CC=CC2=CC=CC=C12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUG1  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUG2  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	alprazolam	N1N=CC=CC2=CC=CC=C12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUG1  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	diltiazem	N1N=CC=CC2=CC=CC=C12	
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUG1  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	isoniazid	N1N=CC=CC2=CC=CC=C12	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUG1  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG2  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	macrolide antibiotics	N1N=CC=CC2=CC=CC=C12	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUG1  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUG2  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	erythromycin	N1N=CC=CC2=CC=CC=C12	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUG1  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUG2 , and grapefruit juice."	benzodiazepines	clarithromycin	N1N=CC=CC2=CC=CC=C12	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUG1  or on the basis of in vitro studies with  DRUG2  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUG1  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUG2  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	benzodiazepines	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	N1N=CC=CC2=CC=CC=C12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUG1  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUG2 ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUG1  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUG2  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	benzodiazepines	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	N1N=CC=CC2=CC=CC=C12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUG1  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUG2  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUG1  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUG2  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUG1  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	diltiazem	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUG1  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	isoniazid	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUG1  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG2  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	macrolide antibiotics	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUG1  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUG2  and  DRUGOTHER , and grapefruit juice."	alprazolam	erythromycin	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUG1  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUG2 , and grapefruit juice."	alprazolam	clarithromycin	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUG1  or other  DRUG2  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	benzodiazepines	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	N1N=CC=CC2=CC=CC=C12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUG1  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUG2 ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUG1  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUG2  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	benzodiazepines	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	N1N=CC=CC2=CC=CC=C12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUG1  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUG2  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUG1  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUG2  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUG1  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	diltiazem	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUG1  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	isoniazid	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUG1  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG2  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	macrolide antibiotics	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUG1  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUG2  and  DRUGOTHER , and grapefruit juice."	alprazolam	erythromycin	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUG1  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUG2 , and grapefruit juice."	alprazolam	clarithromycin	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUG1  (caution is recommended during coadministration with  DRUG2 ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	alprazolam	N1N=CC=CC2=CC=CC=C12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUG1  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUG2  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	benzodiazepines	N1N=CC=CC2=CC=CC=C12	N1N=CC=CC2=CC=CC=C12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUG1  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUG2  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	alprazolam	N1N=CC=CC2=CC=CC=C12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUG1  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUG2  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	alprazolam	N1N=CC=CC2=CC=CC=C12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUG1  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	diltiazem	N1N=CC=CC2=CC=CC=C12	
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUG1  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	isoniazid	N1N=CC=CC2=CC=CC=C12	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUG1  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG2  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	macrolide antibiotics	N1N=CC=CC2=CC=CC=C12	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUG1  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUG2  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	erythromycin	N1N=CC=CC2=CC=CC=C12	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUG1  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUG2 , and grapefruit juice."	benzodiazepines	clarithromycin	N1N=CC=CC2=CC=CC=C12	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUG1 ): Available data from clinical studies of  DRUG2  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	benzodiazepines	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	N1N=CC=CC2=CC=CC=C12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUG1 ): Available data from clinical studies of  DRUGOTHER  other than  DRUG2  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUG1 ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUG2  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUG1 ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	diltiazem	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUG1 ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	isoniazid	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUG1 ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG2  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	macrolide antibiotics	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUG1 ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUG2  and  DRUGOTHER , and grapefruit juice."	alprazolam	erythromycin	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUG1 ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUG2 , and grapefruit juice."	alprazolam	clarithromycin	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUG1  other than  DRUG2  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	alprazolam	N1N=CC=CC2=CC=CC=C12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUG1  other than  DRUGOTHER  suggest a possible drug interaction with  DRUG2  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	alprazolam	N1N=CC=CC2=CC=CC=C12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUG1  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	diltiazem	N1N=CC=CC2=CC=CC=C12	
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUG1  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	isoniazid	N1N=CC=CC2=CC=CC=C12	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUG1  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG2  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	macrolide antibiotics	N1N=CC=CC2=CC=CC=C12	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUG1  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUG2  and  DRUGOTHER , and grapefruit juice."	benzodiazepines	erythromycin	N1N=CC=CC2=CC=CC=C12	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUG1  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUG2 , and grapefruit juice."	benzodiazepines	clarithromycin	N1N=CC=CC2=CC=CC=C12	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUG1  suggest a possible drug interaction with  DRUG2  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUG1  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	diltiazem	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUG1  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	isoniazid	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUG1  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG2  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	macrolide antibiotics	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUG1  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUG2  and  DRUGOTHER , and grapefruit juice."	alprazolam	erythromycin	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUG1  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUG2 , and grapefruit juice."	alprazolam	clarithromycin	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
int	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUG1  for the following:  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	diltiazem	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	
int	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUG1  for the following:  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	isoniazid	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
int	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUG1  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG2  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	alprazolam	macrolide antibiotics	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
int	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUG1  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUG2  and  DRUGOTHER , and grapefruit juice."	alprazolam	erythromycin	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
int	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUG1  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUG2 , and grapefruit juice."	alprazolam	clarithromycin	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUG1 ,  DRUG2 ,  DRUGOTHER  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	diltiazem	isoniazid		CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUG1 ,  DRUGOTHER ,  DRUG2  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	diltiazem	macrolide antibiotics		[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  such as  DRUG2  and  DRUGOTHER , and grapefruit juice."	diltiazem	erythromycin		CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  such as  DRUGOTHER  and  DRUG2 , and grapefruit juice."	diltiazem	clarithromycin		[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUG1 ,  DRUG2  such as  DRUGOTHER  and  DRUGOTHER , and grapefruit juice."	isoniazid	macrolide antibiotics	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  such as  DRUG2  and  DRUGOTHER , and grapefruit juice."	isoniazid	erythromycin	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  such as  DRUGOTHER  and  DRUG2 , and grapefruit juice."	isoniazid	clarithromycin	CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1  such as  DRUG2  and  DRUGOTHER , and grapefruit juice."	macrolide antibiotics	erythromycin	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1  such as  DRUGOTHER  and  DRUG2 , and grapefruit juice."	macrolide antibiotics	clarithromycin	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving  DRUGOTHER  metabolized similarly to  DRUGOTHER  or on the basis of in vitro studies with  DRUGOTHER  or other  DRUGOTHER  (caution is recommended during coadministration with  DRUGOTHER ): Available data from clinical studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  such as  DRUG1  and  DRUG2 , and grapefruit juice."	erythromycin	clarithromycin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	Data from in vitro studies of  DRUG1  suggest a possible drug interaction with  DRUG2  for the following:  DRUGOTHER  and  DRUGOTHER .	alprazolam	alprazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	Data from in vitro studies of  DRUG1  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUG2  and  DRUGOTHER .	alprazolam	sertraline	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
other	Data from in vitro studies of  DRUG1  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUGOTHER  and  DRUG2 .	alprazolam	paroxetine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
int	Data from in vitro studies of  DRUGOTHER  suggest a possible drug interaction with  DRUG1  for the following:  DRUG2  and  DRUGOTHER .	alprazolam	sertraline	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
int	Data from in vitro studies of  DRUGOTHER  suggest a possible drug interaction with  DRUG1  for the following:  DRUGOTHER  and  DRUG2 .	alprazolam	paroxetine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	Data from in vitro studies of  DRUGOTHER  suggest a possible drug interaction with  DRUGOTHER  for the following:  DRUG1  and  DRUG2 .	sertraline	paroxetine	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	"Data from in vitro studies of  DRUG1  other than  DRUG2  suggest a possible drug interaction for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	benzodiazepines	alprazolam	N1N=CC=CC2=CC=CC=C12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
int	"Data from in vitro studies of  DRUG1  other than  DRUGOTHER  suggest a possible drug interaction for the following:  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	benzodiazepines	ergotamine	N1N=CC=CC2=CC=CC=C12	OC(=O)CCCCCCCC(O)=O
int	"Data from in vitro studies of  DRUG1  other than  DRUGOTHER  suggest a possible drug interaction for the following:  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	benzodiazepines	cyclosporine	N1N=CC=CC2=CC=CC=C12	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
int	"Data from in vitro studies of  DRUG1  other than  DRUGOTHER  suggest a possible drug interaction for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	benzodiazepines	amiodarone	N1N=CC=CC2=CC=CC=C12	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
int	"Data from in vitro studies of  DRUG1  other than  DRUGOTHER  suggest a possible drug interaction for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	benzodiazepines	nicardipine	N1N=CC=CC2=CC=CC=C12	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
int	"Data from in vitro studies of  DRUG1  other than  DRUGOTHER  suggest a possible drug interaction for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	benzodiazepines	nifedipine	N1N=CC=CC2=CC=CC=C12	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
int	"Data from in vitro studies of  DRUGOTHER  other than  DRUG1  suggest a possible drug interaction for the following:  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	ergotamine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	OC(=O)CCCCCCCC(O)=O
int	"Data from in vitro studies of  DRUGOTHER  other than  DRUG1  suggest a possible drug interaction for the following:  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	cyclosporine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
int	"Data from in vitro studies of  DRUGOTHER  other than  DRUG1  suggest a possible drug interaction for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	alprazolam	amiodarone	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
int	"Data from in vitro studies of  DRUGOTHER  other than  DRUG1  suggest a possible drug interaction for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	alprazolam	nicardipine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
int	"Data from in vitro studies of  DRUGOTHER  other than  DRUG1  suggest a possible drug interaction for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	alprazolam	nifedipine	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Data from in vitro studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction for the following:  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	ergotamine	cyclosporine	OC(=O)CCCCCCCC(O)=O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Data from in vitro studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction for the following:  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	ergotamine	amiodarone	OC(=O)CCCCCCCC(O)=O	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	"Data from in vitro studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction for the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	ergotamine	nicardipine	OC(=O)CCCCCCCC(O)=O	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Data from in vitro studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction for the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	ergotamine	nifedipine	OC(=O)CCCCCCCC(O)=O	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Data from in vitro studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction for the following:  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporine	amiodarone	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	"Data from in vitro studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction for the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	cyclosporine	nicardipine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Data from in vitro studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction for the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	cyclosporine	nifedipine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Data from in vitro studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ."	amiodarone	nicardipine	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Data from in vitro studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ."	amiodarone	nifedipine	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"Data from in vitro studies of  DRUGOTHER  other than  DRUGOTHER  suggest a possible drug interaction for the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ."	nicardipine	nifedipine	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1	CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1
other	"May interact with  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	cefamandole naftate	cephalothin sodium	[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"May interact with  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	cefamandole naftate	magnesium sulfate	[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O	[MgH2]
other	"May interact with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	cefamandole naftate	prednisolone sodium succinate	[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C
other	"May interact with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	cefamandole naftate	prochlorperazine edisylate	[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)[C@H](O)C1=CC=CC=C1)C(O)=O	CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
other	"May interact with  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	cephalothin sodium	magnesium sulfate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[MgH2]
other	"May interact with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	cephalothin sodium	prednisolone sodium succinate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C
other	"May interact with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	cephalothin sodium	prochlorperazine edisylate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
other	"May interact with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ."	magnesium sulfate	prednisolone sodium succinate	[MgH2]	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C
other	"May interact with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ."	magnesium sulfate	prochlorperazine edisylate	[MgH2]	CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
other	"May interact with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ."	prednisolone sodium succinate	prochlorperazine edisylate	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C	CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
other	Several drug interaction studies have been completed with both  DRUG1  and  DRUG2 .	INVIRASE	FORTOVASE	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	Observations from drug interaction studies with  DRUG1  may not be predictive for  DRUG2 .	FORTOVASE	INVIRASE	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Because  DRUG1  is coadministered, prescribers should also refer to the prescribing information for  DRUG2  regarding drug interactions associated with this agent."	ritonavir	ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	Additional drugs that are not recommended for coadministration with  DRUG1  and  DRUG2  are included below.	INVIRASE	ritonavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	Drugs That Should Not Be Coadministered With  DRUG1 / DRUG2 	INVIRASE	Ritonavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	" DRUG1 :  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and/or life-threatening reactions."	Antiarrhythmics	Amiodarone		CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	" DRUG1 :  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and/or life-threatening reactions."	Antiarrhythmics	bepridil		CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
other	" DRUG1 :  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and/or life-threatening reactions."	Antiarrhythmics	flecainide		FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	" DRUG1 :  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and/or life-threatening reactions."	Antiarrhythmics	propafenone		CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
other	" DRUG1 :  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  CONTRAINDICATED due to potential for serious and/or life-threatening reactions."	Antiarrhythmics	quinidine		CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	" DRUGOTHER :  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and/or life-threatening reactions."	Amiodarone	bepridil	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
other	" DRUGOTHER :  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and/or life-threatening reactions."	Amiodarone	flecainide	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	" DRUGOTHER :  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and/or life-threatening reactions."	Amiodarone	propafenone	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
other	" DRUGOTHER :  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  CONTRAINDICATED due to potential for serious and/or life-threatening reactions."	Amiodarone	quinidine	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	" DRUGOTHER :  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and/or life-threatening reactions."	bepridil	flecainide	CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
other	" DRUGOTHER :  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and/or life-threatening reactions."	bepridil	propafenone	CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
other	" DRUGOTHER :  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  CONTRAINDICATED due to potential for serious and/or life-threatening reactions."	bepridil	quinidine	CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	" DRUGOTHER :  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and/or life-threatening reactions."	flecainide	propafenone	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
other	" DRUGOTHER :  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  CONTRAINDICATED due to potential for serious and/or life-threatening reactions."	flecainide	quinidine	FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	" DRUGOTHER :  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  CONTRAINDICATED due to potential for serious and/or life-threatening reactions."	propafenone	quinidine	CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	" DRUG1 :  DRUG2 *,  DRUGOTHER * CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias."	Antihistamines	astemizole	NCCC1=CNC=N1	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1
other	" DRUG1 :  DRUGOTHER *,  DRUG2 * CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias."	Antihistamines	terfenadine	NCCC1=CNC=N1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	" DRUGOTHER :  DRUG1 *,  DRUG2 * CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias."	astemizole	terfenadine	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	" DRUG1 :  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  DRUGOTHER  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."	Ergot Derivatives	Dihydroergotamine		[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
other	" DRUG1 :  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  DRUGOTHER  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."	Ergot Derivatives	ergonovine		[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO
other	" DRUG1 :  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  DRUGOTHER  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."	Ergot Derivatives	ergotamine		OC(=O)CCCCCCCC(O)=O
other	" DRUG1 :  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  DRUGOTHER  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."	Ergot Derivatives	methylergonovine		[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO
other	" DRUG1 :  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  DRUG2  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."	Ergot Derivatives	ergot		CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@H]1[C@H](C)O[C@H](C[C@@H]1OC)O[C@H]1[C@@H](C)\C=C\C=C2/CO[C@@H]3[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]4C[C@@H](C\C=C1/C)O[C@@]1(CC[C@H](C)[C@@H](C(C)C)O1)C4)[C@]23O.CC[C@@H](C)[C@H]1O[C@@]2(CC[C@@H]1C)O[C@@H]1C\C=C(C)\[C@@H](O[C@@H]3O[C@@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)C4)[C@@H](OC)C3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@@H](C1)C2)[C@]34O
other	" DRUGOTHER :  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  DRUGOTHER  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."	Dihydroergotamine	ergonovine	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O	[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO
other	" DRUGOTHER :  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  DRUGOTHER  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."	Dihydroergotamine	ergotamine	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER :  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  DRUGOTHER  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."	Dihydroergotamine	methylergonovine	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O	[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO
other	" DRUGOTHER :  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  DRUG2  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."	Dihydroergotamine	ergot	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O	CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@H]1[C@H](C)O[C@H](C[C@@H]1OC)O[C@H]1[C@@H](C)\C=C\C=C2/CO[C@@H]3[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]4C[C@@H](C\C=C1/C)O[C@@]1(CC[C@H](C)[C@@H](C(C)C)O1)C4)[C@]23O.CC[C@@H](C)[C@H]1O[C@@]2(CC[C@@H]1C)O[C@@H]1C\C=C(C)\[C@@H](O[C@@H]3O[C@@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)C4)[C@@H](OC)C3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@@H](C1)C2)[C@]34O
other	" DRUGOTHER :  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  DRUGOTHER  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."	ergonovine	ergotamine	[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER :  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  DRUGOTHER  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."	ergonovine	methylergonovine	[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO	[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO
other	" DRUGOTHER :  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  DRUG2  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."	ergonovine	ergot	[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO	CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@H]1[C@H](C)O[C@H](C[C@@H]1OC)O[C@H]1[C@@H](C)\C=C\C=C2/CO[C@@H]3[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]4C[C@@H](C\C=C1/C)O[C@@]1(CC[C@H](C)[C@@H](C(C)C)O1)C4)[C@]23O.CC[C@@H](C)[C@H]1O[C@@]2(CC[C@@H]1C)O[C@@H]1C\C=C(C)\[C@@H](O[C@@H]3O[C@@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)C4)[C@@H](OC)C3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@@H](C1)C2)[C@]34O
other	" DRUGOTHER :  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  DRUGOTHER  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."	ergotamine	methylergonovine	OC(=O)CCCCCCCC(O)=O	[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO
other	" DRUGOTHER :  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  DRUG2  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."	ergotamine	ergot	OC(=O)CCCCCCCC(O)=O	CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@H]1[C@H](C)O[C@H](C[C@@H]1OC)O[C@H]1[C@@H](C)\C=C\C=C2/CO[C@@H]3[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]4C[C@@H](C\C=C1/C)O[C@@]1(CC[C@H](C)[C@@H](C(C)C)O1)C4)[C@]23O.CC[C@@H](C)[C@H]1O[C@@]2(CC[C@@H]1C)O[C@@H]1C\C=C(C)\[C@@H](O[C@@H]3O[C@@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)C4)[C@@H](OC)C3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@@H](C1)C2)[C@]34O
other	" DRUGOTHER :  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute  DRUG2  toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues."	methylergonovine	ergot	[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO	CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@H]1[C@H](C)O[C@H](C[C@@H]1OC)O[C@H]1[C@@H](C)\C=C\C=C2/CO[C@@H]3[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]4C[C@@H](C\C=C1/C)O[C@@]1(CC[C@H](C)[C@@H](C(C)C)O1)C4)[C@]23O.CC[C@@H](C)[C@H]1O[C@@]2(CC[C@@H]1C)O[C@@H]1C\C=C(C)\[C@@H](O[C@@H]3O[C@@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)C4)[C@@H](OC)C3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@@H](C1)C2)[C@]34O
other	 DRUG1 :  DRUG2  CONTRAINDICATED since the coadministration of this product with  DRUGOTHER  in an  DRUGOTHER  regimen reduces the plasma concentrations of  DRUGOTHER .	Antimycobacterial Agents	rifampin	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	 DRUG1 :  DRUGOTHER  CONTRAINDICATED since the coadministration of this product with  DRUG2  in an  DRUGOTHER  regimen reduces the plasma concentrations of  DRUGOTHER .	Antimycobacterial Agents	saquinavir	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUG1 :  DRUGOTHER  CONTRAINDICATED since the coadministration of this product with  DRUGOTHER  in an  DRUG2  regimen reduces the plasma concentrations of  DRUGOTHER .	Antimycobacterial Agents	antiretroviral	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	 DRUG1 :  DRUGOTHER  CONTRAINDICATED since the coadministration of this product with  DRUGOTHER  in an  DRUGOTHER  regimen reduces the plasma concentrations of  DRUG2 .	Antimycobacterial Agents	saquinavir	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER :  DRUG1  CONTRAINDICATED since the coadministration of this product with  DRUG2  in an  DRUGOTHER  regimen reduces the plasma concentrations of  DRUGOTHER .	rifampin	saquinavir	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER :  DRUG1  CONTRAINDICATED since the coadministration of this product with  DRUGOTHER  in an  DRUG2  regimen reduces the plasma concentrations of  DRUGOTHER .	rifampin	antiretroviral	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	 DRUGOTHER :  DRUG1  CONTRAINDICATED since the coadministration of this product with  DRUGOTHER  in an  DRUGOTHER  regimen reduces the plasma concentrations of  DRUG2 .	rifampin	saquinavir	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER :  DRUGOTHER  CONTRAINDICATED since the coadministration of this product with  DRUG1  in an  DRUG2  regimen reduces the plasma concentrations of  DRUGOTHER .	saquinavir	antiretroviral	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
other	 DRUGOTHER :  DRUGOTHER  CONTRAINDICATED since the coadministration of this product with  DRUG1  in an  DRUGOTHER  regimen reduces the plasma concentrations of  DRUG2 .	saquinavir	saquinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	 DRUGOTHER :  DRUGOTHER  CONTRAINDICATED since the coadministration of this product with  DRUGOTHER  in an  DRUG1  regimen reduces the plasma concentrations of  DRUG2 .	antiretroviral	saquinavir	CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	Garlic Capsules Garlic capsules should not be used while taking  DRUG1  ( DRUG2 ) as the sole  DRUGOTHER  due to the risk of decreased  DRUGOTHER  plasma concentrations.	saquinavir	FORTOVASE	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	Garlic Capsules Garlic capsules should not be used while taking  DRUG1  ( DRUGOTHER ) as the sole  DRUG2  due to the risk of decreased  DRUGOTHER  plasma concentrations.	saquinavir	protease inhibitor	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	
other	Garlic Capsules Garlic capsules should not be used while taking  DRUG1  ( DRUGOTHER ) as the sole  DRUGOTHER  due to the risk of decreased  DRUG2  plasma concentrations.	saquinavir	saquinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	Garlic Capsules Garlic capsules should not be used while taking  DRUGOTHER  ( DRUG1 ) as the sole  DRUG2  due to the risk of decreased  DRUGOTHER  plasma concentrations.	FORTOVASE	protease inhibitor	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	
other	Garlic Capsules Garlic capsules should not be used while taking  DRUGOTHER  ( DRUG1 ) as the sole  DRUGOTHER  due to the risk of decreased  DRUG2  plasma concentrations.	FORTOVASE	saquinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	Garlic Capsules Garlic capsules should not be used while taking  DRUGOTHER  ( DRUGOTHER ) as the sole  DRUG1  due to the risk of decreased  DRUG2  plasma concentrations.	protease inhibitor	saquinavir		[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	No data are available for the coadministration of  DRUG1 / DRUG2  or  DRUGOTHER / DRUGOTHER  and garlic capsules.	INVIRASE	ritonavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	No data are available for the coadministration of  DRUG1 / DRUGOTHER  or  DRUG2 / DRUGOTHER  and garlic capsules.	INVIRASE	FORTOVASE	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	No data are available for the coadministration of  DRUG1 / DRUGOTHER  or  DRUGOTHER / DRUG2  and garlic capsules.	INVIRASE	ritonavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	No data are available for the coadministration of  DRUGOTHER / DRUG1  or  DRUG2 / DRUGOTHER  and garlic capsules.	ritonavir	FORTOVASE	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	No data are available for the coadministration of  DRUGOTHER / DRUG1  or  DRUGOTHER / DRUG2  and garlic capsules.	ritonavir	ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	No data are available for the coadministration of  DRUGOTHER / DRUGOTHER  or  DRUG1 / DRUG2  and garlic capsules.	FORTOVASE	ritonavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	" DRUG1 :  DRUG2 ,  DRUGOTHER  WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis."	HMG-CoA Reductase Inhibitors	lovastatin		[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	" DRUG1 :  DRUGOTHER ,  DRUG2  WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis."	HMG-CoA Reductase Inhibitors	simvastatin		[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC
other	" DRUGOTHER :  DRUG1 ,  DRUG2  WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis."	lovastatin	simvastatin	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC
other	" DRUG1 / DRUG2 :  DRUGOTHER ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression."	Sedatives	Hypnotics		
other	" DRUG1 / DRUGOTHER :  DRUG2 ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression."	Sedatives	triazolam		O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	" DRUG1 / DRUGOTHER :  DRUGOTHER ,  DRUG2  CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression."	Sedatives	midazolam		CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER / DRUG1 :  DRUG2 ,  DRUGOTHER  CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression."	Hypnotics	triazolam		O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	" DRUGOTHER / DRUG1 :  DRUGOTHER ,  DRUG2  CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression."	Hypnotics	midazolam		CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	" DRUGOTHER / DRUGOTHER :  DRUG1 ,  DRUG2  CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression."	triazolam	midazolam	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1	CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	calcium channel blockers	dapsone	[Ca]	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	calcium channel blockers	disopyramide	[Ca]	OC(=O)CCCCCCCC(O)=O
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	calcium channel blockers	quinine	[Ca]	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	calcium channel blockers	amiodarone	[Ca]	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	calcium channel blockers	quinidine	[Ca]	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	calcium channel blockers	warfarin	[Ca]	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	calcium channel blockers	tacrolimus	[Ca]	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	calcium channel blockers	cyclosporine	[Ca]	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	calcium channel blockers	ergot derivatives	[Ca]	
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	calcium channel blockers	pimozide	[Ca]	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	calcium channel blockers	carbamazepine	[Ca]	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	calcium channel blockers	fentanyl	[Ca]	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	calcium channel blockers	alfentanyl	[Ca]	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	calcium channel blockers	alprazolam	[Ca]	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	calcium channel blockers	triazolam	[Ca]	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
mechanism	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUG2 ;"	calcium channel blockers	saquinavir	[Ca]	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	dapsone	disopyramide	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	OC(=O)CCCCCCCC(O)=O
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	dapsone	quinine	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	dapsone	amiodarone	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	dapsone	quinidine	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	dapsone	warfarin	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	dapsone	tacrolimus	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	dapsone	cyclosporine	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	dapsone	ergot derivatives	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	dapsone	pimozide	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	dapsone	carbamazepine	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	dapsone	fentanyl	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	dapsone	alfentanyl	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	dapsone	alprazolam	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	dapsone	triazolam	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
mechanism	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUG2 ;"	dapsone	saquinavir	NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	disopyramide	quinine	OC(=O)CCCCCCCC(O)=O	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	disopyramide	amiodarone	OC(=O)CCCCCCCC(O)=O	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	disopyramide	quinidine	OC(=O)CCCCCCCC(O)=O	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	disopyramide	warfarin	OC(=O)CCCCCCCC(O)=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	disopyramide	tacrolimus	OC(=O)CCCCCCCC(O)=O	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	disopyramide	cyclosporine	OC(=O)CCCCCCCC(O)=O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	disopyramide	ergot derivatives	OC(=O)CCCCCCCC(O)=O	
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	disopyramide	pimozide	OC(=O)CCCCCCCC(O)=O	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	disopyramide	carbamazepine	OC(=O)CCCCCCCC(O)=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	disopyramide	fentanyl	OC(=O)CCCCCCCC(O)=O	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	disopyramide	alfentanyl	OC(=O)CCCCCCCC(O)=O	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	disopyramide	alprazolam	OC(=O)CCCCCCCC(O)=O	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	disopyramide	triazolam	OC(=O)CCCCCCCC(O)=O	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
mechanism	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUG2 ;"	disopyramide	saquinavir	OC(=O)CCCCCCCC(O)=O	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinine	amiodarone	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinine	quinidine	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinine	warfarin	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinine	tacrolimus	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinine	cyclosporine	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinine	ergot derivatives	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinine	pimozide	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinine	carbamazepine	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinine	fentanyl	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinine	alfentanyl	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinine	alprazolam	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinine	triazolam	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
mechanism	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUG2 ;"	quinine	saquinavir	[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	amiodarone	quinidine	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	amiodarone	warfarin	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	amiodarone	tacrolimus	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	amiodarone	cyclosporine	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	amiodarone	ergot derivatives	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	amiodarone	pimozide	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	amiodarone	carbamazepine	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	amiodarone	fentanyl	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	amiodarone	alfentanyl	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	amiodarone	alprazolam	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	amiodarone	triazolam	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
mechanism	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUG2 ;"	amiodarone	saquinavir	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinidine	warfarin	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinidine	tacrolimus	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinidine	cyclosporine	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinidine	ergot derivatives	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinidine	pimozide	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinidine	carbamazepine	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinidine	fentanyl	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinidine	alfentanyl	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinidine	alprazolam	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	quinidine	triazolam	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
mechanism	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUG2 ;"	quinidine	saquinavir	CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1.COC1=CC2=C(C=CN=C2C=C1)C(O)C1CC2CCN1CC2C=C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	warfarin	tacrolimus	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	warfarin	cyclosporine	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	warfarin	ergot derivatives	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	warfarin	pimozide	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	warfarin	carbamazepine	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	warfarin	fentanyl	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	warfarin	alfentanyl	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	warfarin	alprazolam	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	warfarin	triazolam	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
mechanism	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUG2 ;"	warfarin	saquinavir	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	tacrolimus	cyclosporine	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	tacrolimus	ergot derivatives	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC	
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	tacrolimus	pimozide	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	tacrolimus	carbamazepine	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	tacrolimus	fentanyl	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	tacrolimus	alfentanyl	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	tacrolimus	alprazolam	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	tacrolimus	triazolam	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
mechanism	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUG2 ;"	tacrolimus	saquinavir	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	cyclosporine	ergot derivatives	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	cyclosporine	pimozide	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	cyclosporine	carbamazepine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	cyclosporine	fentanyl	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	cyclosporine	alfentanyl	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	cyclosporine	alprazolam	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	cyclosporine	triazolam	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
mechanism	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUG2 ;"	cyclosporine	saquinavir	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	ergot derivatives	pimozide		FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	ergot derivatives	carbamazepine		NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	ergot derivatives	fentanyl		CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	ergot derivatives	alfentanyl		CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	ergot derivatives	alprazolam		CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	ergot derivatives	triazolam		O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
mechanism	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUG2 ;"	ergot derivatives	saquinavir		[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	pimozide	carbamazepine	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	pimozide	fentanyl	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	pimozide	alfentanyl	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	pimozide	alprazolam	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	pimozide	triazolam	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
mechanism	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUG2 ;"	pimozide	saquinavir	FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	carbamazepine	fentanyl	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	carbamazepine	alfentanyl	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	carbamazepine	alprazolam	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	carbamazepine	triazolam	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
mechanism	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUG2 ;"	carbamazepine	saquinavir	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	fentanyl	alfentanyl	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	fentanyl	alprazolam	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	fentanyl	triazolam	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
mechanism	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUG2 ;"	fentanyl	saquinavir	CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	alfentanyl	alprazolam	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	alfentanyl	triazolam	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
mechanism	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUG2 ;"	alfentanyl	saquinavir	CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ) may have elevated plasma concentrations when coadministered with  DRUGOTHER ;"	alprazolam	triazolam	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
mechanism	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) may have elevated plasma concentrations when coadministered with  DRUG2 ;"	alprazolam	saquinavir	CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
mechanism	"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) may have elevated plasma concentrations when coadministered with  DRUG2 ;"	triazolam	saquinavir	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
advise	"Since  DRUG1  is coadministered with  DRUG2 , the  DRUGOTHER  label should be reviewed for additional drugs that should not be coadministered."	INVIRASE	ritonavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	"Since  DRUG1  is coadministered with  DRUGOTHER , the  DRUG2  label should be reviewed for additional drugs that should not be coadministered."	INVIRASE	ritonavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	"Since  DRUGOTHER  is coadministered with  DRUG1 , the  DRUG2  label should be reviewed for additional drugs that should not be coadministered."	ritonavir	ritonavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	"Coadministration with compounds that are potent inducers of CYP3A4 (eg,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) may result in decreased plasma levels of  DRUGOTHER ."	phenobarbital	phenytoin	CCC1(CC)C(=O)NC(=O)NC1=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Coadministration with compounds that are potent inducers of CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) may result in decreased plasma levels of  DRUGOTHER ."	phenobarbital	dexamethasone	CCC1(CC)C(=O)NC(=O)NC1=O	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
other	"Coadministration with compounds that are potent inducers of CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) may result in decreased plasma levels of  DRUGOTHER ."	phenobarbital	carbamazepine	CCC1(CC)C(=O)NC(=O)NC1=O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
mechanism	"Coadministration with compounds that are potent inducers of CYP3A4 (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may result in decreased plasma levels of  DRUG2 ."	phenobarbital	saquinavir	CCC1(CC)C(=O)NC(=O)NC1=O	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Coadministration with compounds that are potent inducers of CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ) may result in decreased plasma levels of  DRUGOTHER ."	phenytoin	dexamethasone	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
other	"Coadministration with compounds that are potent inducers of CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ) may result in decreased plasma levels of  DRUGOTHER ."	phenytoin	carbamazepine	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
mechanism	"Coadministration with compounds that are potent inducers of CYP3A4 (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) may result in decreased plasma levels of  DRUG2 ."	phenytoin	saquinavir	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Coadministration with compounds that are potent inducers of CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ) may result in decreased plasma levels of  DRUGOTHER ."	dexamethasone	carbamazepine	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
mechanism	"Coadministration with compounds that are potent inducers of CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) may result in decreased plasma levels of  DRUG2 ."	dexamethasone	saquinavir	[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
mechanism	"Coadministration with compounds that are potent inducers of CYP3A4 (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) may result in decreased plasma levels of  DRUG2 ."	carbamazepine	saquinavir	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
advise	 DRUG1  injection and  DRUG2  should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.	Isoproterenol hydrochloride	epinephrine	CC(C)NCC(O)C1=CC(O)=C(O)C=C1	
advise	" DRUG1  should be used with caution, if at all, when potent inhalational  DRUG2  such as  DRUGOTHER  are employed because of potential to sensitize the myocardium to effects of  DRUGOTHER ."	ISUPREL	anesthetics	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCOC(=O)C1=CC=C(N)C=C1
advise	" DRUG1  should be used with caution, if at all, when potent inhalational  DRUGOTHER  such as  DRUG2  are employed because of potential to sensitize the myocardium to effects of  DRUGOTHER ."	ISUPREL	halothane	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUG1  should be used with caution, if at all, when potent inhalational  DRUGOTHER  such as  DRUGOTHER  are employed because of potential to sensitize the myocardium to effects of  DRUG2 ."	ISUPREL	sympathomimetic amines	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  should be used with caution, if at all, when potent inhalational  DRUG1  such as  DRUG2  are employed because of potential to sensitize the myocardium to effects of  DRUGOTHER ."	anesthetics	halothane	CCOC(=O)C1=CC=C(N)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUGOTHER  should be used with caution, if at all, when potent inhalational  DRUG1  such as  DRUGOTHER  are employed because of potential to sensitize the myocardium to effects of  DRUG2 ."	anesthetics	sympathomimetic amines	CCOC(=O)C1=CC=C(N)C=C1	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  should be used with caution, if at all, when potent inhalational  DRUGOTHER  such as  DRUG1  are employed because of potential to sensitize the myocardium to effects of  DRUG2 ."	halothane	sympathomimetic amines	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC(=O)CCCCCCCC(O)=O
advise	Special consideration should be given to the administration of  DRUG1  in patients receiving  DRUG2  or other drugs that could cause or potentiate hypotension.	ETHYOL	antihypertensive medications	NCCCNCCSP(O)(O)=O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	 DRUG1     Prolonged action of  DRUG2 	Probenecid	etomidate	CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O	CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1
other	 DRUG1      DRUG2  antagonism	Zimelidine	etomidate	CN(C)C\C=C(\C1=CC=C(Br)C=C1)C1=CC=CN=C1	CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1
other	 DRUG1       DRUG2  antagonism	Aminophylline	Etomidate	OC(=O)CCCCCCCC(O)=O	CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1
other	"Due to a theoretical risk of a pharmacodynamic interaction, use of  DRUG1 -containing or  DRUG2  (like  DRUGOTHER  or  DRUGOTHER ) and  DRUGOTHER  within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS)."	ergotamine	ergot-type medications	OC(=O)CCCCCCCC(O)=O	
other	"Due to a theoretical risk of a pharmacodynamic interaction, use of  DRUG1 -containing or  DRUGOTHER  (like  DRUG2  or  DRUGOTHER ) and  DRUGOTHER  within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS)."	ergotamine	dihydroergotamine	OC(=O)CCCCCCCC(O)=O	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
other	"Due to a theoretical risk of a pharmacodynamic interaction, use of  DRUG1 -containing or  DRUGOTHER  (like  DRUGOTHER  or  DRUG2 ) and  DRUGOTHER  within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS)."	ergotamine	methysergide	OC(=O)CCCCCCCC(O)=O	[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO
advise	"Due to a theoretical risk of a pharmacodynamic interaction, use of  DRUG1 -containing or  DRUGOTHER  (like  DRUGOTHER  or  DRUGOTHER ) and  DRUG2  within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS)."	ergotamine	FROVA	OC(=O)CCCCCCCC(O)=O	CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O
other	"Due to a theoretical risk of a pharmacodynamic interaction, use of  DRUGOTHER -containing or  DRUG1  (like  DRUG2  or  DRUGOTHER ) and  DRUGOTHER  within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS)."	ergot-type medications	dihydroergotamine		[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
other	"Due to a theoretical risk of a pharmacodynamic interaction, use of  DRUGOTHER -containing or  DRUG1  (like  DRUGOTHER  or  DRUG2 ) and  DRUGOTHER  within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS)."	ergot-type medications	methysergide		[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO
advise	"Due to a theoretical risk of a pharmacodynamic interaction, use of  DRUGOTHER -containing or  DRUG1  (like  DRUGOTHER  or  DRUGOTHER ) and  DRUG2  within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS)."	ergot-type medications	FROVA		CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O
other	"Due to a theoretical risk of a pharmacodynamic interaction, use of  DRUGOTHER -containing or  DRUGOTHER  (like  DRUG1  or  DRUG2 ) and  DRUGOTHER  within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS)."	dihydroergotamine	methysergide	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O	[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO
advise	"Due to a theoretical risk of a pharmacodynamic interaction, use of  DRUGOTHER -containing or  DRUGOTHER  (like  DRUG1  or  DRUGOTHER ) and  DRUG2  within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS)."	dihydroergotamine	FROVA	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O	CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O
advise	"Due to a theoretical risk of a pharmacodynamic interaction, use of  DRUGOTHER -containing or  DRUGOTHER  (like  DRUGOTHER  or  DRUG1 ) and  DRUG2  within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS)."	methysergide	FROVA	[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO	CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O
other	" DRUG1  ( DRUG2 ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	Selective serotonin reuptake inhibitors	SSRIs	NCCC1=CNC2=CC=C(O)C=C12	
other	" DRUG1  ( DRUGOTHER ) (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	Selective serotonin reuptake inhibitors	fluoxetine	NCCC1=CNC2=CC=C(O)C=C12	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	" DRUG1  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	Selective serotonin reuptake inhibitors	fluvoxamine	NCCC1=CNC2=CC=C(O)C=C12	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	" DRUG1  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	Selective serotonin reuptake inhibitors	paroxetine	NCCC1=CNC2=CC=C(O)C=C12	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	" DRUG1  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	Selective serotonin reuptake inhibitors	sertraline	NCCC1=CNC2=CC=C(O)C=C12	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
effect	" DRUG1  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 ."	Selective serotonin reuptake inhibitors	5-HT1 agonists	NCCC1=CNC2=CC=C(O)C=C12	
other	" DRUGOTHER  ( DRUG1 ) (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	SSRIs	fluoxetine		CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	" DRUGOTHER  ( DRUG1 ) (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	SSRIs	fluvoxamine		ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	" DRUGOTHER  ( DRUG1 ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	SSRIs	paroxetine		FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	" DRUGOTHER  ( DRUG1 ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	SSRIs	sertraline		C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
effect	" DRUGOTHER  ( DRUG1 ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 ."	SSRIs	5-HT1 agonists		
other	" DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	fluoxetine	fluvoxamine	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	" DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	fluoxetine	paroxetine	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	" DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	fluoxetine	sertraline	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
effect	" DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 ."	fluoxetine	5-HT1 agonists	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	
other	" DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	fluvoxamine	paroxetine	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	" DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	fluvoxamine	sertraline	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
effect	" DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 ."	fluvoxamine	5-HT1 agonists	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	
other	" DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	paroxetine	sertraline	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
effect	" DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 ."	paroxetine	5-HT1 agonists	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1	
effect	" DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 ."	sertraline	5-HT1 agonists	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	
advise	"If concomitant treatment with  DRUG1  and an  DRUG2  is clinically warranted, appropriate observation of the patient is advised."	frovatriptan	SSRI	CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O	
other	" DRUG1 : In a prospective study involving six-healthy-male volunteers,  DRUG2  did not affect the metabolism of  DRUGOTHER ."	Terfenadine	dirithromycin	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	" DRUG1 : In a prospective study involving six-healthy-male volunteers,  DRUGOTHER  did not affect the metabolism of  DRUG2 ."	Terfenadine	terfenadine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	" DRUGOTHER : In a prospective study involving six-healthy-male volunteers,  DRUG1  did not affect the metabolism of  DRUG2 ."	dirithromycin	terfenadine	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"These six volunteers received  DRUG1  alone (60 mg twice daily) for 8 days, followed by  DRUG2  in combination with  DRUGOTHER  (500 mg once daily) for 10 days."	terfenadine	terfenadine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"These six volunteers received  DRUG1  alone (60 mg twice daily) for 8 days, followed by  DRUGOTHER  in combination with  DRUG2  (500 mg once daily) for 10 days."	terfenadine	dirithromycin	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	"These six volunteers received  DRUGOTHER  alone (60 mg twice daily) for 8 days, followed by  DRUG1  in combination with  DRUG2  (500 mg once daily) for 10 days."	terfenadine	dirithromycin	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	"The pharmacokinetics of  DRUG1  and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with  DRUG2  alone, and with  DRUGOTHER  plus  DRUGOTHER ."	terfenadine	terfenadine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"The pharmacokinetics of  DRUG1  and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with  DRUGOTHER  alone, and with  DRUG2  plus  DRUGOTHER ."	terfenadine	terfenadine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"The pharmacokinetics of  DRUG1  and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with  DRUGOTHER  alone, and with  DRUGOTHER  plus  DRUG2 ."	terfenadine	dirithromycin	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	"The pharmacokinetics of  DRUGOTHER  and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with  DRUG1  alone, and with  DRUG2  plus  DRUGOTHER ."	terfenadine	terfenadine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"The pharmacokinetics of  DRUGOTHER  and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with  DRUG1  alone, and with  DRUGOTHER  plus  DRUG2 ."	terfenadine	dirithromycin	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	"The pharmacokinetics of  DRUGOTHER  and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with  DRUGOTHER  alone, and with  DRUG1  plus  DRUG2 ."	terfenadine	dirithromycin	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	"in one man, the C max of  DRUG1  was 8.1 ng/mL with  DRUG2  alone and 7.2 ng/mL with  DRUGOTHER  plus  DRUGOTHER ."	terfenadine	terfenadine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"in one man, the C max of  DRUG1  was 8.1 ng/mL with  DRUGOTHER  alone and 7.2 ng/mL with  DRUG2  plus  DRUGOTHER ."	terfenadine	terfenadine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"in one man, the C max of  DRUG1  was 8.1 ng/mL with  DRUGOTHER  alone and 7.2 ng/mL with  DRUGOTHER  plus  DRUG2 ."	terfenadine	dirithromycin	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	"in one man, the C max of  DRUGOTHER  was 8.1 ng/mL with  DRUG1  alone and 7.2 ng/mL with  DRUG2  plus  DRUGOTHER ."	terfenadine	terfenadine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"in one man, the C max of  DRUGOTHER  was 8.1 ng/mL with  DRUG1  alone and 7.2 ng/mL with  DRUGOTHER  plus  DRUG2 ."	terfenadine	dirithromycin	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
mechanism	"in one man, the C max of  DRUGOTHER  was 8.1 ng/mL with  DRUGOTHER  alone and 7.2 ng/mL with  DRUG1  plus  DRUG2 ."	terfenadine	dirithromycin	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	The mean QT c interval (msec) was 369 with  DRUG1  alone and 367 with  DRUG2  plus  DRUGOTHER .	terfenadine	terfenadine	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	The mean QT c interval (msec) was 369 with  DRUG1  alone and 367 with  DRUGOTHER  plus  DRUG2 .	terfenadine	dirithromycin	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
effect	The mean QT c interval (msec) was 369 with  DRUGOTHER  alone and 367 with  DRUG1  plus  DRUG2 .	terfenadine	dirithromycin	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	"Also, in vitro experiments demonstrated a lack of interaction between  DRUG1  and  DRUG2 ."	dirithromycin	terfenadine	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
int	"Thus, the interaction observed between  DRUG1  and  DRUG2  is not expected for  DRUGOTHER ."	erythromycin	terfenadine	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	"Thus, the interaction observed between  DRUG1  and  DRUGOTHER  is not expected for  DRUG2 ."	erythromycin	dirithromycin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	"Thus, the interaction observed between  DRUGOTHER  and  DRUG1  is not expected for  DRUG2 ."	terfenadine	dirithromycin	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
effect	"Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving  DRUG1  concomitantly with other  DRUG2 ."	terfenadine	macrolide antibiotics	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
advise	"In addition, most  DRUG1  are contraindicated in patients receiving  DRUG2  therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances."	macrolides	terfenadine	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	" DRUG1 : Following co-administration of two 250-mg  DRUG2  tablets administered once daily with 200-mg  DRUGOTHER  tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of  DRUGOTHER  was not significantly altered."	Theophylline	dirithromycin	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	" DRUG1 : Following co-administration of two 250-mg  DRUGOTHER  tablets administered once daily with 200-mg  DRUG2  tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of  DRUGOTHER  was not significantly altered."	Theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUG1 : Following co-administration of two 250-mg  DRUGOTHER  tablets administered once daily with 200-mg  DRUGOTHER  tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of  DRUG2  was not significantly altered."	Theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER : Following co-administration of two 250-mg  DRUG1  tablets administered once daily with 200-mg  DRUG2  tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of  DRUGOTHER  was not significantly altered."	dirithromycin	theophylline	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER : Following co-administration of two 250-mg  DRUG1  tablets administered once daily with 200-mg  DRUGOTHER  tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of  DRUG2  was not significantly altered."	dirithromycin	theophylline	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUGOTHER : Following co-administration of two 250-mg  DRUGOTHER  tablets administered once daily with 200-mg  DRUG1  tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of  DRUG2  was not significantly altered."	theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"In general, most patients treated with  DRUG1  who are receiving concomitant  DRUG2  therapy may not require empiric adjustment of  DRUGOTHER  dosage or monitoring of  DRUGOTHER  plasma concentrations."	dirithromycin	theophylline	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"In general, most patients treated with  DRUG1  who are receiving concomitant  DRUGOTHER  therapy may not require empiric adjustment of  DRUG2  dosage or monitoring of  DRUGOTHER  plasma concentrations."	dirithromycin	theophylline	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"In general, most patients treated with  DRUG1  who are receiving concomitant  DRUGOTHER  therapy may not require empiric adjustment of  DRUGOTHER  dosage or monitoring of  DRUG2  plasma concentrations."	dirithromycin	theophylline	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"In general, most patients treated with  DRUGOTHER  who are receiving concomitant  DRUG1  therapy may not require empiric adjustment of  DRUG2  dosage or monitoring of  DRUGOTHER  plasma concentrations."	theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"In general, most patients treated with  DRUGOTHER  who are receiving concomitant  DRUG1  therapy may not require empiric adjustment of  DRUGOTHER  dosage or monitoring of  DRUG2  plasma concentrations."	theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"In general, most patients treated with  DRUGOTHER  who are receiving concomitant  DRUGOTHER  therapy may not require empiric adjustment of  DRUG1  dosage or monitoring of  DRUG2  plasma concentrations."	theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"However,  DRUG1  plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given  DRUG2  plasma concentration for optimal pulmonary function or in patients with  DRUGOTHER  concentrations at the higher end of the therapeutic range."	theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"However,  DRUG1  plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given  DRUGOTHER  plasma concentration for optimal pulmonary function or in patients with  DRUG2  concentrations at the higher end of the therapeutic range."	theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	"However,  DRUGOTHER  plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given  DRUG1  plasma concentration for optimal pulmonary function or in patients with  DRUG2  concentrations at the higher end of the therapeutic range."	theophylline	theophylline	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	" DRUG1  or  DRUG2 : When  DRUGOTHER  is administered immediately following  DRUGOTHER  or  DRUGOTHER , the absorption of  DRUGOTHER  is slightly enhanced."	Antacids	H 2 receptor antagonists		
other	" DRUG1  or  DRUGOTHER : When  DRUG2  is administered immediately following  DRUGOTHER  or  DRUGOTHER , the absorption of  DRUGOTHER  is slightly enhanced."	Antacids	dirithromycin		CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	" DRUG1  or  DRUGOTHER : When  DRUGOTHER  is administered immediately following  DRUG2  or  DRUGOTHER , the absorption of  DRUGOTHER  is slightly enhanced."	Antacids	antacids		
other	" DRUG1  or  DRUGOTHER : When  DRUGOTHER  is administered immediately following  DRUGOTHER  or  DRUG2 , the absorption of  DRUGOTHER  is slightly enhanced."	Antacids	H 2 -receptor antagonists		
other	" DRUG1  or  DRUGOTHER : When  DRUGOTHER  is administered immediately following  DRUGOTHER  or  DRUGOTHER , the absorption of  DRUG2  is slightly enhanced."	Antacids	dirithromycin		CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	" DRUGOTHER  or  DRUG1 : When  DRUG2  is administered immediately following  DRUGOTHER  or  DRUGOTHER , the absorption of  DRUGOTHER  is slightly enhanced."	H 2 receptor antagonists	dirithromycin		CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	" DRUGOTHER  or  DRUG1 : When  DRUGOTHER  is administered immediately following  DRUG2  or  DRUGOTHER , the absorption of  DRUGOTHER  is slightly enhanced."	H 2 receptor antagonists	antacids		
other	" DRUGOTHER  or  DRUG1 : When  DRUGOTHER  is administered immediately following  DRUGOTHER  or  DRUG2 , the absorption of  DRUGOTHER  is slightly enhanced."	H 2 receptor antagonists	H 2 -receptor antagonists		
other	" DRUGOTHER  or  DRUG1 : When  DRUGOTHER  is administered immediately following  DRUGOTHER  or  DRUGOTHER , the absorption of  DRUG2  is slightly enhanced."	H 2 receptor antagonists	dirithromycin		CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
mechanism	" DRUGOTHER  or  DRUGOTHER : When  DRUG1  is administered immediately following  DRUG2  or  DRUGOTHER , the absorption of  DRUGOTHER  is slightly enhanced."	dirithromycin	antacids	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	
mechanism	" DRUGOTHER  or  DRUGOTHER : When  DRUG1  is administered immediately following  DRUGOTHER  or  DRUG2 , the absorption of  DRUGOTHER  is slightly enhanced."	dirithromycin	H 2 -receptor antagonists	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	
other	" DRUGOTHER  or  DRUGOTHER : When  DRUG1  is administered immediately following  DRUGOTHER  or  DRUGOTHER , the absorption of  DRUG2  is slightly enhanced."	dirithromycin	dirithromycin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	" DRUGOTHER  or  DRUGOTHER : When  DRUGOTHER  is administered immediately following  DRUG1  or  DRUG2 , the absorption of  DRUGOTHER  is slightly enhanced."	antacids	H 2 -receptor antagonists		
other	" DRUGOTHER  or  DRUGOTHER : When  DRUGOTHER  is administered immediately following  DRUG1  or  DRUGOTHER , the absorption of  DRUG2  is slightly enhanced."	antacids	dirithromycin		CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	" DRUGOTHER  or  DRUGOTHER : When  DRUGOTHER  is administered immediately following  DRUGOTHER  or  DRUG1 , the absorption of  DRUG2  is slightly enhanced."	H 2 -receptor antagonists	dirithromycin		CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O
other	" DRUG1 :  DRUG2  has been reported to decrease the clearance of  DRUGOTHER  and, thus, may increase the pharmacologic effect of  DRUGOTHER ."	Triazolam	Erythromycin	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	" DRUG1 :  DRUGOTHER  has been reported to decrease the clearance of  DRUG2  and, thus, may increase the pharmacologic effect of  DRUGOTHER ."	Triazolam	triazolam	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	" DRUG1 :  DRUGOTHER  has been reported to decrease the clearance of  DRUGOTHER  and, thus, may increase the pharmacologic effect of  DRUG2 ."	Triazolam	triazolam	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
mechanism	" DRUGOTHER :  DRUG1  has been reported to decrease the clearance of  DRUG2  and, thus, may increase the pharmacologic effect of  DRUGOTHER ."	Erythromycin	triazolam	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
effect	" DRUGOTHER :  DRUG1  has been reported to decrease the clearance of  DRUGOTHER  and, thus, may increase the pharmacologic effect of  DRUG2 ."	Erythromycin	triazolam	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	" DRUGOTHER :  DRUGOTHER  has been reported to decrease the clearance of  DRUG1  and, thus, may increase the pharmacologic effect of  DRUG2 ."	triazolam	triazolam	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1	O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1
other	 DRUG1 : Concomitant administration of  DRUG2  and  DRUGOTHER  has been reported to result in elevated  DRUGOTHER  serum levels.	Digoxin	erythromycin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	 DRUG1 : Concomitant administration of  DRUGOTHER  and  DRUG2  has been reported to result in elevated  DRUGOTHER  serum levels.	Digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	 DRUG1 : Concomitant administration of  DRUGOTHER  and  DRUGOTHER  has been reported to result in elevated  DRUG2  serum levels.	Digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
mechanism	 DRUGOTHER : Concomitant administration of  DRUG1  and  DRUG2  has been reported to result in elevated  DRUGOTHER  serum levels.	erythromycin	digoxin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	 DRUGOTHER : Concomitant administration of  DRUG1  and  DRUGOTHER  has been reported to result in elevated  DRUG2  serum levels.	erythromycin	digoxin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	 DRUGOTHER : Concomitant administration of  DRUGOTHER  and  DRUG1  has been reported to result in elevated  DRUG2  serum levels.	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	 DRUG1 : There have been reports of increased anticoagulant effects when  DRUG2  and oral  DRUGOTHER  were used concomitantly.	Anticoagulants	erythromycin		CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	 DRUG1 : There have been reports of increased anticoagulant effects when  DRUGOTHER  and oral  DRUG2  were used concomitantly.	Anticoagulants	anticoagulants		
effect	 DRUGOTHER : There have been reports of increased anticoagulant effects when  DRUG1  and oral  DRUG2  were used concomitantly.	erythromycin	anticoagulants	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	
other	 DRUG1 : Concurrent use of  DRUG2  and  DRUGOTHER  or  DRUGOTHER  has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.	Ergotamine	erythromycin	OC(=O)CCCCCCCC(O)=O	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	 DRUG1 : Concurrent use of  DRUGOTHER  and  DRUG2  or  DRUGOTHER  has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.	Ergotamine	ergotamine	OC(=O)CCCCCCCC(O)=O	OC(=O)CCCCCCCC(O)=O
other	 DRUG1 : Concurrent use of  DRUGOTHER  and  DRUGOTHER  or  DRUG2  has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.	Ergotamine	dihydroergotamine	OC(=O)CCCCCCCC(O)=O	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
effect	 DRUGOTHER : Concurrent use of  DRUG1  and  DRUG2  or  DRUGOTHER  has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.	erythromycin	ergotamine	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	OC(=O)CCCCCCCC(O)=O
effect	 DRUGOTHER : Concurrent use of  DRUG1  and  DRUGOTHER  or  DRUG2  has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.	erythromycin	dihydroergotamine	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
other	 DRUGOTHER : Concurrent use of  DRUGOTHER  and  DRUG1  or  DRUG2  has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.	ergotamine	dihydroergotamine	OC(=O)CCCCCCCC(O)=O	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
int	"Other drugs Drug interactions have been reported with concomitant administration of  DRUG1  and other medications, including  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	erythromycin	cyclosporine	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
int	"Other drugs Drug interactions have been reported with concomitant administration of  DRUG1  and other medications, including  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	erythromycin	hexobarbital	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1
int	"Other drugs Drug interactions have been reported with concomitant administration of  DRUG1  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	erythromycin	carbamazepine	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
int	"Other drugs Drug interactions have been reported with concomitant administration of  DRUG1  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	erythromycin	alfentanil	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
int	"Other drugs Drug interactions have been reported with concomitant administration of  DRUG1  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	erythromycin	disopyramide	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	OC(=O)CCCCCCCC(O)=O
int	"Other drugs Drug interactions have been reported with concomitant administration of  DRUG1  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	erythromycin	phenytoin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
int	"Other drugs Drug interactions have been reported with concomitant administration of  DRUG1  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	erythromycin	bromocriptine	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C
int	"Other drugs Drug interactions have been reported with concomitant administration of  DRUG1  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	erythromycin	valproate	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	
int	"Other drugs Drug interactions have been reported with concomitant administration of  DRUG1  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	erythromycin	astemizole	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1
int	"Other drugs Drug interactions have been reported with concomitant administration of  DRUG1  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	erythromycin	lovastatin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporine	hexobarbital	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporine	carbamazepine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporine	alfentanil	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporine	disopyramide	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	OC(=O)CCCCCCCC(O)=O
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporine	phenytoin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporine	bromocriptine	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	cyclosporine	valproate	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	cyclosporine	astemizole	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	cyclosporine	lovastatin	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	hexobarbital	carbamazepine	CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	hexobarbital	alfentanil	CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	hexobarbital	disopyramide	CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1	OC(=O)CCCCCCCC(O)=O
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	hexobarbital	phenytoin	CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	hexobarbital	bromocriptine	CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	hexobarbital	valproate	CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1	
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	hexobarbital	astemizole	CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	hexobarbital	lovastatin	CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	carbamazepine	alfentanil	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	carbamazepine	disopyramide	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	OC(=O)CCCCCCCC(O)=O
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	carbamazepine	phenytoin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	carbamazepine	bromocriptine	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	carbamazepine	valproate	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	carbamazepine	astemizole	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	carbamazepine	lovastatin	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	alfentanil	disopyramide	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OC(=O)CCCCCCCC(O)=O
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	alfentanil	phenytoin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	alfentanil	bromocriptine	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	alfentanil	valproate	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	alfentanil	astemizole	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	alfentanil	lovastatin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	disopyramide	phenytoin	OC(=O)CCCCCCCC(O)=O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	disopyramide	bromocriptine	OC(=O)CCCCCCCC(O)=O	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	disopyramide	valproate	OC(=O)CCCCCCCC(O)=O	
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	disopyramide	astemizole	OC(=O)CCCCCCCC(O)=O	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	disopyramide	lovastatin	OC(=O)CCCCCCCC(O)=O	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ."	phenytoin	bromocriptine	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	phenytoin	valproate	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	phenytoin	astemizole	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	phenytoin	lovastatin	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ."	bromocriptine	valproate	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C	
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ."	bromocriptine	astemizole	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ."	bromocriptine	lovastatin	[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ."	valproate	astemizole		FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ."	valproate	lovastatin		[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Other drugs Drug interactions have been reported with concomitant administration of  DRUGOTHER  and other medications, including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ."	astemizole	lovastatin	FC1=CC=C(CN2C(NC3=CC=CC=C23)=NC2CCNCC2)C=C1	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"No drug interaction studies have been conducted for  DRUG1 , however the use of orally administered  DRUG2  could, theoretically, interfere with the release of  DRUGOTHER  in the colon."	COLAZAL	antibiotics	OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
other	"No drug interaction studies have been conducted for  DRUG1 , however the use of orally administered  DRUGOTHER  could, theoretically, interfere with the release of  DRUG2  in the colon."	COLAZAL	mesalamine	OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O	NC1=CC(C(O)=O)=C(O)C=C1
other	"No drug interaction studies have been conducted for  DRUGOTHER , however the use of orally administered  DRUG1  could, theoretically, interfere with the release of  DRUG2  in the colon."	antibiotics	mesalamine	[H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O	NC1=CC(C(O)=O)=C(O)C=C1
other	 DRUG1 : Twelve healthy male volunteers were administered one 200-mg  DRUG2  capsule twice daily for 6 days.	Theophylline	ceftibuten	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O	[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O
other	"With the morning dose of  DRUG1  on day 6, each volunteer received a single intravenous infusion of  DRUG2  (4 mg/kg)."	ceftibuten	theophylline	[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	The effect of  DRUG1  on the pharmacokinetics of  DRUG2  administered orally has not been investigated.	ceftibuten	theophylline	[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O	CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O
other	 DRUG1  or  DRUG2 : The effect of increased gastric pH on the bioavailability of  DRUGOTHER  was evaluated in 18 healthy adult volunteers.	Antacids	H 2 -receptor antagonists		
other	 DRUG1  or  DRUGOTHER : The effect of increased gastric pH on the bioavailability of  DRUG2  was evaluated in 18 healthy adult volunteers.	Antacids	ceftibuten		[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O
other	 DRUGOTHER  or  DRUG1 : The effect of increased gastric pH on the bioavailability of  DRUG2  was evaluated in 18 healthy adult volunteers.	H 2 -receptor antagonists	ceftibuten		[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O
other	A single dose of liquid  DRUG1  did not affect the C max or AUC of  DRUG2 ;	antacid	ceftibuten	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O	[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O
mechanism	"however, 150 mg of  DRUG1  q12h for 3 days increased the  DRUG2  C max by 23% and  DRUGOTHER  AUC by 16%."	ranitidine	ceftibuten	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O	[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O
mechanism	"however, 150 mg of  DRUG1  q12h for 3 days increased the  DRUGOTHER  C max by 23% and  DRUG2  AUC by 16%."	ranitidine	ceftibuten	CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O	[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O
other	"however, 150 mg of  DRUGOTHER  q12h for 3 days increased the  DRUG1  C max by 23% and  DRUG2  AUC by 16%."	ceftibuten	ceftibuten	[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O	[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O
other	The results of assays using red cells from healthy subjects to determine whether  DRUG1  would cause direct Coombs reactions in vitro showed no positive reaction at  DRUG2  concentrations as high as 40  g/mL.	ceftibuten	ceftibuten	[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O	[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C1=CSC(N)=N1)C(O)=O
other	"Additive depressant effect when used with general  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other  DRUGOTHER ."	anesthetics	sedatives	CCOC(=O)C1=CC=C(N)C=C1	
other	"Additive depressant effect when used with general  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other  DRUGOTHER ."	anesthetics	antianxiety drugs	CCOC(=O)C1=CC=C(N)C=C1	
other	"Additive depressant effect when used with general  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other  DRUGOTHER ."	anesthetics	hypnotics	CCOC(=O)C1=CC=C(N)C=C1	
other	"Additive depressant effect when used with general  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other  DRUGOTHER ."	anesthetics	alcohol	CCOC(=O)C1=CC=C(N)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Additive depressant effect when used with general  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other  DRUG2 ."	anesthetics	opiate analgesics	CCOC(=O)C1=CC=C(N)C=C1	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	"Additive depressant effect when used with general  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other  DRUGOTHER ."	sedatives	antianxiety drugs		
other	"Additive depressant effect when used with general  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other  DRUGOTHER ."	sedatives	hypnotics		
other	"Additive depressant effect when used with general  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other  DRUGOTHER ."	sedatives	alcohol		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Additive depressant effect when used with general  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other  DRUG2 ."	sedatives	opiate analgesics		OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	"Additive depressant effect when used with general  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and other  DRUGOTHER ."	antianxiety drugs	hypnotics		
other	"Additive depressant effect when used with general  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and other  DRUGOTHER ."	antianxiety drugs	alcohol		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Additive depressant effect when used with general  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and other  DRUG2 ."	antianxiety drugs	opiate analgesics		OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	"Additive depressant effect when used with general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and other  DRUGOTHER ."	hypnotics	alcohol		CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Additive depressant effect when used with general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and other  DRUG2 ."	hypnotics	opiate analgesics		OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	"Additive depressant effect when used with general  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and other  DRUG2 ."	alcohol	opiate analgesics	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O
other	Interactions for  DRUG1  ( DRUG2 ):  DRUGOTHER  Therapy:  DRUGOTHER  may potentiate the effects of  DRUGOTHER  and vasoactive drugs resulting in postural hypotension.	Vitamin B3	Niacin	OC(=O)CCCCCCCC(O)=O	NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O
other	Interactions for  DRUG1  ( DRUGOTHER ):  DRUG2  Therapy:  DRUGOTHER  may potentiate the effects of  DRUGOTHER  and vasoactive drugs resulting in postural hypotension.	Vitamin B3	Antihypertensive	OC(=O)CCCCCCCC(O)=O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	Interactions for  DRUG1  ( DRUGOTHER ):  DRUGOTHER  Therapy:  DRUG2  may potentiate the effects of  DRUGOTHER  and vasoactive drugs resulting in postural hypotension.	Vitamin B3	Nicotinic acid	OC(=O)CCCCCCCC(O)=O	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	Interactions for  DRUG1  ( DRUGOTHER ):  DRUGOTHER  Therapy:  DRUGOTHER  may potentiate the effects of  DRUG2  and vasoactive drugs resulting in postural hypotension.	Vitamin B3	ganglionic blocking agents	OC(=O)CCCCCCCC(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	Interactions for  DRUGOTHER  ( DRUG1 ):  DRUG2  Therapy:  DRUGOTHER  may potentiate the effects of  DRUGOTHER  and vasoactive drugs resulting in postural hypotension.	Niacin	Antihypertensive	NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1
other	Interactions for  DRUGOTHER  ( DRUG1 ):  DRUGOTHER  Therapy:  DRUG2  may potentiate the effects of  DRUGOTHER  and vasoactive drugs resulting in postural hypotension.	Niacin	Nicotinic acid	NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	Interactions for  DRUGOTHER  ( DRUG1 ):  DRUGOTHER  Therapy:  DRUGOTHER  may potentiate the effects of  DRUG2  and vasoactive drugs resulting in postural hypotension.	Niacin	ganglionic blocking agents	NC(=O)C1=CN=CC=C1.[H]C(O)(CO)[C@@]1([H])OC(=O)C(O)=C1O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	Interactions for  DRUGOTHER  ( DRUGOTHER ):  DRUG1  Therapy:  DRUG2  may potentiate the effects of  DRUGOTHER  and vasoactive drugs resulting in postural hypotension.	Antihypertensive	Nicotinic acid	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
other	Interactions for  DRUGOTHER  ( DRUGOTHER ):  DRUG1  Therapy:  DRUGOTHER  may potentiate the effects of  DRUG2  and vasoactive drugs resulting in postural hypotension.	Antihypertensive	ganglionic blocking agents	ClC1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	Interactions for  DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  Therapy:  DRUG1  may potentiate the effects of  DRUG2  and vasoactive drugs resulting in postural hypotension.	Nicotinic acid	ganglionic blocking agents	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	 DRUG1 : Concomitant  DRUG2  may decrease the metabolic clearance of  DRUGOTHER .	Aspirin	aspirin	CC(=O)OC1=CC=CC=C1C(O)=O	CC(=O)OC1=CC=CC=C1C(O)=O
other	 DRUG1 : Concomitant  DRUGOTHER  may decrease the metabolic clearance of  DRUG2 .	Aspirin	nicotinic acid	CC(=O)OC1=CC=CC=C1C(O)=O	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
mechanism	 DRUGOTHER : Concomitant  DRUG1  may decrease the metabolic clearance of  DRUG2 .	aspirin	nicotinic acid	CC(=O)OC1=CC=CC=C1C(O)=O	OC(=O)C1=C(NC2=CC=C(Cl)C=C2)N=CC=C1
effect	The vasodilating effects of  DRUG1  may be additive with those of other  DRUG2 .	isosorbide dinitrate	vasodilators	[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O	
other	"Effects of Other Drugs on  DRUG1  Based on in-vitro studies,  DRUG2  is metabolized by CYP 3A4."	Aliskiren	aliskiren	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Co-administration of  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	lovastatin	atenolol	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1
other	"Co-administration of  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	lovastatin	warfarin	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Co-administration of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	lovastatin	furosemide	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"Co-administration of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	lovastatin	digoxin	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Co-administration of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	lovastatin	celecoxib	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
other	"Co-administration of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	lovastatin	hydrochlorothiazide	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"Co-administration of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	lovastatin	ramipril	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O
other	"Co-administration of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	lovastatin	valsartan	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
other	"Co-administration of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	lovastatin	metformin	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CN(C)C(=N)NC(N)=N
other	"Co-administration of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  did not result in clinically significant increases in  DRUGOTHER  exposure."	lovastatin	amlodipine	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC
other	"Co-administration of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUG2  exposure."	lovastatin	aliskiren	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Co-administration of  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	atenolol	warfarin	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	"Co-administration of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	atenolol	furosemide	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"Co-administration of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	atenolol	digoxin	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Co-administration of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	atenolol	celecoxib	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
other	"Co-administration of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	atenolol	hydrochlorothiazide	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"Co-administration of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	atenolol	ramipril	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O
other	"Co-administration of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	atenolol	valsartan	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
other	"Co-administration of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	atenolol	metformin	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1	CN(C)C(=N)NC(N)=N
other	"Co-administration of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  did not result in clinically significant increases in  DRUGOTHER  exposure."	atenolol	amlodipine	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC
other	"Co-administration of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUG2  exposure."	atenolol	aliskiren	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	warfarin	furosemide	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	warfarin	digoxin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	warfarin	celecoxib	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	warfarin	hydrochlorothiazide	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	warfarin	ramipril	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	warfarin	valsartan	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	warfarin	metformin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CN(C)C(=N)NC(N)=N
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  did not result in clinically significant increases in  DRUGOTHER  exposure."	warfarin	amlodipine	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUG2  exposure."	warfarin	aliskiren	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	furosemide	digoxin	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	furosemide	celecoxib	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	furosemide	hydrochlorothiazide	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	furosemide	ramipril	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	furosemide	valsartan	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	furosemide	metformin	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CN(C)C(=N)NC(N)=N
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  did not result in clinically significant increases in  DRUGOTHER  exposure."	furosemide	amlodipine	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUG2  exposure."	furosemide	aliskiren	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	digoxin	celecoxib	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	digoxin	hydrochlorothiazide	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	digoxin	ramipril	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	digoxin	valsartan	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	digoxin	metformin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CN(C)C(=N)NC(N)=N
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  did not result in clinically significant increases in  DRUGOTHER  exposure."	digoxin	amlodipine	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUG2  exposure."	digoxin	aliskiren	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	celecoxib	hydrochlorothiazide	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	celecoxib	ramipril	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	celecoxib	valsartan	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	celecoxib	metformin	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F	CN(C)C(=N)NC(N)=N
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  did not result in clinically significant increases in  DRUGOTHER  exposure."	celecoxib	amlodipine	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUG2  exposure."	celecoxib	aliskiren	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	hydrochlorothiazide	ramipril	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	hydrochlorothiazide	valsartan	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	hydrochlorothiazide	metformin	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	CN(C)C(=N)NC(N)=N
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  did not result in clinically significant increases in  DRUGOTHER  exposure."	hydrochlorothiazide	amlodipine	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUG2  exposure."	hydrochlorothiazide	aliskiren	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	ramipril	valsartan	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	ramipril	metformin	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O	CN(C)C(=N)NC(N)=N
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  did not result in clinically significant increases in  DRUGOTHER  exposure."	ramipril	amlodipine	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUG2  exposure."	ramipril	aliskiren	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  and  DRUGOTHER  did not result in clinically significant increases in  DRUGOTHER  exposure."	valsartan	metformin	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O	CN(C)C(=N)NC(N)=N
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUG2  did not result in clinically significant increases in  DRUGOTHER  exposure."	valsartan	amlodipine	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER  did not result in clinically significant increases in  DRUG2  exposure."	valsartan	aliskiren	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUG2  did not result in clinically significant increases in  DRUGOTHER  exposure."	metformin	amlodipine	CN(C)C(=N)NC(N)=N	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER  did not result in clinically significant increases in  DRUG2  exposure."	metformin	aliskiren	CN(C)C(=N)NC(N)=N	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Co-administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1  did not result in clinically significant increases in  DRUG2  exposure."	amlodipine	aliskiren	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
mechanism	Co-administration of  DRUG1  reduced  DRUG2  Cmax up to 50% after multiple dosing.	irbesartan	aliskiren	CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
mechanism	Co-administration of  DRUG1  resulted in about a 50% increase in  DRUG2  Cmax and AUC after multiple dosing.	atorvastatin	aliskiren	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	 DRUG1 : Co-administration of 200 mg twice-daily  DRUG2  with  DRUGOTHER  resulted in an approximate 80% increase in plasma levels of  DRUGOTHER .	Ketoconazole	ketoconazole	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	 DRUG1 : Co-administration of 200 mg twice-daily  DRUGOTHER  with  DRUG2  resulted in an approximate 80% increase in plasma levels of  DRUGOTHER .	Ketoconazole	aliskiren	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	 DRUG1 : Co-administration of 200 mg twice-daily  DRUGOTHER  with  DRUGOTHER  resulted in an approximate 80% increase in plasma levels of  DRUG2 .	Ketoconazole	aliskiren	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
mechanism	 DRUGOTHER : Co-administration of 200 mg twice-daily  DRUG1  with  DRUG2  resulted in an approximate 80% increase in plasma levels of  DRUGOTHER .	ketoconazole	aliskiren	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	 DRUGOTHER : Co-administration of 200 mg twice-daily  DRUG1  with  DRUGOTHER  resulted in an approximate 80% increase in plasma levels of  DRUG2 .	ketoconazole	aliskiren	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	 DRUGOTHER : Co-administration of 200 mg twice-daily  DRUGOTHER  with  DRUG1  resulted in an approximate 80% increase in plasma levels of  DRUG2 .	aliskiren	aliskiren	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Effects of  DRUG1  on Other Drugs  DRUG2  does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and CYP 3A) or induce CYP 3A4."	Aliskiren	Aliskiren	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	"Co-administration of  DRUG1  did not significantly affect the pharmacokinetics of  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	aliskiren	lovastatin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC
other	"Co-administration of  DRUG1  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	aliskiren	digoxin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Co-administration of  DRUG1  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	aliskiren	valsartan	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
other	"Co-administration of  DRUG1  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	aliskiren	amlodipine	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC
other	"Co-administration of  DRUG1  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	aliskiren	metformin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CN(C)C(=N)NC(N)=N
other	"Co-administration of  DRUG1  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	aliskiren	celecoxib	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
other	"Co-administration of  DRUG1  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	aliskiren	atenolol	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1
other	"Co-administration of  DRUG1  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	aliskiren	atorvastatin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
other	"Co-administration of  DRUG1  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	aliskiren	ramipril	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O
other	"Co-administration of  DRUG1  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	aliskiren	hydrochlorothiazide	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	lovastatin	digoxin	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	lovastatin	valsartan	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	lovastatin	amlodipine	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	lovastatin	metformin	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CN(C)C(=N)NC(N)=N
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	lovastatin	celecoxib	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	lovastatin	atenolol	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	lovastatin	atorvastatin	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	lovastatin	ramipril	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	lovastatin	hydrochlorothiazide	[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	digoxin	valsartan	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	digoxin	amlodipine	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	digoxin	metformin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CN(C)C(=N)NC(N)=N
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	digoxin	celecoxib	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	digoxin	atenolol	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	digoxin	atorvastatin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	digoxin	ramipril	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	digoxin	hydrochlorothiazide	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	valsartan	amlodipine	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	valsartan	metformin	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O	CN(C)C(=N)NC(N)=N
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	valsartan	celecoxib	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	valsartan	atenolol	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	valsartan	atorvastatin	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	valsartan	ramipril	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	valsartan	hydrochlorothiazide	CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	amlodipine	metformin	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC	CN(C)C(=N)NC(N)=N
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	amlodipine	celecoxib	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	amlodipine	atenolol	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	amlodipine	atorvastatin	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	amlodipine	ramipril	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	amlodipine	hydrochlorothiazide	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	metformin	celecoxib	CN(C)C(=N)NC(N)=N	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	metformin	atenolol	CN(C)C(=N)NC(N)=N	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	metformin	atorvastatin	CN(C)C(=N)NC(N)=N	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	metformin	ramipril	CN(C)C(=N)NC(N)=N	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	metformin	hydrochlorothiazide	CN(C)C(=N)NC(N)=N	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ."	celecoxib	atenolol	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	celecoxib	atorvastatin	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	celecoxib	ramipril	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	celecoxib	hydrochlorothiazide	CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ."	atenolol	atorvastatin	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ."	atenolol	ramipril	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ."	atenolol	hydrochlorothiazide	CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  or  DRUGOTHER ."	atorvastatin	ramipril	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  or  DRUG2 ."	atorvastatin	hydrochlorothiazide	CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	"Co-administration of  DRUGOTHER  did not significantly affect the pharmacokinetics of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  or  DRUG2 ."	ramipril	hydrochlorothiazide	[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	 DRUG1 : The effects of  DRUG2  on  DRUGOTHER  pharmacokinetics have not been evaluated in a well-controlled clinical trial.	Warfarin	aliskiren	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	 DRUG1 : The effects of  DRUGOTHER  on  DRUG2  pharmacokinetics have not been evaluated in a well-controlled clinical trial.	Warfarin	warfarin	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	 DRUGOTHER : The effects of  DRUG1  on  DRUG2  pharmacokinetics have not been evaluated in a well-controlled clinical trial.	aliskiren	warfarin	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O
other	" DRUG1 : When  DRUG2  was co-administered with  DRUGOTHER , the AUC and Cmax of  DRUGOTHER  were reduced by about 30% and 50%, respectively."	Furosemide	aliskiren	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
other	" DRUG1 : When  DRUGOTHER  was co-administered with  DRUG2 , the AUC and Cmax of  DRUGOTHER  were reduced by about 30% and 50%, respectively."	Furosemide	furosemide	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	" DRUG1 : When  DRUGOTHER  was co-administered with  DRUGOTHER , the AUC and Cmax of  DRUG2  were reduced by about 30% and 50%, respectively."	Furosemide	furosemide	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
mechanism	" DRUGOTHER : When  DRUG1  was co-administered with  DRUG2 , the AUC and Cmax of  DRUGOTHER  were reduced by about 30% and 50%, respectively."	aliskiren	furosemide	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	" DRUGOTHER : When  DRUG1  was co-administered with  DRUGOTHER , the AUC and Cmax of  DRUG2  were reduced by about 30% and 50%, respectively."	aliskiren	furosemide	CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	" DRUGOTHER : When  DRUGOTHER  was co-administered with  DRUG1 , the AUC and Cmax of  DRUG2  were reduced by about 30% and 50%, respectively."	furosemide	furosemide	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
mechanism	Co-treatment with the potent CYP3A4 inhibitor  DRUG1  increases  DRUG2  AUC by 2/3.	ketoconazole	erlotinib	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
advise	"Caution should be used when administering or taking  DRUG1  with  DRUG2  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	TARCEVA	ketoconazole	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
advise	"Caution should be used when administering or taking  DRUG1  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	TARCEVA	atazanavir	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
advise	"Caution should be used when administering or taking  DRUG1  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	TARCEVA	clarithromycin	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
advise	"Caution should be used when administering or taking  DRUG1  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	TARCEVA	indinavir	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
advise	"Caution should be used when administering or taking  DRUG1  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	TARCEVA	itraconazole	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
advise	"Caution should be used when administering or taking  DRUG1  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	TARCEVA	nefazodone	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
advise	"Caution should be used when administering or taking  DRUG1  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	TARCEVA	nelfinavir	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
advise	"Caution should be used when administering or taking  DRUG1  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	TARCEVA	ritonavir	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
advise	"Caution should be used when administering or taking  DRUG1  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	TARCEVA	saquinavir	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
advise	"Caution should be used when administering or taking  DRUG1  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	TARCEVA	telithromycin	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1
advise	"Caution should be used when administering or taking  DRUG1  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ."	TARCEVA	troleandomycin	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
advise	"Caution should be used when administering or taking  DRUG1  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ."	TARCEVA	TAO	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
advise	"Caution should be used when administering or taking  DRUG1  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ."	TARCEVA	voriconazole	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2	CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUG1  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	ketoconazole	atazanavir	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUG1  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	ketoconazole	clarithromycin	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUG1  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	ketoconazole	indinavir	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUG1  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	ketoconazole	itraconazole	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUG1  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	ketoconazole	nefazodone	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUG1  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	ketoconazole	nelfinavir	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUG1  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	ketoconazole	ritonavir	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUG1  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	ketoconazole	saquinavir	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUG1  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	ketoconazole	telithromycin	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUG1  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ."	ketoconazole	troleandomycin	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUG1  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ."	ketoconazole	TAO	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUG1  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ."	ketoconazole	voriconazole	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	atazanavir	clarithromycin	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	atazanavir	indinavir	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	atazanavir	itraconazole	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	atazanavir	nefazodone	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	atazanavir	nelfinavir	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	atazanavir	ritonavir	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	atazanavir	saquinavir	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	atazanavir	telithromycin	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ."	atazanavir	troleandomycin	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ."	atazanavir	TAO	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ."	atazanavir	voriconazole	COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	clarithromycin	indinavir	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	clarithromycin	itraconazole	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	clarithromycin	nefazodone	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	clarithromycin	nelfinavir	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	clarithromycin	ritonavir	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	clarithromycin	saquinavir	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	clarithromycin	telithromycin	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ."	clarithromycin	troleandomycin	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ."	clarithromycin	TAO	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ."	clarithromycin	voriconazole	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC	CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	indinavir	itraconazole	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	indinavir	nefazodone	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	indinavir	nelfinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	indinavir	ritonavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	indinavir	saquinavir	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	indinavir	telithromycin	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ."	indinavir	troleandomycin	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ."	indinavir	TAO	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ."	indinavir	voriconazole	CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12	CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	itraconazole	nefazodone	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	itraconazole	nelfinavir	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	itraconazole	ritonavir	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	itraconazole	saquinavir	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	itraconazole	telithromycin	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ."	itraconazole	troleandomycin	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ."	itraconazole	TAO	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ."	itraconazole	voriconazole	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	nefazodone	nelfinavir	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	nefazodone	ritonavir	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	nefazodone	saquinavir	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	nefazodone	telithromycin	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ."	nefazodone	troleandomycin	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ."	nefazodone	TAO	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ."	nefazodone	voriconazole	NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1	CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	nelfinavir	ritonavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	nelfinavir	saquinavir	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	nelfinavir	telithromycin	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ."	nelfinavir	troleandomycin	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ."	nelfinavir	TAO	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ."	nelfinavir	voriconazole	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C	CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	ritonavir	saquinavir	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	ritonavir	telithromycin	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ."	ritonavir	troleandomycin	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ."	ritonavir	TAO	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ."	ritonavir	voriconazole	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  ( DRUGOTHER ), and  DRUGOTHER  ."	saquinavir	telithromycin	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ."	saquinavir	troleandomycin	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ."	saquinavir	TAO	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ."	saquinavir	voriconazole	[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C	CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  ( DRUGOTHER ), and  DRUGOTHER  ."	telithromycin	troleandomycin	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER  ."	telithromycin	TAO	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  ( DRUGOTHER ), and  DRUG2  ."	telithromycin	voriconazole	[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1	CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  ( DRUG2 ), and  DRUGOTHER  ."	troleandomycin	TAO	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  ( DRUGOTHER ), and  DRUG2  ."	troleandomycin	voriconazole	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	"Caution should be used when administering or taking  DRUGOTHER  with  DRUGOTHER  and other strong CYP3A4 inhibitors such as, but not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ( DRUG1 ), and  DRUG2  ."	TAO	voriconazole	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
mechanism	Pre-treatment with the CYP3A4 inducer  DRUG1  decreased  DRUG2  AUC by about 2/3.	rifampicin	erlotinib	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
advise	"If the  DRUG1  dose is adjusted upward, the dose will need to be reduced upon discontinuation of  DRUG2  or other inducers."	TARCEVA	rifampicin	COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
other	"Other CYP3A4 inducers include, but are not limited to,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and St. Johns Wort."	rifabutin	rifapentine	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(CC1)C1CCCC1)=C2O
other	"Other CYP3A4 inducers include, but are not limited to,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and St. Johns Wort."	rifabutin	phenytoin	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Other CYP3A4 inducers include, but are not limited to,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and St. Johns Wort."	rifabutin	carbamazepine	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Other CYP3A4 inducers include, but are not limited to,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and St. Johns Wort."	rifabutin	phenobarbital	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Other CYP3A4 inducers include, but are not limited to,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and St. Johns Wort."	rifapentine	phenytoin	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(CC1)C1CCCC1)=C2O	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1
other	"Other CYP3A4 inducers include, but are not limited to,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and St. Johns Wort."	rifapentine	carbamazepine	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(CC1)C1CCCC1)=C2O	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Other CYP3A4 inducers include, but are not limited to,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and St. Johns Wort."	rifapentine	phenobarbital	CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(CC1)C1CCCC1)=C2O	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Other CYP3A4 inducers include, but are not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  and St. Johns Wort."	phenytoin	carbamazepine	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
other	"Other CYP3A4 inducers include, but are not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  and St. Johns Wort."	phenytoin	phenobarbital	CCC1(NC(=O)N(C)C1=O)C1=CC=CC=C1	CCC1(CC)C(=O)NC(=O)NC1=O
other	"Other CYP3A4 inducers include, but are not limited to,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  and St. Johns Wort."	carbamazepine	phenobarbital	NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12	CCC1(CC)C(=O)NC(=O)NC1=O
other	Patients taking  DRUG1  or other  DRUG2  should be monitored regularly for changes in prothrombin time or INR	warfarin	coumarin-derivative anticoagulants	[H][C@@](CC(C)=O)(C1=CC=CC=C1)C1=C(O)C2=CC=CC=C2OC1=O	O=C1OC2=CC=CC=C2C=C1
other	Pharmacokinetic evaluation of the  DRUG1 - DRUG2  interaction.	digoxin	amiodarone	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
mechanism	 DRUG1  is known to raise serum  DRUG2  levels.	Amiodarone	digoxin	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"The pharmacokinetic variables for  DRUG1  were determined after a 1.0 mg intravenous dose of  DRUG2  in each subject, before and after oral  DRUGOTHER , 400 mg daily for 3 weeks."	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"The pharmacokinetic variables for  DRUG1  were determined after a 1.0 mg intravenous dose of  DRUGOTHER  in each subject, before and after oral  DRUG2 , 400 mg daily for 3 weeks."	digoxin	amiodarone	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	"The pharmacokinetic variables for  DRUGOTHER  were determined after a 1.0 mg intravenous dose of  DRUG1  in each subject, before and after oral  DRUG2 , 400 mg daily for 3 weeks."	digoxin	amiodarone	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
mechanism	"During  DRUG1  administration, systemic clearance of  DRUG2  was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01)."	amiodarone	digoxin	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	" DRUG1  caused a three- to fivefold increase in serum reverse triiodothyronine levels, but changes in thyroid function were not quantitatively related to the changes in  DRUG2  pharmacokinetics."	Amiodarone	digoxin	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
mechanism	These alterations in  DRUG1  pharmacokinetics produced by  DRUG2  explain the increase in serum  DRUGOTHER  level that has been observed when this drug combination has been used clinically.	digoxin	amiodarone	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
other	These alterations in  DRUG1  pharmacokinetics produced by  DRUGOTHER  explain the increase in serum  DRUG2  level that has been observed when this drug combination has been used clinically.	digoxin	digoxin	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	These alterations in  DRUGOTHER  pharmacokinetics produced by  DRUG1  explain the increase in serum  DRUG2  level that has been observed when this drug combination has been used clinically.	amiodarone	digoxin	CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	"Because there is a theoretical basis that these effects may be additive, use of  DRUG1 -containing or  DRUG2  (like  DRUGOTHER  or  DRUGOTHER ) and  DRUGOTHER  within 24 hours of each other should be avoided."	ergotamine	ergot-type medications	OC(=O)CCCCCCCC(O)=O	
other	"Because there is a theoretical basis that these effects may be additive, use of  DRUG1 -containing or  DRUGOTHER  (like  DRUG2  or  DRUGOTHER ) and  DRUGOTHER  within 24 hours of each other should be avoided."	ergotamine	dihydroergotamine	OC(=O)CCCCCCCC(O)=O	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
other	"Because there is a theoretical basis that these effects may be additive, use of  DRUG1 -containing or  DRUGOTHER  (like  DRUGOTHER  or  DRUG2 ) and  DRUGOTHER  within 24 hours of each other should be avoided."	ergotamine	methysergide	OC(=O)CCCCCCCC(O)=O	[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO
advise	"Because there is a theoretical basis that these effects may be additive, use of  DRUG1 -containing or  DRUGOTHER  (like  DRUGOTHER  or  DRUGOTHER ) and  DRUG2  within 24 hours of each other should be avoided."	ergotamine	AXERT	OC(=O)CCCCCCCC(O)=O	O.[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-]
other	"Because there is a theoretical basis that these effects may be additive, use of  DRUGOTHER -containing or  DRUG1  (like  DRUG2  or  DRUGOTHER ) and  DRUGOTHER  within 24 hours of each other should be avoided."	ergot-type medications	dihydroergotamine		[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
other	"Because there is a theoretical basis that these effects may be additive, use of  DRUGOTHER -containing or  DRUG1  (like  DRUGOTHER  or  DRUG2 ) and  DRUGOTHER  within 24 hours of each other should be avoided."	ergot-type medications	methysergide		[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO
advise	"Because there is a theoretical basis that these effects may be additive, use of  DRUGOTHER -containing or  DRUG1  (like  DRUGOTHER  or  DRUGOTHER ) and  DRUG2  within 24 hours of each other should be avoided."	ergot-type medications	AXERT		O.[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-]
other	"Because there is a theoretical basis that these effects may be additive, use of  DRUGOTHER -containing or  DRUGOTHER  (like  DRUG1  or  DRUG2 ) and  DRUGOTHER  within 24 hours of each other should be avoided."	dihydroergotamine	methysergide	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O	[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO
advise	"Because there is a theoretical basis that these effects may be additive, use of  DRUGOTHER -containing or  DRUGOTHER  (like  DRUG1  or  DRUGOTHER ) and  DRUG2  within 24 hours of each other should be avoided."	dihydroergotamine	AXERT	[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O	O.[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-]
advise	"Because there is a theoretical basis that these effects may be additive, use of  DRUGOTHER -containing or  DRUGOTHER  (like  DRUGOTHER  or  DRUG1 ) and  DRUG2  within 24 hours of each other should be avoided."	methysergide	AXERT	[H][C@@]12CC3=CN(C)C4=C3C(=CC=C4)C1=C[C@H](CN2C)C(=O)NC(CC)CO	O.[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-]
other	 DRUG1 : Coadministration of  DRUG2  resulted in a 27% decrease in  DRUGOTHER  clearance and an increase in Cmax of approximately 6%.	Monoamine Oxidase Inhibitors	moclobemide	OC(=O)CCCCCCCC(O)=O	ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1
other	 DRUG1 : Coadministration of  DRUGOTHER  resulted in a 27% decrease in  DRUG2  clearance and an increase in Cmax of approximately 6%.	Monoamine Oxidase Inhibitors	almotriptan	OC(=O)CCCCCCCC(O)=O	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
mechanism	 DRUGOTHER : Coadministration of  DRUG1  resulted in a 27% decrease in  DRUG2  clearance and an increase in Cmax of approximately 6%.	moclobemide	almotriptan	ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
other	Other  DRUG1  Concomitant use of other  DRUG2  within 24 hours of treatment with  DRUGOTHER  is contraindicated.	5-HT1B/1D Agonists	5-HT1B/1D agonists		
other	Other  DRUG1  Concomitant use of other  DRUGOTHER  within 24 hours of treatment with  DRUG2  is contraindicated.	5-HT1B/1D Agonists	AXERT		O.[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-]
advise	Other  DRUGOTHER  Concomitant use of other  DRUG1  within 24 hours of treatment with  DRUG2  is contraindicated.	5-HT1B/1D agonists	AXERT		O.[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-]
other	 DRUG1 : The pharmacokinetics of  DRUG2  were not affected by coadministration of  DRUGOTHER .	Propanolol	almotriptan	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
other	 DRUG1 : The pharmacokinetics of  DRUGOTHER  were not affected by coadministration of  DRUG2 .	Propanolol	propranolol	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	 DRUGOTHER : The pharmacokinetics of  DRUG1  were not affected by coadministration of  DRUG2 .	almotriptan	propranolol	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2	CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2
other	" DRUG1  ( DRUG2 ):  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	Selective Serotonin Reuptake Inhibitors	SSRIs	NCCC1=CNC2=CC=C(O)C=C12	
other	" DRUG1  ( DRUGOTHER ):  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	Selective Serotonin Reuptake Inhibitors	SSRIs	NCCC1=CNC2=CC=C(O)C=C12	
other	" DRUG1  ( DRUGOTHER ):  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	Selective Serotonin Reuptake Inhibitors	fluoxetine	NCCC1=CNC2=CC=C(O)C=C12	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	" DRUG1  ( DRUGOTHER ):  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	Selective Serotonin Reuptake Inhibitors	fluvoxamine	NCCC1=CNC2=CC=C(O)C=C12	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	" DRUG1  ( DRUGOTHER ):  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	Selective Serotonin Reuptake Inhibitors	paroxetine	NCCC1=CNC2=CC=C(O)C=C12	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	" DRUG1  ( DRUGOTHER ):  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	Selective Serotonin Reuptake Inhibitors	sertraline	NCCC1=CNC2=CC=C(O)C=C12	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
other	" DRUG1  ( DRUGOTHER ):  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 ."	Selective Serotonin Reuptake Inhibitors	5-HT1 agonists	NCCC1=CNC2=CC=C(O)C=C12	
other	" DRUGOTHER  ( DRUG1 ):  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	SSRIs	SSRIs		
other	" DRUGOTHER  ( DRUG1 ):  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	SSRIs	fluoxetine		CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	" DRUGOTHER  ( DRUG1 ):  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	SSRIs	fluvoxamine		ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	" DRUGOTHER  ( DRUG1 ):  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	SSRIs	paroxetine		FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	" DRUGOTHER  ( DRUG1 ):  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	SSRIs	sertraline		C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
other	" DRUGOTHER  ( DRUG1 ):  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 ."	SSRIs	5-HT1 agonists		
other	" DRUGOTHER  ( DRUGOTHER ):  DRUG1  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	SSRIs	fluoxetine		CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
other	" DRUGOTHER  ( DRUGOTHER ):  DRUG1  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	SSRIs	fluvoxamine		ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	" DRUGOTHER  ( DRUGOTHER ):  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	SSRIs	paroxetine		FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	" DRUGOTHER  ( DRUGOTHER ):  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	SSRIs	sertraline		C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
effect	" DRUGOTHER  ( DRUGOTHER ):  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 ."	SSRIs	5-HT1 agonists		
other	" DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	fluoxetine	fluvoxamine	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1
other	" DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	fluoxetine	paroxetine	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	" DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	fluoxetine	sertraline	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
effect	" DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 ."	fluoxetine	5-HT1 agonists	CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1	
other	" DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	fluvoxamine	paroxetine	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
other	" DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	fluvoxamine	sertraline	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
effect	" DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 ."	fluvoxamine	5-HT1 agonists	ClC1=CC2=C(OC3=CC=CC=C3N=C2N2CCNCC2)C=C1	
other	" DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER ."	paroxetine	sertraline	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1
effect	" DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 ."	paroxetine	5-HT1 agonists	FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1	
effect	" DRUGOTHER  ( DRUGOTHER ):  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 ."	sertraline	5-HT1 agonists	C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1	
advise	"If concomitant treatment with  DRUG1  and an  DRUG2  is clinically warranted, appropriate observation of the patient is advised."	AXERT	SSRI	O.[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-]	
other	 DRUG1 : Coadministration of  DRUG2  and  DRUGOTHER  resulted in a 24% increase in plasma concentrations of  DRUGOTHER .	Verapamil	almotriptan	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
other	 DRUG1 : Coadministration of  DRUGOTHER  and  DRUG2  resulted in a 24% increase in plasma concentrations of  DRUGOTHER .	Verapamil	verapamil	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	 DRUG1 : Coadministration of  DRUGOTHER  and  DRUGOTHER  resulted in a 24% increase in plasma concentrations of  DRUG2 .	Verapamil	almotriptan	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
mechanism	 DRUGOTHER : Coadministration of  DRUG1  and  DRUG2  resulted in a 24% increase in plasma concentrations of  DRUGOTHER .	almotriptan	verapamil	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
other	 DRUGOTHER : Coadministration of  DRUG1  and  DRUGOTHER  resulted in a 24% increase in plasma concentrations of  DRUG2 .	almotriptan	almotriptan	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
other	 DRUGOTHER : Coadministration of  DRUGOTHER  and  DRUG1  resulted in a 24% increase in plasma concentrations of  DRUG2 .	verapamil	almotriptan	COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
mechanism	Coadministration of  DRUG1  and the potent CYP3A4 inhibitor  DRUG2  (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of  DRUGOTHER .	almotriptan	ketoconazole	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
other	Coadministration of  DRUG1  and the potent CYP3A4 inhibitor  DRUGOTHER  (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of  DRUG2 .	almotriptan	almotriptan	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
other	Coadministration of  DRUGOTHER  and the potent CYP3A4 inhibitor  DRUG1  (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of  DRUG2 .	ketoconazole	almotriptan	CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
other	"Although the interaction between  DRUG1  and other potent CYP3A4 inhibitors (e.g.,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) has not been studied, increased exposures to  DRUGOTHER  may be expected when  DRUGOTHER  is used concomitantly with these medications."	almotriptan	itraconazole	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
other	"Although the interaction between  DRUG1  and other potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) has not been studied, increased exposures to  DRUGOTHER  may be expected when  DRUGOTHER  is used concomitantly with these medications."	almotriptan	ritonavir	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	"Although the interaction between  DRUG1  and other potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) has not been studied, increased exposures to  DRUGOTHER  may be expected when  DRUGOTHER  is used concomitantly with these medications."	almotriptan	erythromycin	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Although the interaction between  DRUG1  and other potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) has not been studied, increased exposures to  DRUG2  may be expected when  DRUGOTHER  is used concomitantly with these medications."	almotriptan	almotriptan	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
other	"Although the interaction between  DRUG1  and other potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) has not been studied, increased exposures to  DRUGOTHER  may be expected when  DRUG2  is used concomitantly with these medications."	almotriptan	almotriptan	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
other	"Although the interaction between  DRUGOTHER  and other potent CYP3A4 inhibitors (e.g.,  DRUG1 ,  DRUG2 , and  DRUGOTHER ) has not been studied, increased exposures to  DRUGOTHER  may be expected when  DRUGOTHER  is used concomitantly with these medications."	itraconazole	ritonavir	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
other	"Although the interaction between  DRUGOTHER  and other potent CYP3A4 inhibitors (e.g.,  DRUG1 ,  DRUGOTHER , and  DRUG2 ) has not been studied, increased exposures to  DRUGOTHER  may be expected when  DRUGOTHER  is used concomitantly with these medications."	itraconazole	erythromycin	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Although the interaction between  DRUGOTHER  and other potent CYP3A4 inhibitors (e.g.,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) has not been studied, increased exposures to  DRUG2  may be expected when  DRUGOTHER  is used concomitantly with these medications."	itraconazole	almotriptan	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
advise	"Although the interaction between  DRUGOTHER  and other potent CYP3A4 inhibitors (e.g.,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) has not been studied, increased exposures to  DRUGOTHER  may be expected when  DRUG2  is used concomitantly with these medications."	itraconazole	almotriptan	ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
other	"Although the interaction between  DRUGOTHER  and other potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUG1 , and  DRUG2 ) has not been studied, increased exposures to  DRUGOTHER  may be expected when  DRUGOTHER  is used concomitantly with these medications."	ritonavir	erythromycin	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
other	"Although the interaction between  DRUGOTHER  and other potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) has not been studied, increased exposures to  DRUG2  may be expected when  DRUGOTHER  is used concomitantly with these medications."	ritonavir	almotriptan	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
advise	"Although the interaction between  DRUGOTHER  and other potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) has not been studied, increased exposures to  DRUGOTHER  may be expected when  DRUG2  is used concomitantly with these medications."	ritonavir	almotriptan	CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
other	"Although the interaction between  DRUGOTHER  and other potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) has not been studied, increased exposures to  DRUG2  may be expected when  DRUGOTHER  is used concomitantly with these medications."	erythromycin	almotriptan	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
advise	"Although the interaction between  DRUGOTHER  and other potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) has not been studied, increased exposures to  DRUGOTHER  may be expected when  DRUG2  is used concomitantly with these medications."	erythromycin	almotriptan	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
other	"Although the interaction between  DRUGOTHER  and other potent CYP3A4 inhibitors (e.g.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) has not been studied, increased exposures to  DRUG1  may be expected when  DRUG2  is used concomitantly with these medications."	almotriptan	almotriptan	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2	CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
effect	 DRUG1  may augment the activity of other  DRUG2 .	HEMABATE	oxytocic agents	OCC([NH3+])(CO)CO.CCCCC[C@@](O)(C)\C=C\[C@H]1[C@@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)[O-]	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"Hypotension   Patients on  DRUG1  Therapy: Patients on  DRUG2  and especially those in whom  DRUGOTHER  therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of  DRUGOTHER ."	Diuretic	diuretics	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"Hypotension   Patients on  DRUG1  Therapy: Patients on  DRUGOTHER  and especially those in whom  DRUG2  therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of  DRUGOTHER ."	Diuretic	diuretic	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"Hypotension   Patients on  DRUG1  Therapy: Patients on  DRUGOTHER  and especially those in whom  DRUGOTHER  therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of  DRUG2 ."	Diuretic	captopril	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Hypotension   Patients on  DRUGOTHER  Therapy: Patients on  DRUG1  and especially those in whom  DRUG2  therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of  DRUGOTHER ."	diuretics	diuretic	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
effect	"Hypotension   Patients on  DRUGOTHER  Therapy: Patients on  DRUG1  and especially those in whom  DRUGOTHER  therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of  DRUG2 ."	diuretics	captopril	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Hypotension   Patients on  DRUGOTHER  Therapy: Patients on  DRUGOTHER  and especially those in whom  DRUG1  therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of  DRUG2 ."	diuretic	captopril	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
effect	"The possibility of hypotensive effects with  DRUG1  can be minimized by either discontinuing the  DRUG2  or increasing the salt intake approximately one week prior to initiation of treatment with  DRUGOTHER  ( DRUGOTHER  tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg)."	captopril	diuretic	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"The possibility of hypotensive effects with  DRUG1  can be minimized by either discontinuing the  DRUGOTHER  or increasing the salt intake approximately one week prior to initiation of treatment with  DRUG2  ( DRUGOTHER  tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg)."	captopril	captopril	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"The possibility of hypotensive effects with  DRUG1  can be minimized by either discontinuing the  DRUGOTHER  or increasing the salt intake approximately one week prior to initiation of treatment with  DRUGOTHER  ( DRUG2  tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg)."	captopril	captopril	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"The possibility of hypotensive effects with  DRUGOTHER  can be minimized by either discontinuing the  DRUG1  or increasing the salt intake approximately one week prior to initiation of treatment with  DRUG2  ( DRUGOTHER  tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg)."	diuretic	captopril	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"The possibility of hypotensive effects with  DRUGOTHER  can be minimized by either discontinuing the  DRUG1  or increasing the salt intake approximately one week prior to initiation of treatment with  DRUGOTHER  ( DRUG2  tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg)."	diuretic	captopril	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"The possibility of hypotensive effects with  DRUGOTHER  can be minimized by either discontinuing the  DRUGOTHER  or increasing the salt intake approximately one week prior to initiation of treatment with  DRUG1  ( DRUG2  tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg)."	captopril	captopril	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	Agents Having Vasodilator Activity: Data on the effect of concomitant use of other  DRUG1  in patients receiving  DRUG2  for heart failure are not available;	vasodilators	captopril		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"therefore,  DRUG1  or other  DRUG2  (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting  DRUGOTHER ."	nitroglycerin	nitrates	OCC(O)CO	[O-]N(=O)=O
advise	"therefore,  DRUG1  or other  DRUGOTHER  (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting  DRUG2 ."	nitroglycerin	captopril	OCC(O)CO	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
advise	"therefore,  DRUGOTHER  or other  DRUG1  (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting  DRUG2 ."	nitrates	captopril	[O-]N(=O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
effect	Agents Causing Renin Release  DRUG1 's effect will be augmented by  DRUG2  that cause renin release.	Captopril	antihypertensive agents	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
other	"For example,  DRUG1  (e.g.,  DRUG2 ) may activate the renin-angiotensin-aldosterone system."	diuretics	thiazides	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
other	Agents Affecting Sympathetic Activity The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving  DRUG1  alone or with  DRUG2 .	captopril	diuretics	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O
other	"Therefore, agents affecting sympathetic activity (e.g.,  DRUG1  or  DRUG2 ) should be used with caution."	ganglionic blocking agents	adrenergic neuron blocking agents	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
effect	" DRUG1  add some further antihypertensive effect to  DRUG2 , but the overall response is less than additive."	Beta-adrenergic blocking drugs	captopril		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	" DRUG1  such as  DRUG2 ,  DRUGOTHER , or  DRUGOTHER , or  DRUGOTHER  supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium."	Potassium-sparing diuretics	spironolactone	[KH]	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O
other	" DRUG1  such as  DRUGOTHER ,  DRUG2 , or  DRUGOTHER , or  DRUGOTHER  supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium."	Potassium-sparing diuretics	triamterene	[KH]	NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1
other	" DRUG1  such as  DRUGOTHER ,  DRUGOTHER , or  DRUG2 , or  DRUGOTHER  supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium."	Potassium-sparing diuretics	amiloride	[KH]	OC(=O)CCCCCCCC(O)=O
other	" DRUG1  such as  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER , or  DRUG2  supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium."	Potassium-sparing diuretics	potassium	[KH]	[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
other	" DRUGOTHER  such as  DRUG1 ,  DRUG2 , or  DRUGOTHER , or  DRUGOTHER  supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium."	spironolactone	triamterene	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O	NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1
other	" DRUGOTHER  such as  DRUG1 ,  DRUGOTHER , or  DRUG2 , or  DRUGOTHER  supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium."	spironolactone	amiloride	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  such as  DRUG1 ,  DRUGOTHER , or  DRUGOTHER , or  DRUG2  supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium."	spironolactone	potassium	[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O	[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
other	" DRUGOTHER  such as  DRUGOTHER ,  DRUG1 , or  DRUG2 , or  DRUGOTHER  supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium."	triamterene	amiloride	NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1	OC(=O)CCCCCCCC(O)=O
other	" DRUGOTHER  such as  DRUGOTHER ,  DRUG1 , or  DRUGOTHER , or  DRUG2  supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium."	triamterene	potassium	NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1	[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
other	" DRUGOTHER  such as  DRUGOTHER ,  DRUGOTHER , or  DRUG1 , or  DRUG2  supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium."	amiloride	potassium	OC(=O)CCCCCCCC(O)=O	[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O
effect	"Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that  DRUG1  may reduce the antihypertensive effect of  DRUG2 , especially in cases of low renin hypertension."	indomethacin	captopril	COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	"Other  DRUG1  (e.g.,  DRUG2 ) may also have this effect."	nonsteroidal anti-inflammatory agents	aspirin	CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC	CC(=O)OC1=CC=CC=C1C(O)=O
other	 DRUG1 : Increased serum  DRUG2  levels and symptoms of  DRUGOTHER  toxicity have been reported in patients receiving concomitant  DRUGOTHER  and  DRUGOTHER  therapy.	Lithium	lithium	[Li+]	[Li+]
other	 DRUG1 : Increased serum  DRUGOTHER  levels and symptoms of  DRUG2  toxicity have been reported in patients receiving concomitant  DRUGOTHER  and  DRUGOTHER  therapy.	Lithium	lithium	[Li+]	[Li+]
other	 DRUG1 : Increased serum  DRUGOTHER  levels and symptoms of  DRUGOTHER  toxicity have been reported in patients receiving concomitant  DRUG2  and  DRUGOTHER  therapy.	Lithium	lithium	[Li+]	[Li+]
other	 DRUG1 : Increased serum  DRUGOTHER  levels and symptoms of  DRUGOTHER  toxicity have been reported in patients receiving concomitant  DRUGOTHER  and  DRUG2  therapy.	Lithium	ACE inhibitor	[Li+]	
other	 DRUGOTHER : Increased serum  DRUG1  levels and symptoms of  DRUG2  toxicity have been reported in patients receiving concomitant  DRUGOTHER  and  DRUGOTHER  therapy.	lithium	lithium	[Li+]	[Li+]
other	 DRUGOTHER : Increased serum  DRUG1  levels and symptoms of  DRUGOTHER  toxicity have been reported in patients receiving concomitant  DRUG2  and  DRUGOTHER  therapy.	lithium	lithium	[Li+]	[Li+]
other	 DRUGOTHER : Increased serum  DRUG1  levels and symptoms of  DRUGOTHER  toxicity have been reported in patients receiving concomitant  DRUGOTHER  and  DRUG2  therapy.	lithium	ACE inhibitor	[Li+]	
other	 DRUGOTHER : Increased serum  DRUGOTHER  levels and symptoms of  DRUG1  toxicity have been reported in patients receiving concomitant  DRUG2  and  DRUGOTHER  therapy.	lithium	lithium	[Li+]	[Li+]
other	 DRUGOTHER : Increased serum  DRUGOTHER  levels and symptoms of  DRUG1  toxicity have been reported in patients receiving concomitant  DRUGOTHER  and  DRUG2  therapy.	lithium	ACE inhibitor	[Li+]	
effect	 DRUGOTHER : Increased serum  DRUGOTHER  levels and symptoms of  DRUGOTHER  toxicity have been reported in patients receiving concomitant  DRUG1  and  DRUG2  therapy.	lithium	ACE inhibitor	[Li+]	
effect	"If a  DRUG1  is also used, it may increase the risk of  DRUG2  toxicity."	diuretic	lithium	COC(CNC(=O)C1=CC=CC=C1OCC(O)=O)C[Hg]O	[Li+]
other	 DRUG1 : In a study of young healthy male subjects no evidence of a direct pharmacokinetic  DRUG2 - DRUGOTHER  interaction could be found.	Cardiac Glycosides	captopril		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	 DRUG1 : In a study of young healthy male subjects no evidence of a direct pharmacokinetic  DRUGOTHER - DRUG2  interaction could be found.	Cardiac Glycosides	digoxin		[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	 DRUGOTHER : In a study of young healthy male subjects no evidence of a direct pharmacokinetic  DRUG1 - DRUG2  interaction could be found.	captopril	digoxin	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
other	 DRUG1 :  DRUG2  administered concurrently with  DRUGOTHER  does not alter the pharmacokinetics of  DRUGOTHER  in renally impaired hypertensive patients.	Loop Diuretics	Furosemide		NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
other	 DRUG1 :  DRUGOTHER  administered concurrently with  DRUG2  does not alter the pharmacokinetics of  DRUGOTHER  in renally impaired hypertensive patients.	Loop Diuretics	captopril		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	 DRUG1 :  DRUGOTHER  administered concurrently with  DRUGOTHER  does not alter the pharmacokinetics of  DRUG2  in renally impaired hypertensive patients.	Loop Diuretics	captopril		CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	 DRUGOTHER :  DRUG1  administered concurrently with  DRUG2  does not alter the pharmacokinetics of  DRUGOTHER  in renally impaired hypertensive patients.	Furosemide	captopril	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	 DRUGOTHER :  DRUG1  administered concurrently with  DRUGOTHER  does not alter the pharmacokinetics of  DRUG2  in renally impaired hypertensive patients.	Furosemide	captopril	NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	 DRUGOTHER :  DRUGOTHER  administered concurrently with  DRUG1  does not alter the pharmacokinetics of  DRUG2  in renally impaired hypertensive patients.	captopril	captopril	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	 DRUG1 : In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when  DRUG2  and  DRUGOTHER  were administered concomitantly for 6 days.	Allopurinol	captopril	O=C1N=CN=C2NNC=C12	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
other	 DRUG1 : In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when  DRUGOTHER  and  DRUG2  were administered concomitantly for 6 days.	Allopurinol	allopurinol	O=C1N=CN=C2NNC=C12	O=C1N=CN=C2NNC=C12
other	 DRUGOTHER : In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when  DRUG1  and  DRUG2  were administered concomitantly for 6 days.	captopril	allopurinol	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	O=C1N=CN=C2NNC=C12
